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Thesis abstract 
 
Oesophageal adenocarcinoma (OAC) is an aggressive malignancy with a very poor prognosis 
overall. Barrett’s oesophagus (BO) is the only known precursor lesion. Emerging preclinical 
evidence indicates statins, medications commonly used in the primary and secondary prevention 
of cardiovascular disease, inhibit proliferation, promote apoptosis and limit invasiveness of OAC. 
Inhibition of the mevalonate pathway depletes downstream products involved in candidate 
growth-signalling cascades.  
This research aimed to determine: (1) associations between statin use after diagnosis of 
oesophageal carcinoma (OC) and mortality outcomes; (2) the feasibility of assessing adjuvant 
statin therapy in patients with operable OAC in a future phase III randomised controlled trial; and 
(3) associations between statin use and malignant progression to high-grade dysplasia (HGD)/OAC 
in BO populations. 
In a cohort of 4445 patients with OC in a large primary care dataset, the General Practice 
Research Database, post-diagnostic statin use was associated with significant reductions in OC-
specific and all-cause mortality. Significant associations were demonstrated in patients with OAC 
but not in oesophageal squamous cell carcinoma. 
A multi-centre, double-blind, parallel group, randomised, placebo-controlled feasibility trial of 
adjuvant statin therapy recruited patients with operable OAC. In total, 32 patients were 
randomised (1:1) to simvastatin (40mg) or matched placebo. Treatment started from the date of 
discharge following surgery and continued for up to one year. The trial estimated recruitment, 
retention, drug absorption, adherence, safety, quality of life, generalisability, and mortality 
outcomes. The feasibility of a future phase III trial was demonstrated; and derived feasibility 
estimates inform its design and conduct.  
A nested case-control analysis of a cohort with BO registered with the United Kingdom National 
Barrett’s Oesophagus Registry (UKBOR) demonstrated no significant associations between statin 
use and malignant progression. Significant dose and duration-response relationships were not 
demonstrated.  
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1. Chapter 1 - Introduction 
1.1. Barrett’s oesophagus and oesophageal adenocarcinoma 
Barrett’s oesophagus (BO) refers to the replacement of the normal stratified squamous 
epithelium of the lower oesophagus by columnar epithelium, through the process of metaplasia1. 
BO develops as a complication of chronic oesophageal mucosal injury to gastric reflux2, 3. BO is the 
only known premalignant lesion to oesophageal adenocarcinoma (OAC). This is the most common 
histological subtype of oesophageal malignancy in the west, an important gastrointestinal 
epithelial malignancy with a dismal prognosis4, 5. The following describes the history of BO as a 
clinical entity, its epidemiology, pathogenesis, clinical presentation, diagnosis, and clinical 
management. 
1.1.1. History of Barrett’s oeosphagus 
The origins, nature and existence of the columnar-lined oesophagus, commonly termed Barrett’s 
oesophagus, has been the subject of considerable historical confusion and debate. Norman 
Barrett (1903-1979), a distinguished consultant thoracic surgeon at St. Thomas’ Hospital, is 
frequently credited with first describing the eponymous condition in 1950; in fact, Tileston, a 
Harvard pathologist, first characterised the disorder in 19076, 7. In a review of 44 patients with 
“peptic ulcer of the esophagus” he noted “the close resemblance of the mucous membrane about 
the ulcer to that normally found in the stomach”7. In 1931, Findlay and Kelley, from 9 cases, 
proposed the columnar-lined organ was not oesophagus but rather intrathoracic stomach; the 
result of congenital shortening of the oesophagus with resultant herniation and trapping of the 
tubular portion of the stomach in the chest8. This assertion was supported by Barrett in his 
treatise in 19506. He rejected the conclusions of previous pathologists that the mucous 
membrane approximating oesophageal ulcers represented gastric heterotopia. Barrett drew a 
distinction between “reflux oesophagitis”: reflux of acidic gastric juices leading to inflammation of 
the oesophagus potentially complicated by ulceration of squamous mucosa and stricture 
formation; and the lesion described by pathologists previously as “chronic peptic ulcer of the 
oesophagus” surrounded by gastric mucosa, which he asserted arose from the stomach and not 
the oesophagus, and were complicated by “emergencies such as massive bleeding, perforation or 
carcinoma”, typical of classical gastric ulcers6. Three years later Alison and Johnston persuasively 
concluded this columnar-lined structure was in fact the oesophagus and not stomach: “more 
careful examination of such a specimen shows that it has no peritoneal covering, that the 
musculature is that of the normal oesophagus, that there may be islands of squamous epithelium 
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within it, that there are no oxyntic cells in the mucosa, and that in addition to gastric glands there 
are present typical oesophageal mucous glands.”9. They proposed the chronic ulcer which 
develops within the oesophagus lined by gastric mucous membrane be termed “Barrett’s ulcer”; 
to reflect this entity as distinct from gastric ulcers. They asserted their use of the eponym did not 
imply agreement with Barrett’s original view the ulcer arose from intrathoracic stomach; though it 
seems plausible it was also used to appease him. Indeed, in 1957, Barrett revised his position and 
conceded in these cases the lower oesophagus was “lined by columnar epithelium” and did not 
represent stomach10. The eponym, Barrett’s oesophagus, has remained in common use since, 
particularly from the late 1960s11.  
 
The view the disorder was a congenital abnormality was widely held, including by Barrett: “it is 
probably the result of a failure of the embryonic lining of the gullet to achieve normal maturity”; 
and Allison and Johnston, despite the recognition of an association with oesophagitis and hiatus 
hernia in these patients6, 9. Indeed, it was Tileston who first correctly recognised the role of GORD 
in the pathogenesis of the ulceration within the columnar-lined oesophagus: “the first requisite 
for the formation of the peptic ulcer of the oesophagus is an insufficiency of the cardia”7. By the 
1970s the acquired nature of Barrett’s oesophagus and the role of GORD in its pathogenesis were 
established12-15. While the malignant potential of the Barrett’s ulcers had been alluded to in his 
original treatise, this was only widely recognised two decades later in the 1970s6.  
 
The subject of the histological features required to make a diagnosis of Barrett’s have been the 
topic of debate and controversy16, 17. The earliest the histological features were comprehensively 
characterised was in 1976, in a study by Pedersen et al. of 11 patients with Barrett’s oesophagus 
from whom biopsies were been taken from different levels guided by oesophageal manometry18. 
These patients were found to have three types of oesophageal columnar epithelium: a specialised 
columnar epithelium with goblet cells (known commonly today as intestinal metaplasia); a 
junctional (cardia-type) epithelium that comprised mucus secreting cells; and a gastric-fundic type 
(with parietal and chief cells). These three types of columnar epithelium were found to be 
localised to different levels in the oesophagus, respectively proximally to distally, with specialised 
found in the proximal oesophagus adjacent to squamous epithelium; followed by junctional 
epithelium and then the gastric-fundic type in continuity with the proximal stomach. The 
presence of intestinal metaplasia was of particular interest: pathological examination of resected 
oesophageal adenocarcinomas in case-series revealed the malignancy to be in continuity with this 
type of columnar epithelium in the majority of patients19. Therefore, predominantly this type of 
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columnar epithelium, rather than the other two types, was believed to harbour potential to 
undergo dysplasia and hence malignant transformation17. This view was particularly held by 
gastroenterologists in the United States (US), where American Gastroenterology Association 
(AGA) clinical practice guidelines stipulated, “Intestinal metaplasia of the esophagus is the 
premalignant lesion for adenocarcinoma of the esophagus”, and required its presence in order to 
make a diagnosis of Barrett’s oesophagus20.  In contrast, the view proposed in the United 
Kingdom was more relaxed, and required “metaplastic glandular mucosa, whether intestinalised 
or not”21. A number of considerations have recently led to a change in position in the US and 
adopt this view as reflected in their recent clinical practice guidelines: detection of intestinal 
metaplasia using biopsies is subject to considerable sampling error, hence potentially leading to 
under diagnosis; intestinal metaplasia can develop over time within columnar epithelium; and 
most importantly patients with CLO without intestinal metaplasia have also been shown to still 
have an appreciable risk of adenocarcinoma.  
1.1.2. Diagnosis 
The current gold standard modality for diagnosis of Barrett’s is high-definition, white light, 
(transoral as opposed to transnasal) endoscopy22, 23. At least 1cm of visible columnar-lined 
oesophagus measured above the gastro-oesophageal junction with histological confirmation from 
biopsy is required.  The length of metaplastic mucosa should be described using the Prague C & M 
criteria (see figure 1, adapted from Sharma et al24). The current British Society of 
Gastroenterology (BSG) guidelines recommend a minimum endoscopic dataset when reporting 
findings of Barrett’s oesophagus, which in addition to length of metaplasia are: the presence of 
Barrett’s islands (areas of Barrett’s not in continuity with the gastro-oesophageal junction) 
including length and distance from incisors, presence of hiatus hernia and length, visible lesions 
including their number, distance from incisors and classification using the Paris classification, and 
the location and number of biopsies taken22. Biopsies should initially be targeted to visible lesions 
within the Barrett’s segment before proceeding with four-quadrant biopsies every 2cm (the 
Seattle biopsy protocol)25. Histopathological findings, required to corroborate an endoscopic 
diagnosis of Barrett’s oesophagus differ between the UK and US guidelines: the BSG guidelines 
recognise any type of columnar mucosa (expected to be of cardiac, oxyntic or intestinal types), 
whereas the AGA guidelines restrict the definition to the intestinal type22, 23. The presence of 
native oesophageal structures such as oesophageal submucosal glands, while also supportive of a 
diagnosis, are not essential as they are present in a minority of samples26. Once a diagnosis of 
Barrett’s oesophagus has been established, further management will depend on estimated life 
expectancy, patient choice, Barrett’s length and the presence of dysplasia and/or 
adenocarcinoma. 
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Figure 1: Panel A – diagrammatic representation of the landmarks used to define the endoscopic extent of Barrett’s 
oesophagus using the Prague C and M criteria.  
Panel B – corresponding endoscopic image demonstrating the same extent of Barrett’s oesophagus. C (cm) refers to 
the circumferential extent and M (cm) refers to the maximal extent from the gastro-oesophageal junction (GOJ). In 
this example, the area would be defined as C2M5 (adapted from Sharma et al. 2006). 
 
 
1.1.3. Management 
1.1.3.1. Surveillance of non-dysplastic Barrett’s oesophagus 
The aim of endoscopic surveillance of patients with Barrett’s oesophagus is to aid the early 
detection of dysplastic or cancerous lesions, which are more readily amenable to curative 
treatment. The intended benefits of endoscopic surveillance need to be carefully balanced against 
the risk of complications, which are not insignificant: risk of perforation or death is 0.03% and 
0.001% respectively27. Large population-based cohort studies have demonstrated strong 
associations between enrolment in Barrett’s surveillance programs and improved outcomes for 
patients who progress to OAC, in terms of reduced mortality, earlier cancer stage at presentation 
and reduced need for oesophagectomy28-30. However, despite correcting for both lead and length 
time bias, these observational studies are still potentially susceptible to selection bias: those with 
favourable characteristics, such as being younger, fitter, and more motivated, or judged by their 
treating clinician as having a good prognosis, would seem most likely to be selected, agree and 
adhere to surveillance, (compared to prevalent cases of OAC or those with known prior barrett’s 
who did not receive surveillance) thus confounding associations in favour of improved patient 
outcomes. Recent studies of cost-effectiveness of surveillance that consider contemporary 
estimates of malignant progression are conflicting31, 32. Results are awaited of a multi-centre 
randomised-controlled trial, the Barrett’s Oesophagus Surveillance Study (BOSS), which aims to 
definitively establish whether two-yearly endoscopic surveillance is superior to surveillance “at 
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need only” in terms of overall survival and cost-efficacy has completed recruitment and is the 
follow-up phase33. Despite the lack of current trial data, surveillance of Barrett’s oeosphagus is 
widely advocated by clinical practice guidelines and it is routinely conducted in the western 
world22, 23, 34, 35.   
 
The BSG guidelines advocate an algorithm for surveillance of non-dysplastic Barrett’s surveillance 
based on length of Barrett’s segment and the presence of intestinal metaplasia on histology: two 
factors which are consistently associated with malignant progression28, 36-38. If the length is less 
than 3cm and histology confirms gastric metaplasia, a repeat oesophagogastroduodenoscopy 
(OGD) with quadrantic biopsies is advocated22. If these findings are replicated the guidelines 
recommend considering discharging the patient from active follow-up. If the length is less than 
3cm but intestinal metaplasia is confirmed surveillance is recommended every 3-5 years. If the 
length is at least 3cm then repeat OGD is recommended every 2 to 3 years. 
 
1.1.3.2. Dysplasia and intramucosal cancer 
If dysplasia or malignancy is found within a Barrett’s segment either at diagnosis or during follow-
up, it is categorised using the revised Vienna classification for gastrointestinal mucosal neoplasia 
(see table 1, adapted from Schlemper et al.39) according to the degree of abnormal cellular 
architecture. 
 
Category 1 Negative for neoplasia/dysplasia 
Category 2 Indefinite for neoplasia/dysplasia 
Category 3 Non-invasive low grade dysplasia 
 (low grade adenoma/dysplasia) 
Category 4 Non-invasive high grade dysplasia 
  4.1 High grade adenoma/dysplasia 
  4.2 Non-invasive carcinoma (carcinoma in situ) 
  4.3 Suspicion of invasive carcinoma 
Category 5 Invasive neoplasia 
  5.1 Intramucosal carcinoma 
  5.2 Submucosal carcinoma or beyond 
Table 1: Vienna classification of gastrointestinal epithelial neoplasia (adapted from Schlemper et al. 2000). Non-invasive 
indicates absence of evident invasion. Intramucosal indicates invasion into the lamina propria or muscularis mucosae. 
 
In patients with indefinite dysplasia a repeat OGD in 6 months with antireflux medical therapy is 
advised. If no dysplasia is subsequently found, surveillance should follow the recommendations 
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described above for non-dysplastic Barrett’s oesophagus. In patients with low grade dysplasia, 
radiofrequency ablation (RFA) is now the new standard of care, following the results of 
Surveillance vs Radiofrequency Ablation (SURF) study40, 41. Radiofrequency energy is delivered 
endoscopically to Barrett’s segments with either a specially designed balloon (HALO360) device (to 
achieve circumferential ablation) or an articulated, cap-based electrode (HALP90) (to achieve focal 
ablation); with the aim of removing Barrett’s mucosa and reducing risk of neoplastic 
progression42. The SURF study was a European multi-centre, parallel group, open-label, 
randomized controlled trial of radiofrequency ablation (active arm) vs. endoscopic surveillance 
(control) in patients with Barrett’s oesophagus with low grade dysplasia41. The primary outcome 
was neoplastic progression to HGD/adenocarcinoma within three years of randomisation. 68 
patients were allocated to receive ablation (receiving focal and or circumferential ablation for a 
maximum of 5 sessions) and 68 received surveillance only. One patient (1.5%) in the ablation 
group developed the primary outcome vs. 18 (26.5%) in the control group (risk difference 25% 
(95% CI 14.1-35.9), p <0.001). In the ablation arm 12% developed oesophageal stricturing 
requiring endoscopic dilation and there were no adverse events in the control arm. Other adverse 
events previously reported in the literature are mucosal laceration, bleeding and fever43. 
Following ablation, patients are offered high dose proton pump inhibitors (PPIs) to promote 
mucosal healing and growth of new squamous (neosquamous) epithelium44. 
 
High grade dysplasia or early tumours confined to the mucosa (T1a lesions – see table 4, adapted 
from Edge et al.45), were historically treated with radical surgery (oesophagectomy)46. However, 
endoscopic therapy has emerged as the new standard of care, sparing the need for major surgery 
with its associated adverse impact on quality of life, morbidity and mortality. Current BSG 
guidelines advocate expert high resolution endoscopy in all patients with high grade 
dysplasia/suspected intramucosal adenocarcinoma to detect visible abnormalities suitable for 
endoscopic mucosal resection (EMR)22. There exist two methods for endoscopic resection: band 
ligation and the cap and snare technique. Bland ligation involves suction of the target mucosa into 
a cap fixed at the distal end of the endoscope and a rubber band is deployed to create a 
pseudopolyp which is subsequently resected with a snare47. The cap and snare technique involves 
injecting the submucosal space to initially lift the target lesion before its suction into the cap and 
subsequent resection using a preloaded snare22. In addition to the removal of dysplastic Barrett’s 
tissue or intramucosal cancer, EMR has emerged as a valuable staging modality to guide further 
management: by permitting histological assessment of the whole lesion, crucially mapping its 
lateral extent and depth44.  Adequately resected areas of high grade dysplasia or T1a lesions 
confined to the mucosa should be offered RFA to ablate remaining Barrett’s mucosa: 
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metachronous lesions within the Barrett’s segment are common (20%) and observational 
evidence demonstrate patients receiving RFA (vs. no RFA) after EMR have reduced risk of 
recurrence22, 48. A recent European multi-centre observational study (EURO-II) of 107 patients 
with HGD (29%) and T1a cancers (71%) demonstrated patients receiving focal EMR followed by 
RFA, achieved approximately 90% recurrence free survival by 48 months after the first negative 
endoscopy following primary treatment43. In contrast, in patients with T1b lesions (those invading 
the submucosa – see table 4, adapted from Edge et al.45), EMR should be considered non-curative 
and patients should be offered oesophagectomy if they are surgical candidates22. This 
recommendation is born of the observation that lymph node metastases are common with T1b 
lesions (up to 44%), and rare with T1a lesions49-51.  If inspection reveals a flat lining with no visible 
lesions amenable to endoscopic resection, RFA alone is recommended. 
1.1.4. Descriptive epidemiology 
Oesophageal carcinoma: global perspective 
Worldwide, oesophageal carcinoma is the sixth leading cause of cancer-related mortality and the 
ninth most common malignancy52. In 2012, the number of new cases of oesophageal cancer 
approximated the number of attributable deaths: 455 800 and 400 200 respectively53. The bulk of 
disease burden, and hence mortality, rests in developing countries, where it is ranked eighth for 
cancer incidence and fifth for cancer-related mortality; compared to developed countries where it 
is ranked 20th for cancer incidence and 11th for mortality52 (see figures 2 and 3, adapted from 
GLOBOCAN 201254).  In developing verses developed countries, overall the age-standardised 
incidence rates (ASIRs) (per 100 000) are 8.94 vs 3.90, and age-standardised death rates (ASDRs) 
(per 100 000) are 9.11 vs 3.7. The incidence rates for men and women are highest in East Asia, 
sub-Saharan Africa and central Asia; and they are lowest in Andean Latin America, eastern and 
central Europe (particularly in women), North Africa and the Middle East (particularly in men). 
Worldwide in 2013, oesophageal cancer accounted for 9.8 million disability adjusted life years. 
Globally, for men and women, oesophageal carcinoma accounts for the 6th highest cancer-related 
cause of years of life lost, following breast, colorectal, stomach, liver and lung cancer.   
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Figure 2: Geographic representation of the age-standardised incidence rates (per 100 000) for oesophageal carcinoma 
in men and women in 2012. Adapted from GLOBOCAN 2012, International agency for Research on Cancer. 
 
 
Figure 3: Geographic representation of the age-standardised mortality rates (per 100 000) for oesophageal carcinoma 
in men and women in 2012. Adapted from GLOBOCAN 2012, International agency for Research on Cancer. 
 
The global variation in incidence rates of oesophageal carcinoma is more than 21-fold53, and is 
best understood in the context of the two main histological subtypes: OAC and squamous cell 
carcinoma (OSCC) (although there are others including small-cell carcinoma, leiomyosarcoma and 
melanoma). In 2012, of the estimated 455 800 with oesophageal carcinoma, 398 000 were OSCC, 
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the globally predominant histological subtype, particularly in developing countries, 52 000 were 
OAC, predominant in western populations, and 6000 were other carcinomas (see figures 4 and 5 
which demonstrate the global distribution in oesophageal cancer according to the two main 
histological subtypes, adapted from Arnold et al.55). The highest incidence rates of OSCC are found 
in the “oesophageal cancer belt” from Northern Iran to North-Central China and runs through the 
Central Asian republics, where 90% are OSCC. The major risk factors for OSCC are smoking 
tobacco and alcohol excess; other relevant risk factors are mutations of enzymes involved in the 
metabolism of alcohol, achalasia, caustic injury, thoracic radiation, low socioeconomic status, 
poor oral hygiene, certain nutritional deficiencies and non-epidermolytic palmoplantar 
keratoderma56.  In contrast, OAC is increasingly predominant in developed Western populations, 
where OSCC has been observed to be in decline.  
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Figure 4: Geographic representation of the age-standardised incidence rates (per 100 000) for oesophageal 
adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC) in men 2012. Adapted from Arnold et al. 
(2014). 
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Figure 5: Geographic representation of the age-standardised incidence rates (per 100 000) for oesophageal 
adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC) in wonen 2012. Adapted from Arnold et al. 
(2014). 
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Oesophageal carcinoma: United Kingdom perspective 
In the United Kingdom (UK) in 2013, the number of new cases of oesophageal carcinoma was 8 
784, and in the preceding year, the number of attributable deaths was 7 70157. In England and 
Wales, survival rates are among the poorest of all malignancies, similar to lung and pancreatic, 
with overall 5-year survival rates in 2011 estimated at 15.1%58. Of the two main histological 
subtypes of oesophageal malignancy, adenocarcinoma is predominant, accounting for 
approximately two thirds of cases55. The incidence of OAC has risen rapidly since the early 1970s 
such that currently the age-standardised incidence of this subtype is higher in the UK than 
anywhere else in world4. Risk of oesophageal cancer increases with age and the main burden of 
disease rests with older populations: nearly 60% of patients are diagnosed from 70 years of age in 
the UK59. In an analysis of UK cancer registries, in men the age-standardised rates per 100 
000/year are estimated to be 77 in 70-74 year olds, 87 in 75-79 year olds and 111 in 80-84 year 
olds59. 
 
Oesophageal adenocarcinoma epidemic 
A dramatic rise in incidence of OAC, described as an epidemic, has been noted over the last four 
decades, such that it has overtaken OSCC in incidence in western populations, particularly the UK, 
US and western European countries60-62. The largest population-based study to date conducted 
using cancer registries in Europe, the US and Australia, involving 117 946 patients with OAC, 
comprehensively examined its changing incidence4. The majority of patients (99%) were over 40 
years of age at diagnosis, and were male (87.7%). The time from which the incidence began to 
rapidly rise varied by country, from 1976 in Denmark to 1991 in Sweden. The rising incidence 
appeared to have already begun in England by 1971, the earliest point from which the English 
cancer registry data were available. The changing incidence appeared to follow one of two 
calendar period patterns: 1) a stable phase with incidence of 1 case per 100 000 person-years, 
then following an inflection point, an increment of 1-2 cases per 100 000 person-years per decade 
(observed in New Mexico, San Francisco, Hawaii, Denmark, Sweden and Finland); and 2) a 
continuous increase throughout the period of observation (through to 2009 at the latest) of 
approximately 2-3 cases per 100, 000 person years per decade (observed in England, Scotland, the 
US and Australia) (see figure 6, adapted from Edgren et al.4). The second pattern was observed in 
countries where presumably the inflection point had already occurred prior to the period of 
observation captured by the registries. Extrapolating the incidence curves seen in the second 
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pattern of incidence to the point where they would intersect the presumed baseline rate 
observed in the first pattern indicated the earliest estimated inflection point to be 1960 in 
Scotland and England, and early or mid-1970s in the US. The change in incidence appeared best 
explained by a calendar period effect rather than by birth cohort. Furthermore, across all 
registries examined, there was no clear evidence of an abating trend in incidence. While the 
incidence of OAC in women was lower than men in absolute terms, the proportional increase was 
the same overall. Therefore as expected the sex ratio appeared stable over this time and overall 
the incidence was three to nine fold higher in men, with considerable variation by country. The 
current incidence of OAC in England is 12 per 100 000.  
 
Figure 6: Age-standardised incidence of oesophageal adenocarcinoma per 100 000 by calendar period in A) Men and 
B) Women in England and Scotland. Note the scales differ between men and women. Adapted from Edgren 2013. 
Statins and oesophageal adenocarcinoma 
30 
1.1.5. Pathogenesis 
Genetic pathogenesis of oesophageal adenocarcinoma 
Two genomes which can contribute to the development of cancer are the somatic (evolution to 
cancer within nuclei of cells of organs and tissues of the body) and inherited (constitutive 
genomes propagated in the germline)63.  
Somatic genome 
The clonal evolution model of neoplastic progression describes the accumulation of genetic 
abnormalities in initially normal progenitor cell populations which provide a Darwinian selection 
advantage for aberrant clonal populations, which ultimately give rise to invasive malignancy64. 
Linear models propose this occurs in an ordered, stepwise fashion and this would appear to be 
the case for mutations in tumours which develop gradually, such as the evolution of colorectal 
tumours65. However, there is evidence that aberrant somatic genome evolution can arise in a 
branched manner in some solid tumours, including OAC, a process which can occur rapidly66-68. 
Development of an early branch within Barrett’s epithelial cell populations may give rise to a 
stable state, resulting in non-progression as seen in the majority of patients, while for the 
minority, rapid branching and selection pressures could lead to neoplastic progression, and hence 
invasive malignancy63. The threshold for the required somatic genome alterations which herald 
malignancy in Barrett’s may be reached at very different rates: gradual, slow accumulation of 
abnormalities may be seen in those who do not progress; while those exposed to a relevant 
environmental factor or mutational event, may undergo accelerated accumulation and reach this 
threshold sooner. In contrast, even more rapid, “punctuated”, somatic genome alterations can 
arise, whereby an environmental factor or mutational event leads to chromosome instability 
(either an increased rate of loss or gain of whole chromosomes or large regions of 
chromosomes)63. Some genomic alterations involving chromosomes are yet more dramatic and 
can arise from a single cell division – such as chromothripsis (chromosome shattering due to 
errors in chromosome segregation during mitosis) and whole genome doubling69.   
 
OAC typically has very high mutational frequencies, with median 26, 161 (IQR 18, 881 – 66, 225) 
single nucleotide variants (SNVs) per tumour70. The only tumours which exceed this frequency are 
melanoma, and lung cancer, malignancies with a well-defined mutagen71, 72. Barrett’s oesophagus 
is surprisingly also highly mutated with 12, 714 (IQR 6, 604 - 21, 559) SNVs, with mutation rates at 
least double that of multiple myeloma, breast cancer, hepatocellular carcinoma and colorectal 
adenocarcinoma68, 73-76. Owed to its branched evolution, OAC demonstrates marked 
heterogeneity in the spectrum of mutations observed between tumours from different patients 
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but also between paired (adjacent) OAC and Barrett’s oesophagus samples (<20% SNV overlap)68. 
Despite the high mutational frequency observed in OAC, only a few number of genes are 
recurrently mutated (summarised in table 2), the majority of which are loss of function mutations 
to tumour suppressors, whereas no clear oncogenic mutations linked to progression of OAC have 
been identified69, 70, 77. The most commonly mutated gene, tumour suppressor p53, was observed 
in approximately 70% of samples, high enough to have implications for future strategies for early 
detection and prevention. This is in contrast to other mutations identified at much lower 
frequencies thus limiting their future utility, for example, the next most frequently occurring 
mutations,  SMAD4, MYO18B and CDKN2A, were individually observed in only 12% of OAC 
samples70, 77. Indeed similar mutational frequencies of a panel of 26 genes mutated above 
background rate or in pathways of interest (derived from whole-genome sequencing data from 
OAC) were observed between samples from non-dysplastic Barrett’s oesophagus (from 40 
patients whom did not progress during follow-up (over a median of 58 months, range 4-132 
months), 39 patients with HGD and 90 with OAC. Recurrent (≥1) mutations in these genes were 
identified from Barrett’s tissue in 21 (53%) patients with non-dysplastic Barrett’s oesophagus. The 
only mutations which defined disease boundaries between non-dysplastic Barrett’s oesophagus 
and HGD, and between HGD and OAC were, respectively, p53 and SMAD477. A mutational 
signature has been identified, characterised by adenine to cytosine (A>C) transversions (base 
substitutions) at adenine-adenine (AA) sites, accounting for 29% of the total mutations observed 
in OAC70. This would appear to be unique to OAC and has not been identified in other tumour 
types to date. This signature has been found in SNVs which occur both early and late in the 
neoplastic progression of Barrett’s oesophagus68. 
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Mutated 
gene Proportion Gene function 
TP5370, 77 70% Tumour suppressor gene. Plays multiple roles, including regulating cell 
cycle progression, apoptosis, DNA repair, autophagy, differentiation and 
senescence77, 78. Mutation accurately defines boundary between non-
dysplastic Barrett’s oesophagus and Barrett’s with HGD77. 
SMAD477 12% Tumour suppressor gene79. Mutation results in loss of function. Key 
mediator of transforming growth factor beta (TGF-β) signal transduction 
(tumour suppressor pathway). Forms trimer with two R-SMAD 
molecules to form SMAD4-R-SMAD complexes which bind other DNA 
binding transcription factors as partners for transcriptional regulation. 
Mutation accurately defines boundary between Barrett’s with HGD and 
early invasive OAC77. 
MYO18B77 12% Tumour suppressor gene80. Encodes myosin XVIIIB which regulates 
muscle-specific genes when in the nucleus and may influence 
intracellular trafficking when in the cytoplasm. 
SEMA5A77 8% Encodes Semaphorin 5A, a transmembrane bound Semaphorin, a 
member of a family of axonal growth molecules involved in 
development of vascular, skeletal, cardiac systems and immune 
response81. Involved in tumour formation, chemotaxis, cell viability, 
angiogenesis and metastases. 
SWI/SNF 
chromatin 
modelling 
complex70 
20% ARID1A (8%), SMARCA4 (6%), ARID2 (5%), PBRM1 (3%) and JARID2 
(3%)70. All loss of function. Evolutionary conserved, consume ATP to 
mobilise and eject nucleosomes to modulate chromatin compaction82.  
PIK3CA70 6% Gain of function. Encodes the p110ɑ catalytic subunit of 
Phosphatidylinositide 3-kinases (PI3K). PI3K are a ubiquitous family of 
lipid kinases which mediate a number of downstream targets which 
regulate cell proliferation, migration and survival and oncogenic 
transformation83. 
CDKN2A70 12% Also called P16/INK4ɑ/MTS1. Loss of function. Encodes p16 which 
regulates progression through G1/S of the cell cycle84. 
ELMO1 & 
DOCK270 
17% Encodes dimerization partners and intracellular mediators of the Rho 
family GTPase, RAC185. In cancer models, mutated ELMO1 and other 
DOCK family members mediate enhanced migration and invasion86. 
ELMO1 mutation suggested gain of function phenotype and enhances 
invasiveness70. 
KRAS70 3% Gain of function. Mutated RAS leads to constitutively activated 
Raf/MEK/ERK (MAP Kinase signal transduction pathways)87. 
ABCB177 6% Also known as the MDR1 gene. Encodes P-glycoprotein, a cell efflux 
transporter, one of many ubiquitous adenosine triphosphate (ATP)-
binding cassette (ABC) pumps88. 
Table 2: Proportion and function of recurrent mutated genes in oesophageal adenocarcinoma. 
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Chromosomal changes which appear to have an important role in the progression of Barrett’s 
oesophagus to OAC include copy-number changes (aneuploidy), and focal gains and losses68, 89. 
Chromothripsis has been observed in a third of OACs, a much higher frequency than in other 
malignancies (2-5%)69. These events may lead to the formation of double-minute chromosomes: 
extrachromosomal DNA, composed of chromatin which replicates within the cell nucleus, which 
harbour oncogenes, such as MYC and MDM2 (a known inhibitor of p53)69, 90. Further large-scale 
chromosomal rearrangements have also been observed in OAC which can result from breakage-
bridge-fusion cycles69. These are initiated by telomere loss, then followed by fusion of 
unprotected chromosomal ends or sister chromatids and lead to duplications and dramatic copy-
number increases69. Regions amplified by such events can harbour oncogenes (including RCF3, 
MDM2, VEGFA, BCAT1 and KRAS) and provide a selective growth advantage for cancer cells. 
  
Inherited genome 
Array heritability analysis of genome-wide association studies (GWAS) indicate that 24% of OACs, 
and 35% of Barrett’s oesophagus cases are inherited, with a high genetic correlation and 
significant polygenic overlap91, 92. GWAS have identified eight loci within the constitutive genome 
within or near CRTC1, FOXP1, BARX1, ALDH1A2, MHC, FOXF1, GDF7 and TBX5 associated with the 
development of Barrett’s oesophagus and/or OAC93-95. The largest meta-analysis of GWAS in OAC 
and Barrett’s oesophagus to date, respectively including 4112 and 6167 individuals, with 17159 
representative controls, identified nine risk loci, in addition to the eight previously identified, for 
one or other or both these diseases96. This study implicated these previously identified loci with 
both diseases. These new loci were within or near the following genes: CFTR, MSRA, LINC00208 
and BLK, KHDRBS2, TPPP and CEP72, TMOD1, SATB2, HTR3C and ABCC5, and LPA. Pathway 
analysis to investigate potential causal genetic pathways implicated these genes in the 
involvement in negative regulation of muscle-cell differentiation, mesenchyme development, and 
mesenchyme cell differentiation and proliferation96. This finding is of particular interest as hiatal 
hernia and defective relaxation of the lower oesophageal sphincter permit gastro-oesophageal 
reflux; and therefore the harsh environment in which Barrett’s oesophagus and OAC develop. 
Furthermore, the most strongly associated new variant associated with both OAC and Barrett’s 
oesophagus was located within the cystic fibrosis transmembrane conductance regulator (CFTR), 
the chloride channel mutated in cystic fibrosis97. This could plausibly have functional relevance as 
reflux is very common in patients with cystic fibrosis (up to 80%)98. This study identified the first 
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risk locus associated with OAC, independent of Barrett’s oesophagus, rs9823696, located near 
HTR3C and ABCC5 (which plays a role in embryonal development of the gastrointestinal tract)99.  
 
Environmental contribution to malignant progression 
The high mutation rate, variable mutation spectra and mutational signature characterised by A>C 
transversions observed in OAC suggest a causal effect of mutagens in carcinogenesis, potentially 
attributable to oxidative stress mediated by the harsh mutagenic environment created by gastric 
and bile refluxate and resulting inflammation70.  
 
 
1.1.6. Clinical presentation 
Endoscopic surveillance of patients with BO detects only 8% of the total number of cases of 
OAC30. Diagnosis of oesophageal malignancy depends mainly on presentation with symptoms to 
primary care prior to rapid onward referral to secondary care for diagnostic gastroscopy100. The 
most common symptoms are dysphagia and weight loss, and other less common presenting 
symptoms are odynophagia (pain when swallowing), haematemesis (vomiting blood), epigastric 
pain, reflux, haemoptysis (coughing up blood), cough, or symptoms clearly relating to metastatic 
disease, such as hoarseness (indicating involvement of the left recurrent laryngeal nerve), 
abdominal swelling secondary to malignant ascites or lymphadenopathy101, 102. However, there is 
considerable symptomatology overlap between malignant and benign disease. The challenge for 
general practitioners (GPs) is therefore judging when and when not to suspect oesophageal or 
gastric malignancy and hence refer patients for urgent gastroscopy. Risk of undiagnosed 
oesophageal malignancy varies considerably according to presenting symptoms. In a nested case-
control analysis of the General Practice Research Database (GPRD) of patients of at least 40 years 
of age which included 7471 cases of oesophago-gastric malignancy (a selected composite 
endpoint given endoscopy is the diagnostic tool of choice for both) and 32877 controls matched 
by year of birth, gender and practice, quantified the risk of case status and positive predictive 
value according to recorded symptoms in the year prior to the index date103. The strongest risk 
factors were dysphagia (OR 139, 95% CI 112-173), weight loss (OR 8.9, 95% CI 7.1-11.2) and 
epigastric pain (OR 8.8, 95% CI 7.0-11). Unsurprisingly, dysphagia was a dramatically stronger risk 
factor for oesophageal (OR 230, 95% CI 180-300) than gastric cancer (OR 20, 95% CI 14-29) when 
analysed separately, while there were no substantial differences in effect sizes for the other listed 
predictors. The sensitivity of individual symptoms in predicting diagnosis of oesophago-gastric 
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malignancy is low. For example, even for two “red flag” symptoms, dysphagia and weight loss, the 
respective sensitivities are 32% and 8%104. Therefore in primary care, an approach that relied on a 
single symptom, such as dysphagia, to determine the need for urgent diagnostic gastroscopy 
would therefore miss 68% of diagnoses. Current referral pathway recommendations from the 
National Institute of Clinical Excellence (NICE) advise urgent (within two weeks) direct access for 
gastroscopy to assess for oesophageal cancer in people with dysphagia or if aged 55 years and 
over with weight loss and any of: upper abdominal pain, reflux or dyspepsia105. Non-urgent direct 
access gastroscopy is advised in patients over 55 years with at least one of the following: 
treatment resistant dyspepsia; upper abdominal pain with anaemia; raised platelet count with any 
of nausea, vomiting, weight loss, reflux, dyspepsia or upper abdominal pain; or nausea or 
vomiting with at least one of: weight loss, reflux, dyspepsia or abdominal pain. However, the 
studies on which these symptoms are based were mainly conducted in secondary care106, 107, and 
are likely to suffer selection bias and be less relevant to patient population who present to 
primary care, the main point of referral. Furthermore, validation of these recommendations 
(particularly the two week wait referral guidelines in oesophago-gastric cancer) with measures of 
discrimination, calibration and performance are yet to be established. Patients with oesophago-
gastric cancer with classical “red flag” symptoms, compared to those without, have more 
advanced cancer staging (47% vs. 11% International Union Against Cancer stage IV, p < 0.001), are 
less likely to undergo potentially curative surgical resection (50% vs. 95%, p < 0.001) and have 
poorer five-year survival rates (13% vs 42%, p = 0.005)108. Therefore reliance on such “red flag” 
symptoms to guide urgent referral for diagnostic gastroscopy selects out patients who are most 
likely to benefit from rapid diagnosis.  
 
Symptom-based algorithms derived from large UK primary care datasets seem a rational method 
for determining future guidance on which urgent referral pathways should be based. An algorithm 
to estimate the absolute risk of the gastro-oesophageal malignancy in primary care from the 
presence or absence of a number of clinical characteristics has been derived and validated using a 
large UK primary care database, QRESEARCH. The final variables selected for the model were: 
smoking status (non-smoker, ex-smoker, current light, moderate or heavy), dysphagia, abdominal 
pain, appetite loss, haematemesis, weight loss and anaemia (Haemoglobin < 11g/dl in the last 
year) (see table 3). The receiver operating curve statistics were 0.89 for females and 0.92 for 
males. This algorithm together with another risk assessment tool103 has been incorporated into an 
electronic clinical decision support tool, which is integrated into some GP computer systems to 
systematically identify those at the highest risk to facilitate early investigation. Its 
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implementation, effectiveness in impacting cancer-related outcomes and cost-effectiveness is the 
subject of an ongoing two-arm, multi-centre, cluster-randomised, controlled phase II trial109.  
 
Table 3: adjusted hazard ratios, sensitivity, specificity, positive and negative predictive values for diagnosis of 
oesophago-gastric cancer according to documented symptoms and anaemia preceding diagnosis. Adapted from 
Hippisley-Cox and Coupland, 2011. 
Abbreviations: CI, confidence interval; Hb, haemoglobin; NPV, negative predictive value; PPV, positive predictive value. 
Dysphagia 131 (97.5-175.0) 143 (108-189) 32.3 99.5 7.8 99.9
Abdominal pain 4.74 (3.54-6.33) 3.78 (3.32-4.30) 7.5 99.5 2.3 99.9
Appetite loss 10.0 (5.28-19.0) 3.87 (2.82-5.32) 23 90.5 0.3 99.9
Haematemesis 25.2 (14.4-44.2) 7.62 (6.08-9.55) 2.6 99.7 1.1 99.9
Weight loss 3.97 (3.06-5.16) 5.64 (4.67-6.81) 8 99.1 1.2 99.9
Hb < 11g/dl in last year 2.32 (1.84-2.93) 1.79 (1.44-2.23) 8.9 98.9 1.1 99.9
Current symptoms and anaemia
Adjusted hazard ratio 
in women (95% CI)
Adjusted hazard ratio 
in men (95% CI) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
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1.1.7. Management 
The most recent National Oesophago-Gastric Cancer Audit indicates that 40% of patients with 
oesophageal cancer are treated with curative intent, while 60% are managed on a palliative 
pathway110. The mainstay of curative treatment for invasive oesophageal malignancy is 
oesophagectomy (oesophageal resection and reconstruction) with or without 
chemotherapy/chemoradiotherapy111. However, even in patients treated with curative intent, 
outcomes are still frequently poor: 57% develop recurrent cancer within 5 years of surgery112, and 
at best, five-year survival is 45%113, 114. Of those patients with oesophageal carcinoma (including 
both adenocarcinoma and squamous cell carcinoma) who died following discharge after surgery 
in this trial, 85% were attributable to recurrent disease. Consistent with this, from observational 
data, 57% of patients with OAC treated with curative intent develop recurrence within five years 
of surgery112. The focus of management of patients on a palliative pathway is aimed at symptom 
control, improving survival and quality of life with palliative chemotherapy or radiotherapy, and 
endoscopic stenting to improve swallowing difficulties110.  
 
Staging 
Accurate cancer staging is critical to determining management of patients with oesophageal 
cancer. Staging initially includes clinical examination, gastroscopy and computed tomography (CT) 
of the chest, abdomen and pelvis115. The focus of initial staging is to establish the presence of 
obvious metastatic disease111. Further staging modalities, such as positron-emission (PET) CT, 
endoscopic ultrasound (EUS), endoscopic mucosal resection (ER) or laparoscopy are employed to 
determine precise local staging if potentially curative treatments are being considered111, 115. For 
example, it is important to determine the depth of tumour invasion if endoscopic treatment 
modalities are being considered, or to determine the presence of peritoneal metastases in locally 
advanced tumours of the gastro-oesophageal junction for surgical candidates. Clinical guidelines 
advocate the use of the current staging system, the 7th edition of the American Joint Committee 
on Cancer (AJCC)/Union for International Cancer Control (UICC) Cancer staging manual45. Unlike 
the 6th edition, the 7th edition was data driven: all-cause mortality for 4627 patients with cancer of 
the oesophagus or gastro-oesophageal junction who underwent oesophagectomy without pre-
operative chemo/radiotherapy from 13 centres across three continents (North America, Europe, 
Asia) were analysed using random forest methodology to derive stage groupings for which 
survival was monotonically decreasing, distinctive and homogenous116. By convention, stage 0 and 
IV were pre-determined, and respectively refer to tumour in situ (high grade dysplasia) and 
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distant metastatic disease, leaving stage I to III and their sub-categories to be derived. The stage 
groupings are determined from a combination of the extent of the cancer using the tumour, nodal 
and metastases (TNM) classification, the cancer grade and location (see table 4 and 5). 
 
TNM staging Description 
Primary tumour (T)   
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ/High-grade dysplasia 
T1 Tumour invades lamina propria, or submucosa 
T1a Tumour invades mucosa or lamina propria or 
  muscularis mucosae 
T1b Tumour invades sub-mucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
T4a Tumour invades pleura, pericardium, 
  diaphragm or adjacent peritoneum 
T4b Tumour invades other adjacent structures 
  such as aorta, vertebral body or treachea 
Regional lymph nodes (N)   
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1–2 regional lymph nodes 
N2 Metastasis in 3–6 regional lymph nodes 
N3 Metastasis in 7 or more regional lymph nodes 
Distant metastasis (M)   
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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  Adenocarcinoma   Squamous cell carcinoma 
Stage  T N M Grade   T N M Grade Location 
0 is 0 0 1   is 0 0 1 Any 
IA 1 0 0 0-1   1 0 0 1 Any 
IB 1 0 0 3   1 0 0 2-3 Any 
  2 0 0 1-2   2-3 0 0 1 Lower 
IIA 2 0 0 3   2-3 0 0 1 
Upper, 
middle 
            2-3 0 0 2-3 Lower 
IIB 3 0 0 Any   2-3 0 0 2-3 
Upper, 
middle 
  1-2 1 0 Any   1-2 1 0 Any Any 
IIIA 1-2 2 0 Any   1-2 2 0 Any Any 
  3 1 0 Any   3 1 0 Any Any 
  4a 0 0 Any   4a 0 0 Any Any 
IIIB 3 2 0 Any   3 2 0 Any Any 
IIIC 4a 1-2 0 Any   4a 1-2 0 Any Any 
  4b Any 0 Any   4b Any 0 Any Any 
  Any 3 0 Any   Any 3 0 Any Any 
IV Any Any 1 Any   Any Any 1 Any Any 
Abbreviations: M, metastases; N, nodal involvement; T, tumour stage       
Location definitions (distance from incisors): upper thoracic, 20-25cm; middle thoracic 25-30cm; lower 
thoracic 30-40cm 
  
 
Statins and oesophageal adenocarcinoma 
40 
Prognosis 
The overall prognosis of oesophageal malignancy is very poor: survival rates are among the worst 
of all malignancies, similar to lung and pancreatic, with overall 5-year survival rates in England in 
2011 estimated at 15.1%5. One of the main driving contributors is advanced disease at 
presentation: approximately 70% of patients present with non-localised disease (either regional 
[spread to regional lymph nodes] or distal [metastatic disease])5.  Even in patients suitable for 
potentially curative surgery, outcomes are often poor: in those with the earliest tumour stage 
with regional nodal involvement without metastatic disease (stage IIB), 5 year survival rates are 
40% for both OAC and OSCC (see table 4)116.  
 
Prognostic risk factors 
The known prognostic factors for OAC can be divided into demographic, clinico-pathological and 
molecular risk factors. The clinico-pathological factors TNM staging and grade are established 
prognostic variables which inform the 7th edition of the American Joint Committee on Cancer 
(AJCC) Cancer staging manual. In patients undergoing surgery for OAC, response to neo-adjuvant 
chemotherapy determined by tumour downstaging (defined by reduction in T or N stage of 
pathological staging [from the resected specimen] compared to clinical staging [initial staging] is 
independently associated with reduced recurrence (HR 0.49, 95% CI 0.35 – 0.68) and mortality 
(HR 0.50, 65% CI 0.35 – 0.71)114. Similarly, other markers of tumour response to neo-adjuvant 
chemotherapy, such as the Mandard Score (see figure 7117), independently predict survival118.  
Lymphovascular invasion and positive surgical resection margins determined by histological 
examination of the surgical specimen also independently predict recurrence and mortality114. 
Figure 7: Tumour regression grade (Mandard score).  
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A number of prognostic molecular markers for OAC have been identified through 
immunohistochemistry (IHC), whole-genome and whole-exome sequencing. The tumour-
suppressor gene tumour protein 53 (p53) is highly mutated in up to 70% with OAC, and plays 
multiple roles, including regulating cell cycle progression, apoptosis, DNA repair, autophagy, 
differentiation and senescence 77, 78. In a meta-analysis of 11 studies of 644 patients with OAC, 
mutated p53 was associated with higher all-cause mortality (pooled HR 1.46, 95% CI 1.17-1.83) 
independent of clinical stage119. In addition to P53, a recent meta-analysis has identified other 
candidate biomarkers consistently predictive of mortality in OAC: cyclooxygenase-2 (COX-2), CD3 
and CD8+ T cell infiltrate, and epidermal growth factor receptor (EGFR)120, 121. COX-2 is the rate-
limiting enzyme which catalyses arachidonic acid to potentially mitogenic prostaglandins which 
promote cell survival, cell proliferation and angiogenesis122. In an individual patient level meta-
analysis of eight RCTs, including 25 570 patients with 674 cancer-related deaths, (62 were due to 
oesophageal cancer), demonstrated that allocation to aspirin (a COX-2 inhibitor) significantly 
reduced cancer-specific mortality from OAC (pooled HR 0.36, 95% CI 0.21-0.63, p=0.0001); 
although the reduction in mortality very likely reflects a causal reduction in incidence rather than 
an isolated impact on mortality123, 124. COX-2 expression detected by IHC was associated with 
increased risk of all-cause mortality in three studies which included 382 patients (HR 2.47, 95% CI 
1.15-3.79)120. There is growing evidence the adaptive immune response influences solid tumour 
behaviour; and both CD3+ and CD8+ T cell tumour infiltration are associated with reduced 
mortality for gastric and colorectal cancers125, 126. A meta-analysis of two studies which included 
203 patients with OAC demonstrated that tumour CD3+ (HR 0.51, 95% CI 0.32-0.70) and CD8+ 
(pooled HR 0.55, 95% CI 0.32-0.70) T cells infiltration were independently associated with reduced 
risk of all-cause mortality120. The EGFR is a tyrosine kinase receptor which is overexpressed and/or 
amplified in a number of epithelial malignancies and its associated signalling transduction cascade 
mediates tumour cell proliferation, cell survival, adhesion and angiogenesis127. A meta-analysis of 
two studies including 642 patients with OAC demonstrated aberrant EGFR expression was 
associated with higher risk of all-cause mortality (HR 1.65, 95% CI 1.14-2.16)120. A number of other 
potential prognostic molecular markers for OAC have been identified that require validation, 
including the hepatocyte growth factor receptor (Met), tumour macrophage infiltration, FOXM1 
and its target gene PLK1, heat-shock protein and glucose regulated protein expression profiles, 
and insulin-like growth factor binding protein expression128-132. Although none of these 
biomarkers are currently in routine clinical use, there is clinical interest in their application to not 
only further prognosticate patients and allow improved risk stratification to guide treatment, but 
also they may represent novel therapeutic targets120.  
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The challenge for improving prognosis in patients is devising strategies to ensure patient 
presentation at the earliest stage of disease. Oesophago-gastric cancer awareness campaigns are 
operational in the UK, which seek to educate the public and encourage prompt presentation to 
primary care with the well characterised “alarm symptoms”. Nevertheless, public education, and 
symptom-based urgent referral guidelines or algorithms will not address the central driver of poor 
prognosis in this malignancy: early stage tumours do not typically cause the classical symptoms, 
which become apparent usually with advanced disease108, 111. Similarly to other epithelial, 
gastrointestinal malignancies, 25% with oesophageal cancer have three or more consultations 
with their general practitioner prior to referral to hospital for diagnosis133.  
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1.2. HMG-CoA reductase inhibitors 
Mounting preclinical and observational data indicate that 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) inhibitors, better known as statins, exert anti-neoplastic effects against a number of 
malignancies. The following outlines the history of statins, current indications, regulation of the 
mevalonate pathway, its relevance as a potential therapeutic cancer target, preclinical and 
pharmaco-epidemiological evidence relating statin use with disease incidence and mortality. 
1.2.1. History 
Interest in the isolation and development of potent compounds to lower serum cholesterol were 
stimulated by growing evidence for the association between hypercholesterolaemia and 
cardiovascular morbidity and related mortality134. The earliest and most compelling 
epidemiological evidence was from the Framingham Heart Study, a prospective population-based 
cohort conducted in Framingham, Massachusetts, initiated in 1948 of 5, 127 men and women 
aged 30-60 years, followed up for 10 years, which demonstrated the association between serum 
cholesterol and risk of incident coronary heart disease and death within three weeks of MI135.  
 
The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, better known as 
“statins”, were discovered in 1976 by Japanese Biochemist, Akira Endo, with the isolation of ML-
236B (mevastatin) from the fungus, Penicillium citrinum136, 137. Endo demonstrated this compound 
competitively inhibited HMG-CoA, the rate limiting step of the mevalonate pathway, without 
affecting other enzymes in the pathway136, 137. In the same year, a British group, Brown et al. 
independently isolated the same compound (they named it compactin) from Penicillium 
brevicompactum, and determined its molecular structure using a combination of spectroscopy, 
chemical and X-ray crystallography138. Subsequently, Endo demonstrated in a number of animal 
studies that mevastatin significantly and substantially reduced plasma cholesterol in rats, 
monkeys and dogs137, 139, 140. In the earliest human non-randomised clinical study, in 11 patients 
with heterozygous familial hypercholesterolaemia and combined hyperlipoproteinaemia, 
mevastatin administration for between 4-8 weeks led to a significant reduction in serum 
cholesterol (mean reduction 27% [range 11-37%])141. Further human clinical trials of mevastatin 
were initated, but subsequently terminated due to the development of lymphoma observed in 
dogs that received high doses of this drug134. In 1979, another HMG-CoA reductase inhibitor, 
mevinolin, later known as lovastatin, was isolated from Aspergillus terreus142. In animal studies 
this compound was found to be more potent in inhibiting HMG-CoA and reducing plasma 
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cholesterol143. Clinical trials demonstrated its favourable safety profile and tolerability and 
confirmed its efficacy in lowering cholesterol in healthy “normocholesterolaemic” volunteers, a 
finding later confirmed in patients with hypercholesterolaemia144, 145. In 1987 Lovastatin became 
the first statin to be approved by the US Food and Drug Administration146. This experience 
provided the stimulus for the development and marketing of the semi-synthetic statins 
(simvastatin and pravastatin) and synthetic statins (fluvastatin, rosuvastatin, atorvastatin and 
pitavastatin): derivative compounds with even greater potency134, 147.  
 
Since these statins have been approved for market use, their efficacy and safety profile have been 
examined extensively in numerous randomised controlled trials. The Cholesterol Treatment 
Trialist’s (CTT), an international collaboration of investigators which contribute data from large 
RCTs (with a target of at least 1000 participants per included trial, with at least 2 years’ follow-up 
and examine interventions to modify serum lipid levels for individual participant data meta-
analyses) have robustly confirmed the efficacy of statins against a number of cardiovascular 
endpoints both in patients at risk and not at risk of cardiovascular disease148-151. In their first meta-
analysis of 90, 056 participants in 14 randomised controlled trials, allocation to a statin (studies 
included either simvastatin, pravastatin, lovastatin, atorvastatin or fluvastatin as the intervention) 
was effective in the prevention of non-fatal MI, death attributable to coronary heart disease, first 
coronary revascularisation (both coronary artery bypass graft and percutaneous transluminal 
coronary angioplasty) and incident ischaemic stroke148. Studies included patients both at risk and 
not at risk of cardiovascular events. These findings were irrespective of baseline lipid profile and 
other relevant clinical characteristics. There was an approximate linear relationship between 
absolute reduction in low density lipoprotein (LDL) cholesterol and the proportional reduction in 
the event rate for major coronary and vascular events (defined as a composite outcome of 
myocardial infarction or coronary death, stroke, or coronary revascularisation). Significant effects 
on the risk of a major coronary events were apparent during the first year of treatment with 
statins, however effect sizes were even stronger with longer durations of use. In a meta-analysis 
of 39, 612 individuals from five trials, more intensive LDL cholesterol reduction with higher versus 
lower dose statin allocation resulted in significantly fewer major coronary events, coronary 
revascularisations and ischaemic strokes151. Even in patients at low risk of major vascular events 
(lower the 10% five year risk), a group previously not advocated to receive statins, proportional 
reduction in major vascular events was at least as strong compared with higher baseline risk 
groups with statin allocation149.   
Statins and oesophageal adenocarcinoma 
45 
The statins currently available for clinical use in the UK are simvastatin, atorvastatin, pravastatin, 
fluvastatin, and rosuvastatin152. The current licenced indications for statins are for primary 
hypercholesterolaemia, post-transplantation hyperlipidaemia (particularly pravastatin), 
homozygous and heterozygous familial hypercholesterolaemia and for the primary and secondary 
prevention of cardiovascular events152.  
 
1.2.2. The mevalonate pathway: function, cascade and regulation 
The mevalonate pathway is an essential metabolic pathway present in all eukaryotes and plays a 
central role in a number of cellular processes153, 154. Mevalonate is a precursor for a series of sterol 
and non-sterol isoprenoid groups which are incorporated into the end-products of the pathway: 
cholesterol (required for lipoprotein, steroid hormone, vitamin D and bile acid synthesis); haem A 
and ubiquinone (which participate in the electron transport chain); dolichyl-pyrophosphate 
(responsible for N-glycosylation of growth-factor receptors); geranylgeranyl pyrophosphate and 
farnesyl pyrophosphate (responsible for post-translational modification of a number of small 
guanosine triphosphatases [GTP-ases] which have essential roles in controlling signalling 
pathways responsible for proliferation, differentiation and carcinogenesis)155, 156. 
 
At the apex of the mevalonate pathway (figure 8, adapted from Goldstein & Brown and 
Konstantinopoulos153, 156), Acetyl Co-enzyme A (CoA) undergoes cleavage and condensation, 
catalysed by acetyl-CoA thiolase to acetoacetyl-CoA157. Subsequently this enzyme undergoes 
condensation with acetyl-CoA, catalysed by HMG-CoA synthase to HMG-CoA. HMG-CoA 
reductase, the rate-limiting step of the mevalonate pathway, reduces HMG-CoA to mevalonate. 
Subsequently mevalonate kinase, phosphomevalonate kinase then mevalonate pyrophosphate 
decarboxylase respectively convert mevalonate to mevalonate-5-phosphate, mevalonate-5-
pyrophosphate, then isopentenyl pyrophosphate (PP), the first in a series of isoprenoid 
intermediates produced by the pathway157. Isopentenyl-PP is then converted to geranylgeranyl-
PP, and subsequently farnesyl-PP by farnesyl-PP synthase. Farnesyl-PP can then either be 
converted into cholesterol, dolichyl-PP or geranylgeranyl-PP153, 156. 
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Figure 8: Mevalonate pathway: enzymatic cascade, end-products, functions and regulation.  
HMG-CoA reductase is the rate limiting step of the mevalonate pathway which is responsible 
for the production of sterol and non-sterol isoprenoids. Not all enzymes involved in the 
pathway are shown. Adapted from Goldstein & Brown 1990, and Konstantinopoulos 2007. 
Abbreviations: CoA, co-enzyme A; FT-ase, farnesyltransferase; GGT-ase, 
geranylgeranyltransferase; GTP-ases, guanosine triphosphatases; HMG-CoA, 3-hydroxy-3-
methylglutaryl-CoA;  LDL, low density lipoprotein; PP, pyrophosphate.  
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The mevalonate pathway is highly regulated through negative feedback of downstream sterol and 
non-sterol products. Cellular cholesterol is obtained through two sources: endogenous production 
via the mevalonate pathway and exogenous uptake from plasma of LDL cholesterol via the LDL 
receptor. The mevalonate pathway is regulated by intracellular cholesterol through negative 
feedback to inhibit transcription of HMG-CoA synthase, HMG-CoA reductase and the LDL 
receptor153. Non-sterol components also regulate the pathway through negative feedback, via 
post-transcriptional control of HMG-CoA reductase through modulating translation of its 
messenger RNA and by controlling the enzyme’s degradation153, 158. These feedback mechanisms 
are mediated the sterol regulatory element-binding protein (SREPB) family of transcription 
factors159. When sterol levels are high, the SREPBs are inactive and are localised to the 
endoplasmic reticulum (ER). In states of sterol depletion, SREBPs dissociate from the ER and 
translocate to the Golgi, where they are cleaved by site-1 and site-2 protease, before 
translocating to the nucleus where they bind sterol regulatory elements (SREs) of the promoters 
of their target mevalonate pathway genes, therefore restoring sterol and non-sterol 
components159, 160.  
1.2.3. Malignant modulation of the mevalonate pathway 
The hallmarks of cancer proposed by Hanahan and Weinberg in 2000 are sustained proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis and activating invasion and metastasis161. This list was subsequently 
updated in 2011 to also include cancer’s ability to evade immune destruction and reprogramming 
of energetic metabolism162. There are numerous examples of cellular mechanisms of malignant 
modulation of the mevalonate pathway to confer survival advantage159. Accumulating 
experimental data indicate that common recurrent mutations, including p53, can exert gain-of-
function properties to upregulate transcription of mevalonate pathway enzymes to provide 
unrestricted supply of mevalonate pathway products to permit the survival and proliferation of 
malignant cells159. This has been demonstrated in breast cancer previously, where such mutations 
enabled p53 to interact with nuclear SREBP2 in increase transcription of mevalonate pathway 
genes163. The modulation of the mevalonate pathway by certain p53 gain-of-function mutations 
underscores its potential as a viable therapeutic target, especially in the context that p53 
mutations are very common in OAC77. 
 
1.2.4. Anticancer mechanisms of statins 
The actions of statins which appear to be independent of their cholesterol-lowering properties, 
termed their pleiotropic effects, have been characterised in the setting of cardiovascular medicine 
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and include beneficial effects on endothelial function, limiting vascular inflammation, enhancing 
plaque stability, inhibiting platelet aggregation and promoting myocardial contractility164. Further 
compelling examples of the pleiotropic actions of statins are their disparate and well-documented 
non-cardiovascular effects as demonstrated from clinical trial evidence165, including: myopathy148, 
diabetes166, reduced risk of pancreatitis167 and contrast-induced nephropathy168. As the 
mevalonate pathway is such a ubiquitous metabolic cascade with multiple downstream products 
including sterol and non-sterol isoprenoids, it follows that competitive inhibition at its apex (of 
HMG CoA by statins) will exert multiple and a diverse number of actions, some of which are 
relevant to cancer biology. The following summarises the functional relevance of downstream 
products of the mevalonate pathway and how through their depletion, statins may plausibly exert 
anticancer effects. 
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Cholesterol 
Cholesterol is an essential structural component of cellular membranes. Proliferating cancer cells 
rapidly produce cell membranes and increased cholesterol synthesis contributes to this159. 
Patients with cancer have significantly lower serum LDL cholesterol than age and gender matched 
controls, a finding not entirely explained by poor nutritional status169; and may reflect peripheral 
absorption of extracellular cholesterol by cancer cells to meet demand. All statins undergo 
extensive first-pass extraction with relatively low systemic bioavailability, although there are 
differences between individual statins170. Inhibition of cholesterol production by statins, either 
predominantly in the liver and/or locally within tumour cells, could therefore inhibit tumour 
growth and metastases. Whether this is a causal mechanism which could reduce the incidence of 
cancer or improve cancer-related mortality is not clear. Low plasma LDL cholesterol has been 
associated with an increased risk of cancer at a population-level, however a mendelian 
randomisation study did not establish a causal association between genetically reduced LDL 
cholesterol levels (due to polymorphisms that are associated with lifelong reduced plasma LDL 
cholesterol) and risk of cancer171. Hypercholesterolaemia has been shown to be associated with 
reduced mortality from hepatocellular carcinoma at a population level (HR 0.50, 95% CI 0.37-
0.67)172, however this may be explained in part by reverse causation bias - patients with more 
advanced cancer may have lower cholesterol levels; and confounding by medication use - 
hypercholesterolaemic patients would be expected to be more likely to receive statins during 
follow-up. Cholesterol is also a precursor for downstream steroid hormones which are known to 
initiate and further the malignant progression of a number of tumours, including breast and 
prostate cancer173. Given the male predominance of Barrett’s oesophagus and OAC, and the 
expression of androgen receptors in OACs it has been proposed that testosterone may play a role 
in their aetiology174, 175. A meta-analysis of 11 trials demonstrated that allocation to a statin 
significantly lowered serum testosterone176. While observational data indicate the highest quintile 
of circulating free testosterone levels are strongly associated with risk of Barrett’s oesophagus in 
men (OR 5.36, 95% CI 2.21-13.03)175; to date there are no published data which examine the 
association between testosterone levels and risk of OAC and subsequent prognosis. Depletion of 
cholesterol with resultant reduced testosterone could operate as a causal mechanism in 
conferring chemopreventive and therapeutic effects in patients with BO and OAC respectively, 
however there is insufficient evidence to substantiate this hypothesis further. 
Geranylgeranyl pyrophosphate and farnesyl pyrophosphate 
Geranylgeranyl-PP and farnsesyl-PP are responsible for the post-translational modification of a 
number of members of the RAS superfamily of guanosine-triphosphate-bound proteins (GTPases); 
the overexpression or mutation of which is established in the aetiology and prognosis of many 
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solid tumours, including epithelial gastrointestinal malignancies, such as OAC70, 156. The RAS 
superfamily are a functionally diverse group of G proteins involved in many important biological 
processes. They are able to switch between biologically active (GTP-bound) and inactive 
(Guanosine diphosphate [GDP]-bound) conformations177. They include KRAS, NRAS, HRAS, RHOA, 
RHOC, RAC1/2, CDC1/2, RAB, ARL5, SARA1/2 and ARF6156. RAS proteins mediate transmembrane 
signal transduction: they activate the RAF/MEK/ERK pathway which mediates cell growth and cell 
cycle entry by phosphorylation of MAPK family of kinases, and the P13K/AKT pathway modulates 
cell survival, growth and metabolism. Common RAS mutations stabilise the proteins in a 
constitutively active GTP-bound conformation. RAS mutations have also been implicated in 
mediating resistance to chemotherapy agents such as cisplatin178. The RHO subfamily of GTPases 
play important roles in cytoskeleton organisation, cell adhesion and cell motility; and promote 
cell-cycle progression through G1 by regulating cyclin D1 and cyclin-dependent inhibitors. 
Consequently RHO GTPases are implicated in invasion and metastasis, and their overexpression is 
linked to poorer clinical outcomes.  
 
RAS GTPases contain a CAAX motif (c=cysteine, AA=aliphatic amino acid, X=any amino acid) to 
which hydrophobic FPP or GPP form covalent attachment (specifically with the cysteine 
residue)156. This process (termed “farnsesylation” or “lipidation”) creates a lipidated hydrophobic 
domain which localises and tethers RAS proteins to cell membranes permitting their proper 
function. Potent inhibition of the mevalonate pathway with statins depletes geranylgeranyl-PP 
and farnesyl-PP, preventing RAS localisation and limiting downstream effector pathways. The 
functional relevance of this mechanism has been demonstrated in OAC (discussed below in more 
detail)179.  
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1.2.5. Preclinical studies of the effects statins in OAC cell lines 
To date, the effects of a number of statins on cell viability, proliferation and apoptosis on four 
verified OAC cell lines, have been determined179-182. The functional relevance of downstream 
products of the mevalonate pathway and linked signalling cascades, which are of relevance to 
malignant proliferation, have also been demonstrated. 
 
In the OAC cell line, OE33, the effects of three statins – simvastatin, pravastatin, and lovastatin 
were examined on viable cell numbers, proliferation, apoptosis and respective relevant signalling 
pathways were elucidated179. All three statins produced a dose-dependent reduction in cell 
viability (cell numbers). Significant reductions for all three statins were observed at a 50 μM 
concentration when cultured in serum-free media, and at 10 μM concentration when cultured for 
24 hours in 10% fetal calf serum (FCS). There was no quantitative difference between the three 
statins. Separately, the same group demonstrated in FLO-1 cells (another validated OAC cell line) 
that rosuvastatin even at 0.1 μM concentrations have been shown to significantly reduce cell 
viability183. Reduced cell viability was explained by both decreased proliferation (78%, 67% and 
73% reduction respectively with simvastatin, pravastatin and lovastatin) and increased apoptosis 
(between 43-101%, using two different assays) with consistent increases in caspase-3 activity (by 
152-189%) and expression of the pro-apoptotic proteins, Bax and Bad (only pravastatin was used 
to demonstrate this)179. Statins did not affect expression of the anti-apoptotic protein Bcl-2. 
Through “adding back” intermediates of the mevalonate pathway, the investigators systematically 
demonstrated the functional relevance of the components of the mevalonate pathway and hence 
their subsequent depletion by statins. Treatment with mevalonate and farsenyl-pyrophosphate 
substantially attenuated, but did not completely abrogate the effect of statins. Geranyl-geranyl 
pyrophosphate did not alter the effects of simvastatin or pravastatin. This would suggest the 
predominant anti-prolferative/pro-apoptotic mechanism is mediated by farsenylation, rather than 
geranylgeranylation. This was further corroborated by reduced Ras activation in simvastatin 
treated cells, while inhibition of Ras activation was not observed using a specific inhibitor of 
geranylgeranylation. Implicated growth signalling pathways involved in proliferation and cell 
survival, protein kinase B (AKt) and extracellular signal regulated kinase (ERK) activity were 
modulated by simvastatin: pre-treatment with simvastatin before stimulation with 10% FCS 
reduced ERK and Akt activation. P38 MAP Kinase and JNK activity were not affects by statin pre-
treatment. Co-treatment with any of the three statins with either cisplatin or 5-fluorouracil did 
not significantly alter cell viability compared to statin-treated cells without these cytotoxic agents. 
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The same group showed Rosuvastatin caused pro-apoptotic effects in non-malignant BO cells183, 
however, the effects on normal squamous oesophageal mucosa were not determined 
In FLO-1 cells, the effects of simvastatin, atorvastatin and pravastatin were examined on cell 
viability, proliferation, apoptosis and expression of ICAM-1, an adhesion molecule involved in 
transendothelial tumour cell migration, and metastases180, 184-186. Cell viability was attenuated by 
simvastatin at 30 μM and 50 μM concentrations, with consistent reductions in proliferation, and 
increased apoptosis, all with dose-dependent effects. In contrast, treatment with atorvastatin or 
pravastatin did not affect viability, or apoptosis but did attenuate proliferation. All three statins 
significantly attenuated concentrations of cell-surface ICAM-1 expression. However, the 
functional relevance of this finding was not further examined. 
In OE-19 OAC cell lines, exposure to simvastatin reduced cell viability in a dose-dependent manner 
with 10 μM and 30 μM concentrations182. Cyclo-oxygenase-2 (COX-2) expression when stimulated 
by tumour necrosis factor alpha (TNFα) was inhibited by co-treatment with simvastatin at 10 μM. 
Simvastatin treatment increased Bax expression (at 10 μM) and reduced expression of Bcl-2, the 
latter in contrast to OE33 cells179. 
In SKGT-4 OAC cell lines, lovastatin at 4 μM concentrations significantly reduced cell viability and 
suppressed cell invasion (measured using matrigel coated chambers)181. Lovastatin 
downregulated ERK, c-jun and COX-2 expression, and upregulated caspase 3. Nude mouse 
xenografts (SKGT-4 cells treated with and without lovastatin for 3 days were injected into the 
right flank with 50% matrigel) were treated with and without lovastatin orally for 5 days per week 
for 30 days. The weight of xenograft tumours was non-significantly less in Lovastatin treated mice 
(n=5), compared to controls (n=5) assessed at 30 days. There was reduced expression of Ki67, 
phosphorylated ERK and COX-2 in xenograft explants as assessed by immunohistocytochemisty in 
the lovastatin treated mice compared with controls.  
While there is encouraging evidence that statins inhibit proliferation and stimulate apoptosis in 
cell lines, and elucidation of plausible candidate pathways has begun, it is not clear whether these 
findings are of clinical relevance to patients with BO (for the prevention of progression) or OAC to 
(improve cancer-related outcomes). It is difficult to take findings from in vitro studies of malignant 
cells and draw direct inferences about disease prevention. Similarly, in vitro studies cannot be 
expected to adequately mimic tumour cell signalling and behaviour, or host interactions; as such 
in vitro culture conditions differ from the microenvironment that a cell would experience in vivo. 
Future experiments examining the effects of statins in 3D cell culture models of BO and OAC 
would be of interest. Although biological mechanisms implicated in aetiology and prognosis are 
frequently distinct, some do overlap, which may be of relevance to OAC: specific gain-of-function 
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p53 mutations can regulate the mevalonate pathway to harness cellular metabolism, and p53 
mutations confer both higher risk of malignant progression in BO and are associated with worse 
prognosis in established tumours77, 119. An accumulating number of well-conducted observational 
studies suggest significant inverse associations between statin use and cancer incidence and 
mortality in patients with malignancy187-190. Taken together, supportive preclinical and 
observational data indicate the potential for statins as novel chemopreventive or therapeutic 
strategies deserves further research.  
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1.2.6. Observational evidence for the association between statin use 
and cancer-related outcomes 
The following summarises the wider observational literature which examines associations 
between statin use and mortality outcomes in patients with malignancy overall. There is a paucity 
of data on the relationship between statin use and survival in patients with OAC. The following 
therefore considers the results and methodological considerations for studies conducted in 
patients with colorectal carcinoma (CRC) for which key tenets may be applicable. 
 
Statin use and cancer-related outcomes overall 
Associations between statin use and cancer related outcomes in populations with cancer have 
been examined extensively across many tumour types in the observational literature, with the 
weight of evidence suggesting significant inverse associations. The most recent systematic review 
and meta-analysis of observational studies on the subject included 95 cohorts with over 1.1 
million patients diagnosed with cancer191. The most common sites to be investigated in individual 
epidemiological studies were prostate (32.6%), breast (15.8%) and colorectal cancers (9.5%), 
followed by renal cell carcinoma (5.3%), bladder, hepatocellular, lung and uterine cancers (each 
4.2%). Haematological malignancies (lymphoma, leukaemia and myeloma), biliary tract, gastric 
and neurological malignancies are relatively under-represented, as such accounting for less than 
3% of studies each. The total number of participants examined for each site varies substantially: 
breast cancer (208, 780 participants), prostate cancer (108, 399), colorectal carcinoma (44, 476) 
and lung cancer (15, 846) account for the majority. Statin exposures measured vary considerably 
between and within studies, including their measurement pre-diagnosis, at the time of diagnosis 
and post-diagnosis. Investigators examined cancer-related outcomes include all-cause mortality, 
cancer-specific mortality, progression-free survival and disease-free survival. Statin use was 
significantly associated with a reduced risk of all-cause mortality (HR 0.70, 95% CI 0.66-0.74 
pooled from 55 studies), cancer-specific mortality (HR 0.60, 95% CI 0.47-0.77 pooled from 32 
studies), progression-free survival (HR 0.67, 95% CI 0.56-0.81 pooled from 22 studies), and 
disease-free survival (HR 0.53, 95% CI 0.40-0.72 pooled from 9 studies). Exposure to statins 
measured separately pre and post-diagnosis of cancer were each associated with significant 
improvements in all-cause mortality, cancer specific mortality, progression-free survival and 
disease-free survival in pooled analyses, with no evidence of significance differences between 
these subgroups of exposure (pre vs. post diagnosis, all p values > 0.1), see table 6 (adapted from 
Mei et al.191). Evidence of publication bias was demonstrated for studies which reported all-cause 
mortality (egger’s p value < 0.001) but not the other outcomes listed. Subgroup analysis 
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demonstrated that stratification of studies by quality (the exact method for assessing study 
quality was not specified), yielded different effect sizes: modest effect sizes (HR 0.81, 95% CI 0.77-
0.85, from 29 pooled studies) were observed in studies assessed of higher quality, while larger 
effect sizes (HR 0.57, 95% CI 0.47-0.68) were observed for studies assessed of lower quality, for 
the outcomes of all-cause mortality.  
Statin exposure and outcome 
Number of 
studies 
Hazard Ratio 
(95% CI) 
P for subgroup 
difference 
All cause mortality       
Prediagnosis 31 0.74 (0.68-0.79) 0.133 
Postdiagnosis 24 0.65 (0.60-0.72)   
Cancer-specific mortality       
Prediagnosis 21 0.64 (0.55-0.73) 0.809 
Postdiagnosis 12 0.65 (0.55-0.76)   
Progression-free survival       
Prediagnosis 11 0.65 (0.49-0.88) 0.734 
Postdiagnosis 8 0.73 (0.60-0.91)   
Disease-free survival       
Prediagnosis 5 0.48 (0.26-0.88) 0.539 
Postdiagnosis 4 0.60 (0.44-0.81)   
Table 4: Subgroup analyses of statin exposure (measure pre or postdiagnosis) and associations with cancer-related 
outcomes. Adapted from Mei 2007. 
 
While the pooled estimates of the association between statin use and cancer-related outcomes 
were significant and remained so when stratified according to tumour site, statin exposure and 
mortality outcome, there was considerable heterogeneity between studies pooled overall (I2 
92.9%, heterogeneity P < 0.001). This is not unexpected, as there were considerable variations in 
study characteristics, including those highlighted above, also disease stage investigated, duration 
of follow-up and the setting and location of the research. Nevertheless, even when stratified for 
tumour site and mortality outcome, heterogeneity was still significant (I2 > 50%) for most sites and 
outcomes tested. Funnel plot inspection revealed asymmetry and suggests possible contributory 
publication bias.  
 
Therefore, while it is encouraging that statin use overall is associated with significant 
improvements in cancer-related outcomes, this finding per se is of limited value as it is difficult to 
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interpret and is not necessarily of direct clinical relevance: the epidemiological evidence base 
needs to be carefully considered for each cancer site separately before concluding whether a 
causal association may exist.  Design considerations which demonstrate features suggestive of 
causal associations, such as the Bradford Hill criteria, can be informative192. However, it should be 
noted the absence or presence of any or all nine criteria can neither absolutely confirm nor refute 
causality. Methodological appraisal is required to identify shortcomings commonly encountered 
in this field, such as immortal time-bias, confounding and channeling bias/reverse causation bias 
which may offer alternative, more likely explanations for associations.  
 
Post diagnosis statin use and mortality in patients with colorectal carcinoma 
The only other epithelial gastro-intestinal adenocarcinoma in which associations have been 
extensively examined is CRC. Clearly there are major distinctions between OAC and CRC as disease 
entities in terms of aetiology, cancer biology and outcomes; nevertheless shared treatment 
effects exist between the two (as demonstrated by the widespread use of platinum-based 
chemotherapy regimens in both diseases), and insights may therefore be gained from appraising 
the evidence relating statin use and outcomes in patients with CRC. To date, 11 studies have 
examined associations between statin use following diagnosis of CRC and all-cause mortality187, 193-
202; and four have examined associations with cancer-specific mortality187, 196, 199, 200. Cancer-
specific mortality, where deaths due to other causes are censored, is an outcome of particular 
interest in attempting to infer causality with the purported anti-neoplastic effects of statins, as a 
means of negating the known cardiovascular benefits and considering competing risks of death. 
The two largest studies were population-based cohort studies which addressed both of these 
outcomes and were conducted by the same research group, using consistent methodology187, 199. 
The first was conducted using the Clinical Practice Research Datalink (CPRD), a large primary care 
healthcare dataset (described in detail below), with linkage to the National Cancer Registry and 
the office for national statistics dataset187. In total 7657 patients with incident stage I-III CRC, 
diagnosed from 1998 to 2009, who survived at least one year following diagnosis were identified. 
Statin use was modelled as a time-dependent covariate, with exposure lagged by 6 months. Statin 
use post-diagnosis (prescribed to 53% after diagnosis) was associated with significant reductions 
in all-cause mortality (HR 0.75, 95% CI 0.66-0.84) and cancer-specific mortality (HR 0.71, 95% CI 
0.61-0.84). Analyses were adjusted for year of diagnosis, age at diagnosis, gender, tumour stage 
and grade, surgery/chemotherapy/radiotherapy within 6 months of diagnosis, smoking, co-
morbidity, deprivation, and use of concomitant medications (also measured as time-varying co-
variates) including low dose aspirin, angiotensin converting enzyme (ACE) inhibitors and 
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metformin. Cumulative dose-response relationships were demonstrated with stronger 
associations observed in patients receiving higher cumulative dosages (accounting for the statin 
used within class and potency) than patients receiving lower dosages for both all-cause and 
cancer-specific mortality. The second study was conducted in Scotland, using the Scottish cancer 
registry, the prescribing information system, the general/acute inpatient and day case dataset, 
the outpatient attendance dataset and the national records of Scotland death record187, 196, 199, 200. 
A cohort of 8391 incident Duke’s A-C CRC patients, diagnosed from 2009-2012, were identified 
after patients who died in the first year after diagnosis were excluded. Again, a lag of six months 
was applied to post-diagnosis statin exposure, and adjustment was made for the same factors 
listed above (except ACE inhibitors and metformin). Statin use (observed in 76%) was not 
significantly associated with cancer-specific (HR 0.90, 95% CI 0.77-1.05) or all-cause mortality (HR 
0.90, 0.80-1.02). New initiation post-diagnosis (excluding prior users) was inversely associated 
with cancer-specific (HR 0.64, 95% CI 0.42-0.99) and all-cause mortality (HR 0.68, 95% CI 0.48-
0.96), however these estimates were informed by relatively few events: 24 and 42 respectively. 
There was no convincing evidence for either duration-response or cumulative dose-response 
relationships for either cancer-specific or all-cause mortality.  
 
While these two studies did not yield truly distinct results: there was overlap of reported 
confidence intervals between both studies for the primary exposures (from 0.77-0.84 for cancer-
specific mortality; and 0.80-0.84 for all-cause mortality); the non-significant finding observed in 
the Scottish cohort study, neither excludes nor confirms an inverse association. Nevertheless, it is 
of interest estimates from the Scottish cohort did not reach significance, or demonstrate other 
features consistent with a causal relationship (such as cumulative duration-response relationship). 
This finding may rest with differences in unmeasured lifestyle factors between the two studies 
(unmeasured confounders) and advances in detection (the bowel cancer screening programme) 
and treatment (oxaliplatin-based chemotherapy) which were well established during the study 
period of the Scottish study, and were introduced during the course of the CPRD study and were 
potentially associated with statin use; although the former would be expected to have been 
addressed through adjusting for stage. Systematic differences between populations in adherence 
to statins would introduce measurement error and potentially bias results to the null. It is not 
possible to test this hypothesis in these cohorts: routine healthcare datasets accurately define 
dispensed prescriptions, but do not measure adherence. The use of lagged exposures could also 
have feasibly biased associations to the null. The practice of lagging exposures is used to subvert 
reverse causation in the context of cancer recurrence: where a recurrence may influence 
exposure (statin use)203. While these studies did not examine recurrence specifically, disease 
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progression in non-curative cohorts or recurrence in curative cohorts is a logical precursor to 
cancer-specific mortality. It is highly probable that these events are of relevance to these cohorts 
and could in themselves influence statin prescription or adherence. In theory, the duration of lag 
periods also requires accurate assumptions for the latent period for recurrent disease or 
progression and the period over which the exposure is expected to exert a plausible biological 
effect at a population level203. In practice, however, these details are not known with any degree 
of certainty, and the duration of any selected lagged exposure is therefore at best based on 
assumptions and at worst arbitrary. A lagged exposure would be expected to systematically draw 
associations to the null, and could therefore bias associations such that null hypotheses are falsely 
accepted: person-time in exposed participants, after the onset of exposure, is classified as non-
exposed for the duration of the lagged period, while periods after are assigned to the exposed 
groups. This is demonstrated in sensitivity analyses for the CPRD study, with HRs for cancer-
specific mortality incrementally approaching the null the longer the lag period applied (HR 0.71, 
95% CI 0.61-0.84, for a 6 month lag; HR 0.77, 95% CI 0.66-0.90, for a one year lag; and HR 0.84, 
95% CI 0.69-1.02 for a 2 year lag). Furthermore, lagging exposures for all post-diagnostic statin 
users where many would be expected to have also been prior users (58.7% of post-diagnosis users 
also used statins pre-diagnosis in the CPRD study), would seem potentially superfluous: patients 
with prior use would be expected to have still have received ongoing statin exposure while 
harbouring an undiagnosed tumour.  
  
In a systematic review and meta-analysis of 11 studies, including 21 030 participants, post 
diagnosis statin use was significantly inversely associated with all-cause mortality (HR 0.84, 95% CI 
0.73-0.98), with substantial heterogeneity (I2 69%, heterogeneity P < 0.001)199. In four studies, 
including 19, 152 patients, post diagnosis statin was not significantly associated with cancer-
specific mortality (HR 0.84, 95% CI 0.68-1.04), with evidence of heterogeneity (I2 67%, 
heterogeneity P = 0.03). Both pooled estimates included the two large CRC cohorts described 
above. Heterogeneity may be ascribed to substantial differences in the included studies, which 
included community and hospital-based studies, early and advanced disease, and not all studies 
accounted for time-dependent covariates. 
 
Statin use and mortality in patients with oesophageal carcinoma 
There are only two previous epidemiological investigations which have examined the association 
between statin use and mortality in patients with OC189, 204. The first, conducted in Denmark, 
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included 277, 204 patients, 98% of the Danish population diagnosed with cancer from many 
primary sites, from 1995 to 2007189. Participants were followed until December 2009 such that at 
least 2 years’ follow-up per patient was possible.  The study used linkage between the Danish 
Cancer Registry; the Danish Civil Registration System (which uniquely identified all Danish 
inhabitants and provided complete data on emigrations, date and cause of death, age and 
gender); and the Danish Registry of Medicinal Products Statistics (containing electronic 
information on dispensed medications, including the Anatomical Therapeutic Chemical (ATC) 
Classification System to define the precise statin dispensed, dosage and amount dispensed). All 
participants were aged over 40 years as statin exposure was expected to be unlikely in younger 
patients. Statin use was measured prior to the date of cancer diagnosis (to two years previously), 
with the intention of preventing reverse causation bias. Regular statin use was defined as use 
within 6 months of the date of cancer diagnosis and separately received two prescriptions within 
2 years of diagnosis. This exposure definition was considered a proxy for statin use before and 
after cancer diagnosis. In total 18, 721 patients (6.7% of the cohort) were defined as statin users 
prior to diagnosis of cancer. This proportion of statin use is low, but may reflect the time period 
selected and the inclusion of relatively young patients. The association between pre-diagnosis 
statin use and cancer-specific mortality was estimated (censoring for deaths due to other causes) 
to account for competing risk of death. In total, 162, 067 deaths were registered as due to cancer 
during follow-up. Overall, statin use (compared to patients who had never used statins) was 
significantly inversely associated with cancer-specific mortality (HR 0.85, 95% CI 0.82-0.87) and all-
cause mortality (HR 0.85, 0.83-0.87). Analyses were adjusted for gender, ethnicity, age at 
diagnosis, cancer stage (using the TNM classification), chemotherapy, radiotherapy, diagnosis of 
cardiovascular disease and diabetes preceding cancer diagnosis, year of birth, educational 
attainment, and size of residential area. A clear dose-response relationship was not evident for 
categories of dosage based on the penultimate statin prescription dose prior to diagnosis (HR 
0.82, 95% CI 0.81-0.85, for low dose; HR 0.87, 95% CI 0.83-0.89, for the standard dose; and HR 
0.87, 95% CI 0.81-0.91, for the higher dose category). This definition would not necessarily 
account for the actual cumulative dose received and would not be expected to sensitive to 
changes in dose over time (although this is a lesser concern). A separate matched propensity 
score analysis (patients were matched for the probability for statin initiation based on 
prescriptions of other medications for chronic illnesses – diuretics, calcium channel blockers, anti-
hypertensives, warfarin, beta blockers, bronchodilators and anti-depressants) yielded very similar 
estimates to the full cohort study. Aspirin use was not adjusted for and could plausibly have 
confounded associations123. There were considerable missing data on covariates – particularly 
cancer staging (missing in 34%) and chemotherapy and radiotherapy (each missing in 72%). 
Missing data was handled using the “missing indicator method”, an approach which is not advised 
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and which can readily lead to biased estimated associations even when data are assumed to be 
missing completely at random205. Multiple imputation (if assumptions of missingness were 
justified) or complete case analysis may therefore have been preferable. In the subgroup of 4398 
with oesophageal malignancy (a composite diagnosis, not identified by histological subtype) of 
whom 3328 died during follow-up from their index cancer, statin use was significantly inversely 
associated with cancer-specific mortality (HR 0.81, 95% CI 0.69-0.95). Dose response analyses 
were not repeated in individual cancer cohorts, and therefore it is not known whether such 
relationship existed for OC. New statin use, initiated after diagnosis of cancer, was not assessed 
and therefore through measuring statin use pre-diagnosis exclusively (while attempting to avoid 
reverse-causation bias) could have underestimated treatment effects if they existed. 
Furthermore, defining regular statin use in the two years until the date of cancer diagnosis may 
not fully address reverse-causation bias: patients with more advanced OC (compared to those 
with less advanced disease) may have a lower propensity to be prescribed statins if symptomatic 
management or further investigation is more likely to take priority over primary prevention of 
cardiovascular disease immediately prior to diagnosis of cancer.  
 
The second study was a single-centre cohort study based at the MD Anderson Centre, Texas, 
US204. In total, 1174 patients with OC (78% OAC, 20% OSCC), including surgical and non-surgical 
cohorts (560 and 614 patients respectively), with stage I-IV disease were included. Patients 
treated at the centre between 1998 and 2012 were included. The aim of the study was to 
examine associations between seven common comorbidities and 18 medication groups and the 
outcomes of all-cause mortality, cancer specific survival and Non-cancer specific survival.  In total, 
400 (34%) of the cohort were classified as statin users, measured at baseline as documented in 
the medical notes, although a more detailed exposure definition was not provided. Non-
significant inverse associations were observed between statin use and all-cause mortality (HR 
0.92, 95% CI 0.76-1.11) and cancer-specific survival (HR 0.87, 95% CI 0.70-1.07). Analyses were 
adjusted for age, race, histology, tumour location, BMI, smoking, performance status, clinical 
stage, radiation modality and surgery for all-cause mortality. In addition, for cancer-specific 
mortality analyses were adjusted for grade and tumour length. The main strength of this study is 
the comprehensive collection of data on clinical and tumour characteristics which could feasibly 
otherwise confound associations. With up to 75 potential comparisons, the risk for type 1 error 
was substantial. Furthermore, statin exposure was not the primary focus of this study. Therefore 
further analyses which may help infer causality were not conducted, such as the evaluation of 
dose-response relationships. Statin use was also only assessed at a single point in time, and would 
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not have considered treatment effects for new use. Associations were not stratified by 
histological subtype. 
 
In summary, while studies which have examined the relationship between statin use (measured 
pre or post-diagnosis) and outcomes in patients with cancer overall have generally estimated 
significant inverse associations, uncertainty remains over whether causal relationships could exist 
for particular individual tumour sites189, 191. Such is the nature of observational research, that 
competing explanations for significant associations may operate, such as immortal-time bias and 
confounding, specifically reverse causation bias206. Some of the most rigorous and well-conceived 
observational studies in patients with CRC which employ advanced approaches to avoid these 
sources of bias, may have unintentionally underestimated statin treatment effects. There is a 
relative paucity of data on the association between statin use and survival in patients with OC 
and, to date, aside the current study there are no other published cohorts to date which examine 
associations between statin use measured after diagnosis and mortality in patients with 
oesophageal cancer or more importantly, according to histological subtypes189, 204, 207. 
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1.2.7. Trial evidence of statin as therapeutic agents 
 
Randomised controlled trials 
Cancer-related mortality has been assessed in patients allocated to statin therapy/high dose 
compared to placebo/low dose use, in the cholesterol treatment trialists’ collaboration (see table 
7 for summary of current trial evidence), an individual patient data meta-analysis on 27 RCTs, 
which demonstrated no significant difference when used for a median of 5 years208. While this 
study provides reassurance at a wider population level that statin use does not markedly increase 
the incidence of malignancy, following concerns raised by the PROSPER209 and CARE210 trials 
(which respectively showed increased incidence of gastrointestinal and breast cancers), it is more 
difficult to draw inferences about mortality, as all patients with a diagnosis of cancer prior to 
randomisation (including 164 with OC) were excluded. Therefore, most patients would be 
expected to be cancer free at the point of randomisation.  
 
Relevance of current clinical trials 
Published RCTs which directly assess statins in patients with gastro-intestinal malignancy 
(including colorectal, gastric and pancreatic cancer) show no evidence of therapeutic benefit197, 211, 
212. However, these trials are of little direct relevance to curative cohorts with OAC in terms of 
gauging potential therapeutic efficacy. Studies selected participants with advanced malignancy197, 
211-213, received short durations of allocated statin treatment197, 211-213, and had small sample 
sizes197, 211-213. Selected patient groups were therefore probably least likely to benefit from statin 
therapy, and studies were not powered to examine smaller treatment effects. The studies also 
suffered substantial methodological limitations and risked bias.  Reassuringly there is no evidence 
of increased toxicity, in terms of absolute numbers of adverse events according or their severity, 
in patients allocated to statins197, 211, 212. This is of relevance, as there was considerable overlap 
between chemotherapy regimens used in these trials and those use in current UK practice as peri-
operative agents.  
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First author  
(year)  
Country 
Design 
Tumour site 
 
Stage 
Number of 
Patients 
Active (n) Control (n) Treatment 
duration 
Outcome(s) Comments 
Cholesterol 
Treatment Trialists’ 
Collaboration208 
(2012) 
 
International 
collaboration 
 
Individual patient 
data meta-analysis of 
27 RCTs 
 
Cancer free at 
randomisation 
 
Any site and 
stage during 
follow-up 
 
164 with OC 
174, 149 In statin vs. 
control: A, 
F, L, P, R 
(67, 258) 
 
In more 
intensive 
vs. less: A, 
S (19, 829) 
In statin vs. 
control: 
placebo 
(67, 279) 
 
In more 
intensive vs. 
less: A, S, P 
(19, 783) 
In statin vs. 
control: 
median 4.8 
years 
 
In more 
intensive vs. 
less: median 
5.1 years 
Cancer incidence 
Statin vs. control: RR, 1.00, 95% 
CI 0.96-1.05 
More intensive vs. less: RR, 1.00, 
95% CI 0.93-1.07 
Cancer mortality 
Statin vs. control: RR 1.00 (0.93-
1.08) 
More intensive vs. less: RR 0.93 
(0.82-1.06). 
OC deaths: statin/more (45/87, 
087); control/less (55/97062) 
(p=0.36) 
Cancers first 
diagnosed prior to 
randomisation 
excluded (150 with 
OC excluded). 
Statin/intensive 
regimen exposure 
likely preceded 
cancer 
development. 
Lim197 (2015) 
 
South Korea 
 
Phase III, 5 centres 
Colorectal 
 
Stage IV 
269 S40 plus 
FOLFIRI/X
ELIRI (134) 
Placebo plus 
FOLFIRI/XEL
IRI (135) 
Statin 
exposure: 
median 6 (1-
36) 21 day 
cycles during 
which S 
administered 
daily 
PFS (primary) 
HR 1.03, 95% CI 0.77–1.37, 
p=0.86 
PFS with KRAS mutation 
p=0.86 
 
Short durations of 
treatment. No 
clinically significant 
increase in toxicity 
with S. 
Kim211 (2014) 
 
South Korea 
 
Phase III, 9 centres 
Gastric (64%) or 
GOJ (36%) 
 
Stage IV 
244 S40 plus 
CX 
placebo plus 
CX 
In active 
group: median 
4.4 months 
 
In control 
group: median 
4.5 months 
PFS (primary) 
HR 0.93, 95% CI 0.68-1.26 
P=0.66  
OS (secondary) 
HR 0.97, 95% CI 0.72-1.3 
p=0.82 
No clinically 
significant increase 
in toxicity with S. 
Konings212 (2010) 
 
Netherlands 
 
Phase II, 3 centres 
 
 
Gastric 
 
NS. “advanced” 
not resectable 
30 P40 plus 
ECX  
Placebo plus 
ECX 
In active 
group: mean 
3.6 21 day 
cycles. 
 
In control: 
mean 4.5 21 
day cycles 
PFR at 6 months (primary) 
5/15 responders in active arm 
7/15 responders in control arm 
(p=0.47) 
No clinically 
significant increase 
in toxicity in P40 
plus ECX arm. 
Statins and oesophageal adenocarcinoma 
64 
Hong213 (2013) 
 
South Korea 
 
Phase II, 4 centres 
Pancreatic 
 
Locally advanced 
(12%) 
Stage IV (88%) 
114 S40 plus G Placebo plus 
G 
In active 
group: median 
two cycles 
(range 1-25) 
21 day cycles. 
 
In control: 
mean four 
(range 1-22) 
21 day cycles 
Time to progression (primary) 
2.4, 95% CI 0.7-4.1 months in 
active arm 
3.6, 95% CI 3.1-4.1 months in 
control group 
p=0.90 
No clinically 
significant increase 
in toxicity with S. 
Kawata214 (2001) 
 
Japan 
 
Randomised open 
label trial, Single 
centre 
Hepatocellular 
carcinoma 
 
Unresectable 
disease 
Stage II or III 
(~30%) 
Stage IV (~70%) 
83 P20-40  No placebo P administered 
for 16.5 (SD 
9.8) months 
All-cause mortality 
HR 0.42, 95% CI 0.20-0.83, 
p=0.02 
Median survival in active arm 18 
months 
Median survival in control arm 9 
months 
Open label. 
Baseline groups 
well balanced for 
known prognostic 
markers in 
hepatocellular 
carcinoma. 
Garwood215 (2009) 
 
US 
 
Pilot study, 6 centres 
 
 
Ductal carcinoma 
in situ or breast 
cancer 
 
Stage I 
40 F80 F20 21-50 days Ki-67 (proliferative biomarker) 
Median 7.2% (IRQ 0-13.4) 
reduction in active vs control arm 
(p=0.008) in subgroup of high 
grade tumours (n=15). 
 
No comparison 
reported between 
treatment groups 
overall. 
Subgroup analyses 
at risk of type 1 
error. 
Han216 (2011) 
 
South Korea 
 
Open label, phase II, 
single centre 
Non-squamous 
cell lung cancer, 
failed at least one 
platinum-based 
chemotherapy. 
75% 
adenocarcinoma. 
 
Stage IIIB/IV 
106 S40 + Gef Gef NS Response rate 
31.5%, 95% CI, 19.1–43.9% in 
active arm 
38.5%, 95% CI, 25.3–51.7% in 
placebo arm 
(p=0.666) 
Progression-free survival 
HR 0.89, 95% CI 0.60-1.32, 
p=0.491 
No clinically 
significant increase 
in toxicity with S, 
either in terms of 
frequency of AEs or 
severity 
Table 5: Summary of randomised controlled trials which assess statins in patients with solid tumours 
Abbreviations: A, atorvastatin; F, fluvastatin; L, lovastatin; P, pravastatin; R, rosuvastatin; CX, capecitabine, cisplatin; ECX, epirubicin, cisplatin, capecitabine; FOLFIRI/XELIRI, irinotecan, capecitabine, 
leucovorin, 5-fluorouracil; G, gemcitabine; GOJ, gastro-oesophageal; OS, overall survival; PFS, progression free survival; RCT, randomised controlled trial; TAE, transcatheter arterial embolization; 5-FU, 
5-fluorouracil; Gef, Gefitinib 
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1.2.8. Observational evidence for association between statin use and 
oesophageal malignancy 
 
Previous epidemiological studies: general population cohorts 
The association between statin use and oesophageal malignancy in the general population has 
been examined previously. The most recent published observational study based within 
QRESEARCH (a large anonymised healthcare dataset from contributing general practices 
throughout the UK which use the EMIS computer system217) demonstrated in a nested case-
control analysis of 3159 patients with OC (a composite diagnosis) matched to 13041 controls, a 
non-significant inverse association between statin use and OC (OR 0.88, 95% CI 0.77-1.01, 
p=0.072)218. Statin exposure was considered for all patients until one year prior to the index date 
for all participants. Analyses were adjusted for Townsend quintile (a proxy for socioeconomic 
status), BMI, smoking, MI, coronary heart disease, diabetes, hypertension, stroke, rheumatoid 
arthritis, use of NSAIDs, COX-2 inhibitors, and aspirin. Cumulative duration-response analyses did 
not suggest evidence of a biological gradient: statin use for < 12 months, OR 0.82, 95% CI 0.67-
1.02; 13-24 months, OR 0.91, 95% CI 0.71-1.36; 25-48 months OR 0.82, 95% CI 0.66-1.02; >49 
months, OR 1.04, 95% CI 0.83-1.30. This study has a number of strengths: first, it is a suitably large 
study to examine with sufficient power associations between statin use and risk of OC; second, 
the use of a nested case-control approach is appropriate given that OC can be considered a rare 
outcome overall; third, the exposure window excluded the year prior to index therefore excluded 
recent drug use, a time period where statins may not reasonably be expected to exert a biological 
effect; and fourth, this study used a representative dataset and should be generalisable to the 
wider UK population. The most notable limitation is the outcome: OC is recorded as a composite 
diagnosis (including presumably any histological subtype of oesophageal malignancy), and clearly 
adenocarcinoma and squamous cell carcinoma (among other rare subtypes) are different disease 
entities, with differing epidemiology, aetiology, and biology56, 219. Therefore a composite diagnosis 
of OC when examining disease aetiology has diminished value and is difficult to interpret. 
 
To address this specific issue, we conducted a nested case-control study using the GPRD220. In 
total, between January 2000 and December 2009 (a period purposefully selected for the high 
prevalence of statin use), 4220 cases of incident OC were matched to 15570 controls.  All 
participants required at least 1 year’s up-to-standard records within the database. A subset of 
cases were linked to the national cancer registry to confirm the histological subtype. Regular 
statin use (the primary exposure definition) was defined as a minimum of 10 months’ dispensed 
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statin prescriptions in the year preceding the index date for both cases and controls. Participants 
with < 10 months’ prescriptions were excluded, leaving 581 cases of OAC matched to 2167 
controls; and 332 cases of OSCC matched to 1242 controls. Regular statin use was inversely 
associated with risk of OAC (OR 0.58, 95% CI 0.39-0.87, p=0.009) with evidence of both dose (p for 
trend = 0.036) and duration-response relationships (p for trend = 0.005). These associations 
persisted in sensitivity analyses where follow-up for participants was restricted equally to at least 
5 years. Regular statin use was not significantly associated with OSCC (OR 0.61, 95% CI 0.35-1.06, 
p=0.081), with no significant dose (p for trend=0.057) or duration-response (p for trend=0.249) 
relationships. However, between 1-5 years’ use of statins was inversely associated with OSCC (OR 
0.51, 95% CI 0.27-0.98), although caution should be applied in the interpretation of this subgroup 
as the number of cases and controls were small (13 and 18 participants respectively). Cases were 
matched for calendar time (using the index date), gender, year of birth (+/- 3 years), and general 
practice (a proxy for socioeconomic status). Analyses were adjusted for smoking status, (alcohol 
intake for OSCC), BMI, prescription of aspirin, NSAIDs and PPIs. The main strength of this study 
was the use of electronic healthcare records to ascertain case and control status, independent to 
exposure status, and linkage with the cancer registry to determine the histological subtype of 
malignancy. The main limitation is the exposure definition: while it ensures that exposure 
duration is potentially sufficient to mediate a biological effect, statin use initiated in the year prior 
to diagnosis (a period when malignancy would be present, but undiagnosed) would not 
necessarily satisfy the assumption of a temporal relationship. Nevertheless, the 93% of cases and 
96% of controls used statins for > 1 year prior to index, for a median duration of 3 years (IQR 1.78-
4.37) for cases and 3.1 years for controls (IQR 1.91-5.19). 
 
While both of these studies would be expected to be generalizable to the wider UK population, 
they would not necessarily be applicable to patients with Barrett’s oesophagus.  
 
Previous epidemiological studies: Barrett’s cohorts 
There are seven contemporaneous epidemiological investigations (summarized in table 8) which 
examine associations between statin use and risk of HGD and/or OAC in populations with BO188, 
221-226. The most recent US nested case-control study within the national Veteran affairs (VA) 
datasets (fully electronic health record dataset) included 311 cases of OAC (with known prior BO) 
matched to 856 controls with BO who had not progressed by the index date of cases (date of 
diagnosis)188. This study supersedes two previous smaller studies conducted in the same base-
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population227, 228. BO diagnoses were ascertained from 2004 to 2010 and cases were identified 
until 2011. All participants were male and were matched for year of birth (within +/- one year) 
and date of prior BO (within +/- three years). Statin use was ascertained from electronic pharmacy 
records from the Veterans Health Administration inpatient and outpatient datasets. Statin 
exposure was defined when dispensed after diagnosis of BO and until 90 days prior to OAC 
diagnosis. Statin use was inversely associated with risk of OAC (OR 0.65, 95% CI 0.47-.91) adjusted 
for age at BO diagnosis, smoking, BMI, medication use (individually, PPIs, NSAIDs, H2As), the 
number of gastroscopies prior to the date of diagnosis and index date (a means of limiting healthy 
user bias). There was no clear evidence for a duration response for the association between statin 
use and malignant progression (< 6 months, OR 0.82, 95% CI 0.52-1.31; 6-18 months, 0.52, 0.32-
0.85; and > 18 months 0.64, 0.40-1.01). Significant inverse associations were observed for late 
stage OAC with statin use (OR 0.44, 95% CI 0.25-0.79), but not for early stage OAC (OR 0.85, 0.54-
1.33). Dose-response associations were not reported. This study’s main strengths are the use of 
electronic data systems to capture medication exposures and the implementation of a nested 
case-control analyses within prospectively collected patient dataset. While it is possible that 
prescriptions dispensed outside the VA would not be recorded, the prevalence of statin use was 
sufficiently high (40% of cases, and 50% of controls) and of the order expected, that such 
prescriptions causing significant measurement error is a lesser concern. Time-dependent 
exposures would also be adequately controlled for using the fixed exposure window definition. 
One limitation is this study may not account for latency: short exposures to statins satisfy the 
definition of statin use, and medication initiated within 100 days of diagnosis of OAC would 
unlikely seem related to the malignancy’s aetiology. Furthermore, such exposure definitions risk 
selection bias, specifically another guise of reverse causation bias: in the time preceding diagnosis 
(likely months) patients with malignancy would be expected to have more frequent interactions 
with their general practitioner or treating clinician than controls133, and therefore have a greater 
propensity to receive treatment for unrelated conditions, such as lipid lowering medications; 
although this would be expected to draw associations to the null. All participants were male, 
therefore limiting the external validity of the study (albeit the majority of patients with known BO 
are male). 
 
A prospective cohort study conducted from three university medical centres and 15 endoscopy 
units in the Netherlands included 570 patients with BO (including non-dysplastic metaplasia and 
LGD), with 2, 738 person-years of follow-up, of whom 38 progressed (26 with HGD and 12 with 
OAC)224. Consensus for the diagnosis of any grade of dysplasia was made with at least two 
pathologists, of which at least one was considered expert. Patients with BO were diagnosed 
between November 2003 and December 2004. Patients with intestinal metaplasia and BO 
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measuring at least 2cm (M2) were included. Statin use was ascertained from a questionnaire 
administered at each surveillance visit and was cross-checked with pharmacy records. Any use of 
statins (the primary exposure) was defined as a prescription of at least one month’s duration 
during follow-up. Using this definition, statin use was inversely associated with risk of progression 
in a non-time dependent cox regression model (HR 0.46, 95% CI 0.21 – 0.99), adjusted for age, 
gender, length of BO, baseline histology, and use of NSAIDs, low dose aspirin, and PPIs. This 
exposure definition and analysis is susceptible to immortal-time bias: the time period between 
entry to the cohort and exposure to statins (immortal time) is otherwise erroneously considered 
exposed, therefore biasing statin users to lower incidence rate of progression, and a biased 
underestimate of the HR for malignant progression229. In a subsequent time-dependent Cox 
regression model (the ideal approach), which enabled patients to move from periods of non-
exposure to periods of exposure following initiation of a statin, risk of malignant progression was 
non-significantly inversely associated (HR 0.55, 95% CI 0.23-1.29)230.  In non-time dependent cox 
regression models there was no convincing evidence for a duration-response relationship (≤ 5 
years’ statin exposure, HR 0.51, 95% CI 0.18–1.47; and > 5 years, HR 0.49, 95% CI 0.18-1.29; p for 
trend=0.204). The main strengths of this study are its prospective cohort design, the use of 
pharmacy databases to validate medication exposures, and use of expert GI pathologists to reach 
consensus for the diagnosis of dysplasia. However, the study is likely to be underpowered given 
the low number of events, as expected for a cohort of this size and the known low overall rate of 
malignant progression in patients with no dysplasia36. It is not clear whether accurate start dates 
for medications could be ascertained at follow-up: doing so only at intervals dictated by 
surveillance risks measurement error when considering time-dependent exposures. Again, recent 
exposure (to the date of diagnosis of cases, or incident date) as is considered in this study would 
be expected to have little biological basis for influencing the process of malignant progression 
(latency). 
 
A UK single centre case-control study included 85 patients with OAC, and 170 controls with BO 
recruited from September 2009 to July 2011221. Cases required confirmation of diagnosis by the 
upper gastrointestinal MDT by a specialist gastrointestinal pathologist. Cases also included 
Siewert I and II lesions, and both prevalent and incident cancers. Included patients with controls 
with BO were at least 3cm in length, with intestinal metaplasia, and were diagnosed at least one 
year prior to their most recent endoscopy appointment. Drug use was ascertained from patient 
interviews conducted before or after their endoscopy (which determined case/control status), 
and cross checked with the referral letter when possible. Statin exposure was defined by patient 
recall of use for at least 6 months before the date of cancer diagnosis or current surveillance 
endoscopy. Height and weight were measured at the time of the interview for the controls, and 
Statins and oesophageal adenocarcinoma 
69 
cases were asked to estimate their weight one year before presentation. Statin use was 
significantly inversely associated with risk of OAC (OR 0.57, 95% CI 0.28-0.94), adjusted for age, 
BMI, smoking, alcohol, aspirin, metformin and NSAIDs. Significant dose (≤ 40mg daily, OR 0.59, 
95% CI 0.27-0.98; > 40mg OR 0.31, 95% CI 0.05-0.97; p for trend < 0.05) and duration (0.5-2 years, 
OR 0.77, 95% CI 0.29-1.87; 2-5 years, OR 0.58, 95% CI 0.27-1.43; > 5 years OR 0.41, 95% CI 0.15-
0.85; p for trend < 0.05) response relationships were demonstrated. Given the short time period 
over which participants were recruited (approximately 22 months), calendar time would be 
expected to have been controlled for to a degree. Differential ascertainment methods of 
exposures between cases and controls is a significant limitation, as such an approach can readily 
lead to information bias. This study primarily captured drug exposures by patient interview 
(potentially soon after cancer diagnosis for cases), such an approach could feasibly lead to 
differential recall between cases and controls (recall bias) and considerable error, if non-
differential; although the authors stated that patient reported exposure “invariably correlated 
with that seen in the medical records”. Although the significant duration and dose-response 
relationships are consistent with a causal relationship, caution should be used in their 
interpretation: models were unstable, with wide confidence intervals attributable to the few 
cases and controls distributed between exposure categories (for example two cases and 14 
controls comprised the > 40mg dose category). The exposure definition to statins included use 
within 6 months before interview, as with the other studies discussed, this would appear not to 
consider biological latency.  
 
A population-based cohort study in the UK GPRD using primary care data included a large BO 
cohort (n=9, 660) and followed patients up for a diagnosis of OC (a composite diagnosis as 
histological confirmation was not possible) using read codes225. Progressors diagnosed with OC 
within 12 months of BO diagnosis (prevalent cancers) were excluded. In total, 103 patients 
developed OC 12 months after diagnosis of BO. Exposure to statins was ascertained from 
electronic prescription data and analysed using two distinct methods: first, a “conventional” 
binary approach whereby exposure was defined by use of statins at baseline analysed with Cox 
proportional hazard regression; and second, a proportion days covered (PDC) approach whereby 
the cumulative duration of statin prescriptions dispensed during follow-up was divided by the 
total duration of follow-up, expressed as a percentage, analysed with time-dependent marginal 
structural equation models. Using the conventional approach, statin use at baseline was not 
significantly associated with malignant progression (HR 0.61, 95% CI 0.34-1.10). Using the PDC 
approach, statin use was significantly inversely associated with risk of malignant progression (HR 
0.61, 95% CI 0.45-0.83). Models were adjusted for age, gender, smoking, BMI, hiatal hernia, type 2 
Diabetes Mellitus, PPI use, metformin use, insulin use, and “oral anti-diabetic medications”. The 
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main strength of this study is its prospective design, large cohort size and electronic 
ascertainment of exposures (which optimally identifies statin prescriptions, a routine prescription 
administered in primary care) and outcomes. The use of time-dependent marginal structural 
models avoid immortal time bias and theoretically handles time-dependent confounding231. This 
study has several limitations: first, although it may be reasonable to conclude that most 
oesophageal malignancies which develop during follow-up of patients with BO are 
adenocarcinomas, this is not known with certainty in this population; and this study would have 
benefitted from linkage to the National Cancer Registry for confirmation of the histological 
subtype of OC in a subset. Second, while read codes for OC have been shown to be reliable in the 
GPRD, when validated against cancer registrations232, it is not clear whether read codes for BO 
are: to date there are no published validation studies of this condition.  
 
The Seattle Barrett’s Esophagus Study included a baseline cohort of 411 patients with Barrett’s 
oesophagus (80, 19.5% had HGD at baseline) of which 56 (13.6%) progressed to OAC during follow 
up223.  Patients with less than five months’ follow-up were excluded. Medication use was 
ascertained by interview at baseline and each subsequent surveillance appointment. Statin use 
was defined based on recall during follow-up. Statin use was non-significantly inversely associated 
with progression to OAC (HR 0.68, 95% CI 0.30-1.54) in time-dependent analyses, adjusted for 
age, sex, smoking and NSAID use. This study’s strength is its prospective design and capture of 
time-dependent variables. This study has several limitations: first, it may be underpowered with 
only 56 events; second, 19.5% of the cohort had HGD at baseline making comparisons with other 
studies difficult (as HGD was frequently the outcome of interest in other studies), and generalising 
the findings to wider populations with BO difficult; third, patients who progressed to 
adenocarcinoma within one year should be considered as prevalent cases and measurement of 
statin exposure during this period should not be considered as having played an aetiological role 
and therefore this study did not consider a plausible window of latency.  
 
A nested case-control study based within the Health Improvement Network (THIN) database 
included 55 patients with prior BO (diagnosed greater than one year previously) who developed 
OC during follow-up and 3, 694 patients with BO with no record of progression to cancer within 
one year of diagnosis222. OAC was confirmed in 34 of these cases from a number of sources: free-
text entry in THIN, chemotherapy consistent with OAC and death certificates. Medication 
exposure data were retrieved from the database differentially for cases and controls: for cases, 
drug prescription data was censored from one year before the first code denoting diagnosis of 
OC; while the same procedure was not applied to the BO controls (exposure measurement was 
until the index date). Exposure to the medication groups of interest was classified according to 
Statins and oesophageal adenocarcinoma 
71 
ever use. Cox proportional hazard regression estimated the association between ever use and 
malignant progression, adjusted for age, gender and smoking. Statin use was non-significantly 
inversely associated with risk of malignant progression (HR 0.82, 95% CI 0.43-1.56). This study’s 
main strength is the available routinely recorded drug prescription data. This study has several 
limitations: first, the study may be underpowered despite a large control population as the 
absolute number of cases was relatively low; second, given “ever use” definitions, analyses are 
likely susceptible to immortal time bias; third, differential censorship for exposures between cases 
and controls would likely bias estimates for drug exposures towards inverse associations; and 
fourth, OC and BO are diagnoses which are yet to be validated in THIN, nevertheless, given the 
similarities with other large routine healthcare datasets in the UK, these diagnoses would still be 
expected to be valid217.  
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Study 
(year) 
location 
Design 
Source Time 
period 
Number 
of 
patients 
Cases 
with 
known 
prior BO 
Statin use: 
definition 
ascertainme
nt 
prevalence 
Outcomes Risk estimates of 
statins (vs. none) 
Covariates 
matched/ 
adjusted 
fora 
Limitations 
Nguyen188 
(2015) 
 
US 
 
Nested 
case-
control 
study 
VA 
database 
2004-
2011 
OAC: 311 
BO 
controls: 
856 
 
Definition 
of BO and 
length not 
provided. 
311 
(100%) 
Filled 
(dispensed 
prescription) 
between 90 
days prior to 
OAC/index 
date and 
date of BO. 
 
40.2% cases 
54% controls 
OAC Statin use (primary 
definition), OR 0.65, 
95% CI 0.47-.91 
Duration responses 
< 6 months, OR 0.82, 
95% CI 0.52-1.31;  
6-18 months, 0.52, 
0.32-0.85;  
> 18 months 0.64, 
0.40-1.01 
Matched: 1, 
2, 12 
Adjusted: 
4-7, 12, 14, 
15 
Limited account for 
biological latency. 
Susceptible to time-
window bias. 
Kastelein2
24, 230 
(2011)  
 
Netherlan
ds 
 
Cohort 
Three 
medical 
academic 
centres 
and 15 
endoscop
y units 
BO: 2003-
2004 
HGD/OA
C: NS 
HGD/OA
C: 38 
BO 
cohort: 
570 
38 
(100%) 
Patient 
interview, 
questionnaire
, pharmacy 
records. 
Ever use (1 
month 
prescription) 
during follow-
up. 
 
36.7% in 
whole cohort. 
HGD/OAC Ever use (primary 
definition) in non-time 
dependent analysis, 
HR 0.46, 95% CI 0.21 
– 0.99; time-
dependent analysis: 
HR 0.55, 95% CI 0.23-
1.29. 
≤ 5 years’ statin 
exposure, HR 0.51, 
95% CI 0.18 – 1.47; > 
5 years, HR 0.49, 95% 
CI 0.18-1.29 
Adjusted: 
1,2,5, 7, 8, 
13 
Statin use definition 
includes potentially short 
exposure windows. 
Non-time dependent 
analyses risk immortal 
time bias. Drug exposure 
determined at surveillance 
intervals. 
No account of biological 
latency. 
Beales221 
(2012) 
 
UK 
 
Case-
control 
study 
Single 
centre 
2009-
2011 
OAC: 85 
BO 
controls: 
170 
5 (5.9%) Patient 
interview and 
referral letter. 
Use for at 
least 6 
months. 
20% cases. 
 
35.3% 
controls. 
OAC 6 month’s use (primary 
exposure), OR 0.57, 
95% CI 0.28-0.94; 
≤  40mg daily, OR 
0.59, 95% CI 0.27-
0.98;  
> 40mg OR 0.31, 95% 
CI 0.05-0.97;  
p for trend for dose 
response relationship 
< 0.05; 
Adjusted: 1, 
4, 7, 8, 9, 
10, 12 
Drug exposure 
ascertainment with patient 
interviews -recall bias, 
and measurement error. 
No account of biological 
latency. 
Susceptible to time-
window bias. 
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0.5-2 years, OR 0.77, 
95% CI 0.29-1.87;  
2-5 years, OR 0.58, 
95% CI 0.27-1.43;  
> 5 years OR 0.41, 
95% CI 0.15-0.85;  
p for trend for duration 
response relationships 
< 0.05 
 
Iyer225 
(2015)  
 
UK 
 
Cohort 
GPRD 
(Routine 
healthcar
e dataset 
within 
primary 
care) 
1991-
2010 
OC: 103 
BO: 9660 
103 
(100%) 
Electronic 
prescription 
records. 
Binary use at 
baseline. 
Proportion 
days covered 
(PDC). 
 
27.6% in 
whole cohort. 
OC Use at baseline, HR 
0.61, 95% CI 0.34-
1.10; 
PDC, HR 0.61, 95% CI 
0.45-0.83. 
Adjusted: 1, 
2, 4, 5, 9, 
14, 18, 19.   
No histological 
confirmation of subtype of 
OC. 
No account of biological 
latency. 
BO is yet to be validated 
in the GPRD. 
Time periods investigated 
include periods of 
negligible statin 
prescriptions. 
Kantor223 
(2012) 
 
US 
 
Cohort 
Seattle 
Barrett’s 
Esophagu
s Study 
 
Single 
centre 
1999-
2009 
EAC: 56 
BO: 411 
(80 had 
HGD at 
baseline) 
56 
(100%) 
Interview at 
surveillance 
intervals. 
 
13.6% in 
whole cohort. 
OAC HR 0.68, 95% CI 0.30-
1.54 
Adjusted: 1, 
2, 4, 7 
Drug exposure 
determined at surveillance 
intervals. 
HGD at baseline in 
19.5%. 
No account of biological 
latency. 
Cooper222 
(2014) 
 
UK 
 
Nested 
case-
control 
THIN 
(Routine 
healthcar
e dataset 
within 
primary 
care) 
1988-
2004 
OC: 55 
BO: 3694 
55 
(100%) 
Electronic 
prescription 
records. 
 
Ever use. 
 
30.5% in the 
whole cohort. 
OC HR 0.82, 95% CI 0.43-
1.56 
Adjusted: 1, 
2, 4 
Likely under-powered. 
No histological 
confirmation of subtype of 
OC. 
Ever use exposure 
definition risks immortal 
time bias. 
Susceptible to time-
window bias. 
Masclee22
6 (2015) 
UK and 
THIN and 
IPCI 
THIN: 
1996-
2011 
THIN  
OAC: 40 
BO: 656 
1409 
(100%) 
Exposure 
window not 
defined.  
OAC 
HGD/OAC 
>3 years OR, 0.5, 95% 
CI 0.1-1.7 
<0.8 DDD OR 1.0, 
Matched: 1, 
2, 11, 21 
Adjusted: 
Multiple testing. 
Limited adjustment for 
confounders. 
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Netherlan
ds 
Nested 
case-
control 
IPCI: 
1996-
2012 
IPCI 
5: OAC 
12: HGD 
BO: 753 
 
Electronic 
prescription 
records. 
According to 
duration and 
DDD per day 
 
26.3% in 
cases 
25.5% in 
controls 
 
95% CI 0.5-2.1 
≥0.8 <1.2 DDD OR 
0.7, 95% CI 0.2-3.1 
≥1.2 DDD per day 0.8, 
95% CI 0.3-2.4 
 
20 No account of biological 
latency. 
Table 6: Observational studies which examine associations between statin use and malignant progression in patients with Barrett’s Oesophagus  
Abbreviations: DDD, defined daily dose; OAC, oesophageal adenocarcinoma; GPRD, general practice research database; HGD, high-grade dysplasia; IPCI, integrated primary care information database; 
NS, not stated; OC REF, reference category; THIN, the health improvement network US, United States; 
a1, Age; 2, gender; 3, year of OAC diagnosis; 4, smoking, 5, PPI use; 6 H2A use; 7, NSAID use; 8, aspirin use; 9, metformin; 10 alcohol use; 11, date of BO diagnosis; 12, age at BO diagnosis; 13 dysplasia; 
14, BMI; 15, number of gastroscopies prior to index; 16, hiatus hernia; 17 Type II diabetes; 18, insulin; 19, other oral hypoglycaemic agents; 20, duration of follow-up since BO diagnosis; 21, country
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2. Chapter 2 – The association between post-diagnostic statin use and 
survival in patients with oesophageal carcinoma: a population-based 
cohort study 
2.1. Abstract 
Background 
Oesophageal cancer (OC) is a significant cause of cancer-related mortality worldwide. Statins have 
anti-carcinogenic effects in OC cell lines. The aim of this study was to determine whether statin 
use following diagnosis of OC, including the histological subtypes, is associated with reduced OC-
specific and all-cause mortality.  
Methods 
A cohort of 4445 men and women in the United Kingdom diagnosed with OC between January 
2000 and November 2009 and followed-up until November 2011 were identified using the 
General Practice Research Database. Cox proportional hazard regression analysis with time-
dependent exposures estimated the association between post-diagnostic statin use and OC-
specific and all-cause mortality.  
Results 
The median survival of the whole cohort was 9.2 months (IQR 3.7-23.2). The median survival in 
post-diagnostic statin users was 14.9 months (IQR 7.1-52.3) and in non-users was 8.1 months (IQR 
3.3-20).  Post-diagnostic statin use was associated with a decreased risk of OC-specific mortality 
(adjusted Hazard Ratio [HR] 0.62, 95% CI 0.44-0.86) and all-cause mortality (HR 0.67, 95% CI 0.58-
0.77) for the full cohort. In patients with oesophageal adenocarcinoma (OAC), post-diagnostic use 
of statins was associated with decreased risk of OC-specific mortality (HR 0.61, 95% CI 0.38-0.96) 
and all-cause mortality (HR 0.63, 95% 0.43-0.92). This effect was not observed in patients with 
oesophageal squamous cell carcinoma (OSCC). There was no evidence of effect modification on 
associations by pre-diagnostic statin use. 
Conclusions 
In a large population-based cohort, post-diagnostic statin use in patients with OC was associated 
with reduced OC-specific and all-cause mortality, specifically in those with OAC but not OSCC. 
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2.2. Introduction 
 
Oesophageal cancer (OC) is the 5th and 8th most common cause of cancer-related death in men 
and women respectively worldwide233. Of the two main histological subtypes, oesophageal 
squamous cell carcinoma (OSCC) is globally predominant, while oesophageal adenocarcinoma 
(OAC), the incidence of which has rapidly risen since the 1970s, is the most common form in the 
west4, 233. Most patients with OC present with advanced disease and are often only amenable to 
palliative management. Consequently, the overall 5-year survival rate is approximately only 15%5.  
 
Novel clinical interventions to improve prognosis in patients with OC are required. There has been 
a considerable research focus on the potential anti-cancer effects of statins (3-hydroxy-3-
methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors), which are commonly prescribed for 
the primary and secondary prevention of cardiovascular disease234. A body of basic research has 
demonstrated that statins promote apoptosis and limit proliferation in OAC and OSCC cell lines179, 
180, 182, 235. A number of well-conducted epidemiological studies have demonstrated that use of 
statins post-diagnosis is associated with reduced risk of cancer-specific mortality in a number of 
malignancies, including prostate, breast and colorectal carcinoma187, 190, 236. Furthermore, at a 
population level their use is inversely associated with development of the histological subtypes of 
OC220. A population-based cohort study in Denmark demonstrated that statin use prior to 
diagnosis of OC was associated with a 19% decrease in cancer-specific mortality189.  Whether 
statin use following diagnosis of OC, a more relevant time period for clinical intervention, 
improves survival is unknown. Furthermore, whether or not statins exert differential effects on 
survival for the two main histological subtypes, OAC and OSCC, is unknown. Therefore, the 
primary aim of this epidemiological study was to determine whether statin use following 
diagnosis of OC, including the histological subtypes, is associated with reduced OC-specific and all-
cause mortality. Secondary aims were to determine whether pre-diagnostic statin use is an effect 
modifier on the association between post-diagnostic statin use and survival; determine whether a 
dose-response relationship exists; and determine whether differential effects exist according 
statin type. 
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2.3. Methods 
Data sources 
This study was conducted using three databases: the United Kingdom (UK) General Practice 
Research Database (GPRD), the UK National Cancer Registry (NCR) and the Office of National 
Statistics (ONS) database. The GPRD is the world’s largest electronic database of prospective 
demographic, lifestyle and medical data in a primary care setting237. At the time of data 
extraction, 4 million patients were registered at 488 general practices, covering 6% of the UK 
population. The age and sex distributions of participants in the GPRD are comparable with the 
National Population Census, and the distribution of participating practices is representative of the 
UK population238. General Practitioners (GPs) prospectively record incident diagnoses and medical 
procedures using a modified Read/Oxford Medical Information System (OXMIS) classification 
system. Filled drug prescriptions issued by GPs are automatically recorded and coded using the UK 
Prescription Pricing Authority Dictionary. Data recorded on diagnostic codes to identify diseases, 
including OC, and drug prescriptions in the GPRD have been shown to be valid in independent 
studies232, 239, 240. Linkage between databases used a deterministic algorithm based on the patient 
National Health Service number, postcode, gender and date of birth. The NCR contains 
information on tumour site (coded using the International Classification of Diseases, 10th Revision 
[ICD-10]), histology, cancer stage and treatment modalities. A comprehensive list of codes to 
define the study cohort and covariates have been included in appendix A. Approximately half of 
GPRD practices were linked to the NCR at the time of data extraction. For patients with data 
linked to the NCR, ONS data was available to determine cause of death. The GPRD group have 
obtained blanket approval from a multi-centre ethics committee for observational research 
conducted within the database. The study protocol was approved by the MHRA Independent 
Scientific Advisory Committee (approved protocol number: 11_131). 
 
Study cohort 
Participants with incident oesophageal or oesophagogastric junction cancers, diagnosed between 
1st January 2000 to 30st November 2009, and followed-up until 1st November 2011 were identified 
from the GPRD. Patients were included with no prior history of cancer. All patients were required 
to be diagnosed at least one year after the contributing practice had received its “up-to-standard” 
date: the time from which the practice was considered to generate continuous high quality data 
fit for research. The histological subtype for a subset of patients was determined through linkage 
to the NCR. ICD codes were used to confirm oesophageal (C15) and oesophago-gastric junctional 
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(C16) cancers, and specific morphology codes were used to obtain the histological subtypes: OAC, 
oesophagogastic junctional adenocarcinoma (OGJA) and OSCC. Follow-up was from the date of 
diagnosis until death, or until they were transferred out of the GPRD or the date of last data entry, 
whichever came first.  
 
Statin use 
Exposure to the following statins currently in clinical use in the UK were extracted: Simvastatin, 
Atorvastatin, Pravastatin, Rosuvastatin and Fluvastatin.  Post-diagnostic statin use was defined as 
a prescription of any of these statins recorded in the GPRD at any time after the date of diagnosis. 
Post-diagnostic statin use was included as a time-dependent covariate in the models to avoid 
immortal-time bias: whereby a span of cohort follow-up during which death could not occur (i.e. 
between diagnosis and the first statin prescription) is inappropriately introduced due to the 
definition of the exposure of interest206. Patients were considered unexposed until the first post-
diagnosis prescription, from which point they were considered continuously exposed until the end 
of follow-up. Deeming patients continuously exposed sought to minimize reverse causation bias, 
whereby ultimately discontinuation could reflect poor prognosis and therefore death may 
otherwise be more likely inappropriately classified during an “unexposed” period241. Exposure to 
the individual statins listed above was also considered in survival analyses. To investigate the 
possibility of healthy survivor bias in the statin users post-diagnosis, the intervals between 
diagnosis and statin initiation for all statin users post-diagnosis were presented using a Kaplan-
Meier plot (figure 12).  
 
Pre-diagnosis statin use was also an exposure of interest. It was defined as a prescription of any of 
the statins recorded above in the GPRD for a minimum of two months between 6 and 18 months 
prior to diagnosis. This definition sought to minimize reverse causation bias, whereby 
symptomatic OC (and hence likely more advanced disease) could influence prescribing practice or 
medication use. Pre-diagnosis statin use was determined for the following three reasons: it was 
entered as a covariate in models of post-diagnostic statin use to determine whether it modifies 
the effect of post-diagnosis statin use on survival; in sensitivity analyses the association between 
pre-diagnosis statin use on survival was determined to consider an exposure to statin use, 
alternative to post-diagnosis statin use, in which the potential effect of reverse-causation bias 
would be expected to be minimal; and finally it was used to determine categories for dose-
response analyses. Statin users were categorized as low (equivalent to ≤ 20mg simvastatin) or 
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high (equivalent to > 20mg simvastatin) dose users based on the mean daily dose for statin 
prescriptions collected between 6-18 months prior to diagnosis. Cumulative statin dose was 
determined using categories of cumulative defined-daily dose (DDD). The DDD, a standardized 
measure of drug exposure as defined by the World Health Organization, is the assumed average 
maintenance dose per day for a drug used for its main indication in adults242. For example, 1 DDD 
is equivalent to a single dose of 30mg Simvastatin or 20mg Atorvastatin. The median cumulative 
DDD collected between 6-18 months prior to diagnosis in the whole cohort was the threshold for 
cumulative dose categories. Post-diagnostic mean or cumulative dose-response analyses were not 
examined a priori as the dose categories would be expected to be a function of survival time. In a 
post-hoc analysis we conducted dose-response analyses using the dose (expressed in DDDs) of the 
first statin prescribed post-diagnosis to determine the dose category. 
 
Covariates 
The following covariates which could plausibly confound associations between post-diagnostic 
statin use and survival were extracted from the GPRD: age at diagnosis, gender, body mass index 
(BMI) at the time closest to and preceding diagnosis, smoking status, cardiovascular diseases 
(coronary artery, cerebrovascular and peripheral vascular disease) and diabetes mellitus, surgery 
(either esophagectomy, esophago-gastrectomy or extended gastrectomy) recorded within 6 
months of diagnosis and medication use (aspirin, angiotensin converting enzyme inhibitors [ACEi] 
and angiotensin 2 receptor blockers [ARBs], beta-blockers and non-steroidal anti-inflammatory 
drugs [NSAIDs]). Use of these medications were extracted both post-diagnosis and pre-diagnosis 
using the same exposure definitions as for statin use. The following covariates were extracted 
from the NCR: chemotherapy, radiotherapy and surgery (either esophagectomy, esophago-
gastrectomy or extended gastrectomy) recorded within 6 months of diagnosis. 
 
Outcome measures 
The outcome measures were OC-specific and all-cause mortality. All-cause mortality was 
determined for all study patients in the GPRD. OC-specific mortality was determined for the 
subset of participants with data linked to the NCR and ONS datasets where OC was listed in part 
one of the death certificate.  
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Statistical analysis 
Descriptive statistics were used to summarize the characteristics of the cohort, including the 
histological subtypes; and separately for pre and post-diagnosis statin users. The characteristics 
between statin users and non-users were compared using the Chi-squared test for categorical 
data, two sample t-test for age and the Mann-Whitney U test for survival time. Crude rates of OC-
specific and all-cause mortality were calculated which reflect time-dependent exposure to statins. 
To account for the time-varying nature of drug exposures, Cox proportional hazard regression 
with time-dependent exposures, estimated the associations between statin use (versus non-use) 
post-diagnosis on OC-specific and all-cause mortality for the full cohort and the histological 
subtypes. In OC-specific analyses, deaths due to any other cause were censored, a valid approach 
to examine causal treatment effects on the cause-specific hazard, and therefore account for 
competing risks243, 244. Concomitant medication use and surgery were included as time-dependent 
covariates in the models. Surgery was not included in multivariable analyses of the full cohort 
(total OC, n= 4445) as it was under-recorded in the GPRD, however it was included with cohorts 
linked to the NCR, where it was more comprehensively recorded. Survival curves according to 
post-diagnosis statin use were constructed using Cox proportional hazard regression with time-
dependent exposures. For analyses of pre-diagnosis statin use, follow-up began from the date of 
diagnosis, and all included covariates were measured prior to this date. Cancer stage was 
incomplete for 95.9% of the cohort and was therefore not included in multivariable analyses. 
Tests for interaction examined for any effect modification of pre-diagnosis statin use on the 
association between post-diagnostic statin use and mortality. A test for linear trend was applied 
across dose categories.  
 
Sensitivity analyses 
We performed a number of sensitivity analyses to determine the robustness of our findings. As 
previously outlined, the association between pre-diagnosis statin use on OC-specific and all-cause 
mortality for the full cohort and the histological subtypes was examined. To determine whether 
treatment modality (surgery, chemotherapy and radiotherapy) was an important confounder in 
the relationship between post-diagnostic statin use and OC-specific and all-cause mortality, 
analyses were repeated with and without these covariates in the model. To explore the potential 
impact of reverse causation bias on analyses of post-diagnostic statin use and consider latency, 
the cohort was restricted to those surviving at least three months, all drug exposures were lagged 
for at least three months and all new prescriptions in the final three months of life were ignored. 
In a post-hoc analysis, the effect of post-diagnosis statin use on-cause and OC-specific mortality 
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stratified by pre-diagnosis cardiovascular disease status were performed as effect sizes could 
differ according to their indication (primary versus secondary prevention). All analyses were 
performed with STATA version 11 (StataCorp LP, College Station, Texas, USA). 
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2.4. Results 
Cohort 
In total, 4676 patients identified from the GPRD with oesophageal or esophago-gastric junctional 
carcinoma met the inclusion criteria (figure 9). From these, 231 (5%) patients were excluded as 
they had no follow-up from diagnosis. The main cohort (total OC) comprised 4445 patients of 
whom 3655 died during follow-up. In total, 1530 (34.4%) patients were linked to the NCR in whom 
there were 1323 all-cause and 805 OC-specific deaths. Of these 1165 had complete information 
on both histology and site including 602 with OAC, 221 with OGJA and 342 with OSCC.  
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Patients diagnosed with oesophageal or oesophago-gastric junctional 
carcinoma between January 1st, 2000 to 30th November 2009 
At least 12 months follow-up prior to date of diagnosis 
(n= 4676) 
Study cohort (total OC) 
(n = 4445) 
All-cause deaths  
(n = 3655) 
Excluded 
No follow-up from 
diagnosis (n = 231) 
Histological subtypes 
(n = 1165) 
OAC 
(n = 602) 
All-cause deaths (n = 518) 
OC-specific deaths (n = 349) 
OGJA 
(n = 221) 
All-cause deaths (n = 189) 
OC-specific deaths (n = 103) 
OSCC 
(n = 342) 
All-cause deaths (n = 297) 
OC-specific deaths (n = 202) 
Total OC linked to the 
cancer registry 
(n = 1530) 
All-cause deaths (n = 1323) 
Cancer-specific deaths 
(n = 805) 
Excluded 
Not linked to cancer 
registry (n = 2915) 
Excluded 
Inadequate data on 
histology or site from 
cancer registry  
(n = 365) 
Figure 9: Flow chart of study participants 
Abbreviations: OAC, oesophageal adenocarcinoma; OC, oesophageal carcinoma; OGJA, oesophagogastric 
junctional adenocarcinoma; OSCC, oesophageal squamous cell carcinoma 
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Clinical characteristics 
Overall, patients in the whole cohort were more likely to be male, smokers and overweight or 
obese (table 9). Median survival for the whole cohort was 9.2 months (inter-quartile range 3.7-
23.2). Post diagnosis statin use was observed in 18.7% of patients. Accounting for immortal-time, 
the median survival in post-diagnosis statin users was 14.9 months (IQR 7.1-52.3) and in non-
users was 8.1 months (IQR 3.3-20).  Most patients with OAC and OGJA were male and overweight, 
whereas the majority of patients with OSCC were female and had a normal or low BMI. Data on 
surgery was more complete for the histological subtypes (as additional surgical data was available 
from the NCR) than the whole cohort.  
 
Pre and post-diagnosis statin use was more common among patients with OAC and OGJA than for 
those with OSCC. Pre and post-diagnosis statin users (compared to no pre and no post-diagnosis 
statin users respectively) were more likely to be older, male, overweight, smokers, have 
associated cardiovascular diseases or diabetes, and use aspirin, ACEi/ARBs or beta-blockers (all p 
values < 0.001) (table 10). Post-diagnosis statin users were more likely to have had surgery 
compared to those who did not use statins post-diagnosis (24.9% vs. 21.2% respectively, p = 
0.018); whereas pre-diagnosis statin users were less likely to have had surgery than those who did 
not use statins pre-diagnosis (17.5% vs. 23% respectively, p < 0.001). 830 patients were prescribed 
statins post-diagnosis in the whole cohort, of whom 163 were new users. Of these 117 (72%) 
were started without a prior history of cardiovascular disease (suggesting their indication for 
primary prevention), and 46 (28%) were started after a record of cardiovascular disease 
(suggesting their indication for secondary prevention). Of all patients who used statins following 
diagnosis, 90% were prescribed within 6 months of diagnosis (figure 12). 
 
Statins and oesophageal adenocarcinoma 
85 
 
  Total EC EAC  OGJA ESCC  
Characteristics (n=4445) (n=602) (n=221) (n=342) 
Age (years), mean (SD) 70.8 (11.5) 70.7 (11.3) 68.3 (11.6) 71.8 (12.1) 
Male gender, n (%) 2913 (65.5) 468 (77.7) 171 (77.4) 136 (39.8) 
Smoking status, n (%)         
Ever 2701 (64.3) 348 (62.0) 127 (60.2) 187 (59.2) 
Unknown1 244 (5.5) 41 (6.8) 10 (4.5) 26 (7.6) 
Body mass index (kg/m2), n (%)         
< 25 1460 (40.2) 168 (35.0) 58 (31.4) 160 (59.0) 
≥ 25 < 30 1435 (39.5) 215 (44.8) 76 (41.1) 80 (29.5) 
≥ 30 737 (20.3) 97 (20.2) 51 (27.6) 31 (11.4) 
Unknown1 813 (18.3) 122 (20.3) 36 (16.3) 71 (20.8) 
Comorbidities, n (%)         
Diabetes mellitus 347 (7.8) 52 (8.6) 17 (7.7) 18 (5.3) 
Cardiovascular diseases 771 (17.3) 99 (16.4) 28 (12.7) 57 (16.7) 
Oesophageal cancer treatment, n (%)         
Surgery 973 (21.9) 196 (32.6) 98 (44.3) 92 (26.9) 
Chemotherapy 325 (7.3) 146 (24.3) 60 (27.1) 68 (19.9) 
Radiotherapy 231 (5.2) 88 (14.6) 9 (4.1) 78 (22.8) 
Median survival, months (IQR) 
9.2 (3.7-23.2) 9.6 (4.0-23.3) 10.6 (4.2-24.8) 
8.6 (4.0-
18.7) 
Prior medication use         
Statin prescription, n (%) 908 (20.4) 101 (16.8) 30 (13.6) 39 (11.4) 
Aspirin prescription, n (%) 998 (22.5) 130 (21.6) 44 (19.9) 74 (21.6) 
Beta-blocker prescription, n (%) 685 (15.4) 96 (15.9) 36 (16.3) 51 (14.9) 
ACEi or ARB prescription, n (%) 947 (21.3) 117 (19.4) 31 (14.0) 58 (17.0) 
NSAID prescription, n (%) 391 (8.8) 51 (8.5) 16 (7.2) 29 (8.5) 
Post diagnosis medication use         
Statin prescription, n (%) 830 (18.7) 104 (17.3) 35 (15.8) 31 (9.1) 
Aspirin prescription, n (%) 839 (18.9) 116 (19.3) 39 (17.6) 48 (14.0) 
Beta-blocker prescription, n (%) 709 (16.0) 99 (16.4) 32 (14.5) 43 (12.6) 
ACEi or ARB prescription, n (%) 889 (20.0) 109 (18.1) 38 (17.2) 33 (9.6) 
NSAID prescription, n (%) 793 (17.8) 128 (21.3) 41 (18.6) 65 (19.0) 
Table 7: Baseline demographic and clinical characteristics of the cohort stratified by histological subtype and site 
Abbreviations: ACEi, angiotensin conversing inhibitor; ARB, angiotensin receptor blocker; OC, oesophageal cancer; OAC, 
oesophageal adenocarcinoma; OGJA, oesophagogastric junctional adenocarcinoma; OSCC, oesophageal squamous cell 
carcinoma; NSAID, non-steroidal anti-inflammatory drugs. 
1Percentages presented for unknown categories reflect overall proportion of missing data for the relevant covariate; 
while percentages presented for known categories refer to complete data only 
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No pre-
diagnostic 
statin use 
Pre-
diagnostic 
statin use 
  No post-
diagnostic 
statin use 
Post-diagnostic 
statin use 
  
      
Characteristics (n=3537) (n=908) p-value (n=3615) (n=830) p-value 
Age (years), mean (SD) 70.4 (12.0) 72.3 (9.3) <0.001 70.7 (11.9) 71.3 (9.2) 0.137 
Male gender, n (%) 2249 (63.6) 664 (73.1) <0.001 2291 (63.4) 622 (74.9) <0.001 
Smoking status, n (%)             
Ever 2037 (61.6) 664 (74.4) <0.001 2102 (62) 599 (73.7) <0.001 
Unknown1 229 (6.5) 15 (1.7)   227 (6.3) 17 (2.0)   
Body mass index (kg/m2), n (%)             
< 25 1202 (43.1) 258 (30.7) 
<0.001 
1246 (43.3) 214 (28.4) 
<0.001 
≥ 25 < 30 1085 (38.9) 350 (41.7) 1109 (38.5) 326 (43.2) 
≥ 30 505 (18.1) 232 (27.6) 523 (18.2) 214 (28.4) 
Unknown1 745 (21.1) 68 (7.5)   737 (20.4) 76 (9.2)   
Comorbidities, n (%)             
Diabetes Mellitus 180 (5.1) 167 (18.4) <0.001 236 (6.5) 111 (13.4) <0.001 
Cardiovascular diseases 419 (11.8) 352 (38.8) <0.001 491 (13.6) 280 (33.7) <0.001 
Oesophageal cancer treatment, n 
(%)             
Surgery 814 (23.0) 159 (17.5) <0.001 766 (21.2) 207 (24.9) 0.018 
Chemotherapy 282 (8.0) 43 (4.7) 0.323 280 (21.4) 45 (20.5) 0.786 
Radiotherapy 202 (5.7) 29 (3.2) 0.265 203 (15.5) 28 (12.8) 0.302 
Median survival, months (IQR) 9.2 (3.7-23.3) 9.5 (4.0-23.1) 0.913 8.1 (3.3-20.0) 14.9 (7.1-52.3) <0.001 
Prior medication use             
Statin prescription, n (%) 0 (0) 908 (100) N/A 262 (7.2) 646 (77.8) <0.001 
Aspirin prescription, n (%) 470 (13.3) 528 (58.1) <0.001 572 (15.8) 426 (51.3) <0.001 
Beta-blocker prescription, n (%) 371 (10.5) 314 (34.6) <0.001 417(11.5) 268 (32.3) <0.001 
ACEi or ARB prescription, n (%) 483 (13.7) 464 (51.1) <0.001 567 (15.7) 380 (45.8) <0.001 
NSAID prescription, n (%) 296 (8.4) 95 (10.5) 0.047 306 (8.5) 85 (10.2) 0.103 
Post diagnosis medication use             
Statin prescription, n (%) 184 (5.2) 646 (71.1) <0.001 0 (0) 831 (100) NA  
Aspirin prescription, n (%) 456 (12.9) 383 (42.2) <0.001 390 (10.8) 449 (54.1) <0.001 
Beta-blocker prescription, n (%) 419 (11.8) 290 (31.9) <0.001 385 (10.7) 324 (39.0) <0.001 
ACEi or ARB prescription, n (%) 493 (13.9) 396 (43.6) <0.001 437 (12.1) 452 (54.5) <0.001 
NSAID prescription, n (%) 635 (18.0) 158 (17.4) 0.698 598 (16.5) 195 (23.5) <0.001 
Table 8: Baseline demographic and clinical characteristics of the whole cohort stratified by statin use 
Abbreviations: ACEi, angiotensin conversing inhibitor; ARB, angiotensin receptor blocker; OC, oesophageal cancer; OAC, 
oesophageal adenocarcinoma; OGJA, oesophagogastric junctional adenocarcinoma; OSCC, oesophageal squamous cell 
carcinoma; NSAID, non-steroidal anti-inflammatory drugs  
1Percentages presented for unknown categories reflect overall proportion of missing data for the relevant covariate; 
while percentages presented for known categories refer to complete data only 
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Post-diagnosis statin use and survival 
In the full cohort post-diagnosis statin use was associated with decreased OC-specific (HR 0.62, 
95% CI 0.44-0.86) and all-cause mortality (HR 0.67, 95% CI 0.58-0.77) (table 11, figure 10 and 11). 
Post-diagnosis statin use was associated with reduced OC-specific (HR 0.61, 95% CI 0.38-0.96) and 
all-cause mortality (HR 0.63, 95% CI 0.43-0.92) in patients with OAC only, but not for the other 
subtypes.  There was no significant interaction of pre-diagnosis statin use on the effect of post-
diagnostic statin use on OC-specific or all-cause mortality for whole cohort or the subtypes. Post-
diagnosis use of Simvastatin and Atorvastatin, but not the other statins, was associated with 
reduced OC-specific mortality (table 12). Post-diagnosis use of each of the individual statins 
investigated was associated with decreased all-cause mortality. 
 
 
Table 9: Oesophageal cancer-specific and all-cause mortality according to post-diagnostic use of statins 
Abbreviations: ARB, angiotensin receptor blocker; ACEi, angiotensin conversing enzyme inhibitor; OC, oesophageal 
cancer; OAC, oesophageal adenocarcinoma; OGJA, oesophagogastric junctional adenocarcinoma; OSCC, oesophageal 
squamous cell carcinoma; NSAID, non-steroidal anti-inflammatory drugs. 
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, pre-diagnosis 
statin use, post-diagnosis use of aspirin, beta-blockers, NSAIDs, and ACEi/ARBs 
2Adjusted for 1 except surgery 
3p for interaction between pre and post-diagnosis statin use on survival 
Mortality rate (95% CI) Unadjusted HR Adjusted HR
Cohort Statin exposure (per 100 person-years) (95% CI) (95% CI)
OC-specific mortality
Total OC No post-diagnosis statin use 1311 (85.7) 1848.3 38.9 (36.2-41.9) 1.00 (reference) 1.00 (reference)
(n=1530) Post-diagnosis statin use 219 (14.3) 426.8 20.1 (16.3-24.9) 0.71 (0.57-0.89) 0.62 (0.44-0.86)
1
0.817
OAC No post-diagnosis statin use 498 (82.7) 728.6 41.5 (37.0-46.4) 1.00 (reference) 1.00 (reference)
(n = 602) Post-diagnosis statin use 104 (17.3) 237.4 19.8 (14.9-26.4) 0.70 (0.51-0.96) 0.61 (0.38-0.96)
1
0.374
OGJA No post-diagnosis statin use 186 (84.2) 303.1 42.3 (36.6-48.8) 1.00 (reference) 1.00 (reference)
(n = 221) Post-diagnosis statin use 35 (15.8) 66.9 34.6 (21.2-56.5) 0.63 (0.33-1.21) 0.58 (0.20-1.69)
1
0.062
ESCC No post-diagnosis statin use 310 (90.6) 440.0 30.7 (25.0-37.6) 1.00 (reference) 1.00 (reference)
(n = 342) Post-diagnosis statin use 31 (9.1) 46.2 15 (8.0-27.8) 1.08 (0.65-1.81) 0.65 (0.29-1.46)
1
0.756
All-cause mortality
Total OC No post-diagnosis statin use 3615 (81.3) 4905.9 62.2 (60.0-64.5) 1.00 (reference) 1.00 (reference)
(n=4445) Post-diagnosis statin use 830 (18.7) 1379.5 43.7 (40.4-47.3) 0.82 (0.75-0.89) 0.67 (0.58-0.77)
2
0.599
OAC No post-diagnosis statin use 498 (82.7) 728.6 60.7 (55.3-66.6) 1.00 (reference) 1.00 (reference)
(n = 602) Post-diagnosis statin use 104 (17.3) 237.4 32.0 (25.6-40.1) 0.75 (0.59-0.96) 0.63 (0.43-0.92)
1
0.290
OGJA No post-diagnosis statin use 186 (84.2) 303.1 61.8 (54.9-69.6) 1.00 (reference) 1.00 (reference)
(n = 221) Post-diagnosis statin use 35 (15.8) 66.9 54.1 (36.5-80.0) 0.80 (0.51-1.24) 0.82 (0.38-1.73)
1
0.418
ESCC No post-diagnosis statin use 311 (90.9) 440.0 54.8 (47.0-63.8) 1.00 (reference) 1.00 (reference)
(n = 342) Post-diagnosis statin use 31 (9.1) 46.2 34.4 (22.9-51.8) 1.12 (0.74-1.68) 0.78 (0.41-1.50)
1
0.751
Number of 
patients, n (%)
p for 
interaction3
Person-
Years
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Figure 10: Adjusted time-dependent Cox proportional hazard regression survival curves with hazard ratios for 
oesophageal cancer-specific mortality stratified according to post-diagnosis statin use 
Abbreviations: ACEi, angiotensin conversing enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence 
interval; HR, hazard ratio; NCR, National Cancer Registry; NSAID, non-steroidal anti-inflammatory drugs  
A – Total oesophageal carcinoma cases linked to NCR (n = 1222)  
B – Oesophageal adenocarcinoma (n=470) 
C – Oesophagogastric junctional adenocarcinoma (n=184)  
D – Oesophageal squamous cell carcinoma (n = 267)  
All adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, pre-diagnosis 
statin use, post-diagnosis use of aspirin, beta-blockers, ACEi/ARBs and NSAIDs 
Only cases with complete body mass index and smoking data included 
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Figure 11: Adjusted time-dependent Cox proportional hazard regression survival curves with hazard ratios for all-cause 
mortality stratified according to post-diagnosis statin use 
Abbreviations: ACEi, angiotensin conversing enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence 
interval; HR, hazard ratio; NSAID, non-steroidal anti-inflammatory drugs  
A – Total oesophageal carcinoma cases (n = 3595)  
B – Oesophageal adenocarcinoma (n=470) 
C – Oesophagogastric junctional adenocarcinoma (n=184)  
D – Oesophageal squamous cell carcinoma (n = 267)  
A adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, pre-diagnosis statin use, 
post-diagnosis use of aspirin, beta-blockers, ACEi/ARBs and NSAIDs 
B, C, D adjusted for above including surgery 
Only cases with complete body mass index and smoking data included 
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  Number of 
patients, n 
(%) Person-Years 
Mortality rate 
(95% CI) Unadjusted HR Adjusted HR 
Statin type 
(per 100 person-
years) (95% CI) (95% CI) 
OC-specific 
mortality           
No statin 1311 (85.69) 1703.91 42.2 (39.2-45.4) 1.00 (reference) 1.00 (reference) 
Simvastatin 128 (8.37) 381.4 11.8 (8.8-15.8) 0.67 (0.50-0.91) 0.61 (0.41-0.89)1 
Pravastatin 20 (1.31) 29.8 33.6 (18.1-62.5) 1.00 (0.54-1.87) 1.09 (0.56-2.12)1 
Atorvastatin 63 (4.12) 137.1 21.9 (15.3-31.3) 0.81 (0.56-1.17) 0.56 (0.35-0.90)1 
Rosuvastatin 3 (0.2) 8.7 0 NA  NA  
Fluvastatin 5 (0.33) 14.3 7 (1-49.8) 0.23 (0.03-1.63) 0.24 (0.03-1.76)1 
All-cause mortality           
No statin 3615 (81.33) 4592.4 66.5 (64.1-68.9) 1.00 (reference) 1.00 (reference) 
Simvastatin 516 (11.61) 1066.3 34.4 (31.1-38.1) 0.83 (0.75-0.93) 0.68 (0.58-0.79)2 
Pravastatin 57 (1.28) 132.6 30.9 (22.8-42) 0.69 (0.51-0.94) 0.58 (0.41-0.82)2 
Atorvastatin 214 (4.81) 397.6 42.3 (36.3-49.2) 0.87 (0.74-1.02) 0.70 (0.58-0.85)2 
Rosuvastatin 32 (0.72) 56.4 39 (25.7-59.2) 0.68 (0.45-1.04) 0.63 (0.40-0.99)2 
Fluvastatin 11 (0.25) 40.0 12.5 (5.2-30) 0.36 (0.15-0.88) 0.33 (0.14-0.80)2 
Table 10: Mortality according to first statin type used post-diagnosis of oesophageal carcinoma 
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, surgery, diabetes, aspirin, beta-
blockers, ACEi/ARB use and NSAIDs 
2Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, aspirin, beta-blockers, 
ACEi/ARB use and NSAIDs 
 
Dose-response associations 
No significant dose-response associations for either mean dose or cumulative dose in the 6-18 
months prior to diagnosis were observed in the cohort for which OC-specific mortality data was 
available (n=1530) (p for trend 0.486 and 0.718 respectively) (see table 13). However, for all-cause 
mortality (n = 4445) there were significant dose-response associations for mean and cumulative 
dose categories (p for trend 0.003 and 0.002 respectively). For the dose response analyses 
defined by the first prescribed statin dose post diagnosis, while there were significant trends 
across dose categories, the point estimates did not consistently decrease from low to high dose 
use. 
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Table 11: Dose-response associations between statins use and risk of oesophageal cancer-specific and all-cause 
mortality 
Abbreviations: ACEi, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; DDD, defined daily 
dose; OC, oesophageal cancer;   
1Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, surgery, aspirin, beta-
blockers, ACEi/ARB use and NSAIDs 
2Adjusted for 1 except surgery 
3Dose categories determined using the first statin dose prescribed post-diagnosis 
4Low dose equivalent to ≤ 20mg Simvastatin; high dose equivalent to > 20mg Simvastatin 
5Measured between 6-18 months prior to diagnosis of OC 
6Cut off of 224 DDDs selected as the median value in whole cohort 
 
Mortality rate (95% CI) Unadjusted Adjusted
Statin exposure Person-Years (per 100 person-years) HR (95% CI) HR (95% CI)
OC-specific mortality
Post-diagnosis statin use3
No statin use 1311 (85.69) 1848.3 38.9 (36.2-41.9) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 118 (7.71) 245.1 18.8 (14.1-25.1) 0.70 (0.52-0.95) 0.56 (0.38-0.83)
1
High dose statin use4 101 (6.6) 181.7 22 (16.1-30.0) 0.73 (0.53-1.00) 0.69 (0.46-1.03)
1
P for trend 0.007 0.029
Pre-diagnosis statin use5
No statin use 1301 (85.0) 1980.6 34.8 (32.3-37.5) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 149 (9.7) 232.8 42.4 (33.9-53.1) 1.08 (0.85-1.36) 0.90 (0.68-1.19)
1
High dose statin use4 80 (5.2) 61.7 34.5 (25.2-47.2) 0.89 (0.65-1.23) 0.92 (0.64-1.33)
1
P for trend 0.770 0.486
≥ 1 < 224 DDD6 146 (9.5) 191.2 36.6 (29.0-46.3) 0.97 (0.76-1.24) 0.89 (0.67-1.20)
1
≥ 224 DDD6 83 (5.4) 103.2 44.6 (33.4-59.5) 1.07 (0.79-1.44) 0.99 (0.70-1.39)
1
P for trend 0.820 0.718
All-cause mortality
Post-diagnosis statin use3
No statin use 3615 (81.3) 4905.9 62.2 (60.0-64.5) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 379 (8.5) 691.4 39.5 (35.1-44.5) 0.80 (0.70-0.90) 0.64 (0.54-0.75)
2
High dose statin use4 451 (10.2) 688 48.0 (43.1-53.4) 0.83 (0.74-0.93) 0.70 (0.60-0.82)
2
P for trend <0.001 <0.001
Pre-diagnosis statin use5
No statin use 3537 (79.6) 5128.2 56.8 (54.8-58.9) 1.00 (reference) 1.00 (reference)
Low  dose statin use4 463 (10.4) 570.5 66.6 (60.2-73.7) 1.06 (0.95-1.18) 0.90 (0.80-1.02)
2
High dose statin use4 445 (10.0) 586.6 61.7 (55.7-68.4) 0.95 (0.86-1.07) 0.83 (0.73-0.94)
2
P for trend 0.706 0.003
≥ 1 < 224 DDD6 463 (10.4) 581.2 65.6 (59.3-72.5) 1.04 (0.94-1.16) 0.91 (0.80-1.02)
2
≥ 224 DDD6 445 (10.0) 575.9 62.7 (56.5-69.5) 0.97 (0.87-1.08) 0.82 (0.72-0.93)
2
P for trend 0.789 0.002
Number of 
patients, n (%)
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Sensitivity analyses 
Pre-diagnosis statin use was associated with decreased all-cause mortality (HR 0.87, 95% CI 0.78-
0.96) but not OC-specific mortality (HR 0.90, 95% CI 0.71-1.16) for the full cohort (table 14). No 
significant associations were observed between pre-diagnosis statin use and OC-specific and all-
cause mortality for the histological subtypes. Including and excluding treatment modality 
(surgery, chemotherapy, radiotherapy) as individual covariates in models in analyses of post-
diagnostic statin use did not materially alter the strength or precision of estimates (see table 15). 
Restricting the cohort to those who survived at least 3 months from diagnosis had a variable 
impact on associations between post-diagnostic statin use and survival: associations remained a 
similar magnitude in the full cohort for the assessment of all-cause mortality (main analysis: HR 
0.67, 95% CI 0.58-0.77; sensitivity analysis: HR 0.70, 95% CI 0.60-0.82), however lost significance 
in the assessment of OC-specific mortality  (main analysis: HR 0.62, 95% CI 0.44-0.86; sensitivity 
analysis HR 0.84, 95% CI 0.58-1.20). Lagging drug exposures weakened associations with OC-
specific and all-cause mortality in the full cohort while they were strengthened for associations in 
patients with OAC. Ignoring new prescriptions in the final three months of follow-up did not 
materially alter associations for: OC-specific mortality for the full cohort (main analysis: HR 0.62, 
95% CI 0.44-0.86; sensitivity analysis: HR 0.60, 95% CI 0.43-0.84); all-cause mortality for the full 
cohort (main analysis: HR 0.67, 95% CI 0.58-0.77; sensitivity analysis: HR 0.54, 95% CI 0.47-0.63); 
OC-specific mortality in patients with OAC (main analysis: HR 0.61, 95% CI 0.38-0.96; sensitivity 
analysis: HR 0.53, 95% CI 0.32-0.85); or for all-cause mortality in patients with OAC (main analysis: 
HR 0.63, 95% CI 0.43-0.92; sensitivity analysis: HR 0.49, 95% CI 0.33-0.73). For sensitivity analyses 
which stratified for pre-diagnosis cardiovascular disease status, risk of OC-specific mortality with 
post-diagnosis statin use was HR 0.66, 95% CI 0.44-1.00 (no cardiovascular disease) and HR 0.35, 
95% CI 0.20-0.63 (with cardiovascular disease); and for all-cause mortality with post-diagnosis 
statin use HR 0.66, 95% CI 0.56-0.79 (no cardiovascular disease) and HR 0.66, 95% CI 0.52-0.83 
(with cardiovascular disease). 
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Table 12: Oesophageal cancer-specific mortality according to pre-diagnostic use of statins 
Abbreviations: ARB, angiotensin receptor blocker; ACEi, angiotensin conversing enzyme inhibitor; OC, oesophageal 
cancer; OAC, oesophageal adenocarcinoma; OGJA, oesophagogastric junctional adenocarcinoma; OSCC, oesophageal 
squamous cell carcinoma; NSAID, non-steroidal anti-inflammatory drugs 
Adjusted for age, gender, body mass index, smoking status, cardiovascular diseases, diabetes, aspirin, beta-blockers, 
ACEi/ARB use and NSAIDs 
 
 
 
Mortality rate (95% CI) Unadjusted HR Adjusted HR
Cohort Statin exposure (per 100 person-years) (95% CI) (95% CI)
EC-specific mortality
Total OC No pre-diagnosis statin use 1301 (85.0) 1980.6 34.8 (32.3-37.5) 1.00 (reference) 1.00 (reference)
(n=1530) Pre-diagnosis statin use 229 (15.0) 294.5 39.4 (32.8-47.3) 1.01 (0.83-1.22) 0.91 (0.71-1.16)
OAC No pre-diagnosis statin use 501 (83.2) 817.6 35.5 (31.6-39.8) 1.00 (reference) 1.00 (reference)
(n = 602) Pre-diagnosis statin use 101 (16.8) 148.3 39.8 (30.8-51.3) 1.07 (0.81-1.41) 0.81 (0.55-1.20)
OGJA No pre-diagnosis statin use 191 (86.4) 326.7 27.2 (22.1-33.5) 1.00 (reference) 1.00 (reference)
(n = 221) Pre-diagnosis statin use 30 (13.6) 43.3 32.3 (19.2-54.6) 0.96 (0.55-1.69) 0.82 (0.40-1.69)
OSCC No pre-diagnosis statin use 303 (88.6) 444.2 39.8 (34.4-46.2) 1.00 (reference) 1.00 (reference)
(n = 342) Pre-diagnosis statin use 39 (11.4) 42.0 59.6 (40.3-88.2) 1.21 (0.79-1.84) 1.08 (0.65-1.79)
All-cause mortality
Total OC No pre-diagnosis statin use 3543 (79.6) 5128.2 56.8 (54.8-58.9) 1.00 (reference) 1.00 (reference)
(n=4445) Pre-diagnosis statin use 908 (20.5) 1157.1 64.1 (59.7-68.9) 1.00 (0.93-1.09) 0.86 (0.78-0.95)
OAC No pre-diagnosis statin use 501 (83.2) 817.6 52.6 (47.8-57.8) 1.00 (reference) 1.00 (reference)
(n = 602) Pre-diagnosis statin use 101 (16.8) 148.3 59.3 (48.1-73.1) 1.08 (0.86-1.35) 0.77 (0.56-1.06)
OGJA No pre-diagnosis statin use 191 (86.4) 326.7 50.2 (43.1-58.5) 1.00 (reference) 1.00 (reference)
(n = 221) Pre-diagnosis statin use 30 (13.6) 43.3 57.8 (39.0-85.5) 0.96 (0.63-1.46) 0.72 (0.42-1.24)
OSCC No pre-diagnosis statin use 303 (88.6) 444.2 59.0 (52.3-66.6) 1.00 (reference) 1.00 (reference)
(n = 342) Pre-diagnosis statin use 39 (11.4) 42.0 83.4 (59.9-116.2) 1.18 (0.83-1.68) 0.95 (0.62-1.46)
Person-Years
Number of 
patients, n (%)
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Figure 12: Kaplan-Meier plot of time to first statin prescription following diagnosis of oesophageal carcinoma among 
post-diagnosis statin users 
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2.5. Discussion 
This large population-based cohort study of patients with incident OC found that post-diagnosis 
statin use was associated with a 39% reduction in OC-specific mortality and 33% reduction in all-
cause mortality. In patients with OAC specifically, post-diagnosis statin use was associated with a 
39% reduction in OC-specific mortality and 37% reduction in all-cause mortality. There were no 
significant improvements in survival associated with post-diagnosis statin use for OSCC or OGJA. 
Pre-diagnosis statin use did not significantly modify effects observed for post-diagnosis statin use 
on mortality. Significant dose and cumulative dose-response relationships were observed for pre-
diagnosis statin use and all-cause mortality in the whole cohort. Estimates of the association 
between statin use and mortality for the histological subtypes, OGJA and OSCC, including the 
dose-response analyses with OC-specific mortality as the outcome, lacked precision. It therefore 
may not be possible to exclude a weak or moderate effect in these groups. While there were 
significant trends across dose categories defined by the first prescribed statin dose post-diagnosis, 
the estimated hazard ratios did not consistently decrease from low to high dose use suggesting 
that we should cautiously interpret this finding. It should be noted this approach would not take 
into account changes in dose or a cumulative exposure.   
 
Biological mechanisms 
Our findings are consistent with experimental studies which have demonstrated that statins 
promote apoptosis and limit proliferation and invasiveness in OAC cell lines179, 180, 182, 235. Inhibition 
of HMG-CoA reductase by statins decreases production of downstream intermediates of the 
mevalonate pathway, including farnesyl pyrophosphate, which are required for the prenylation 
and consequent membrane localisation of guanosine-triphosphate-bound proteins, including 
Ras245. Through limiting Ras farnesylation, statins reduce two protein kinases, extracellular signal-
related protein kinase and protein kinase B/Akt, both of which are responsible for promoting cell 
survival and growth signal transduction in OAC cell lines179. Statins also reduce, in a dose-
dependent manner, intracellular adhesion molecule-1180, an adhesion molecule involved in trans-
endothelial tumour cell migration and metastatic spread185, 186. Whether these mechanisms 
operate to explain the associations observed in this study is not clear. 
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Comparison with previous work 
As far as we are aware, this is the first observational study to investigate the effect of statin use 
post-diagnosis on survival in patients with OC. However, one large observational study of 295, 925 
patients diagnosed with cancer of any site within the entire Danish population examined the 
effect of statin use pre-diagnosis on cancer-specific mortality189. This study used a similar 
definition of pre-diagnosis statin exposure employed in our study, but also included all 
prescriptions between diagnosis and 18 months previously. In a sub-analysis of 4, 398 cases of OC, 
pre-diagnosis statin use was associated with reduced cancer-specific mortality (adjusted HR 0.81, 
95% CI 0.69-0.95).  This was similar to the effect size that we observed (HR 0.87, 95% CI 0.78-0.96) 
on all-cause mortality (n = 4445). However, while the effect size for pre-diagnosis statin use on 
OC-specific mortality in our study was similar, the estimate lacked precision, likely reflecting 
limited power to detect associations (HR 0.90, 95% CI 0.71-1.15) (n = 1530). Similarly to our study, 
significant amounts of data were missing for cancer stage, radiotherapy and chemotherapy. Use 
of concomitant medications that could plausibly confound associations were not included in 
multivariable analyses. The effect of dose-response on OC mortality specifically was not reported. 
This study did not determine associations according to the histological subtype. 
 
Strengths and limitations 
This study had several strengths. Read codes used to identify patients with OC in the GPRD have 
been shown to be valid (positive predictive value 0.97, sensitivity 0.92, and specificity 0.99)232. 
Overall five-year survival was 12.5%, consistent with UK data, suggesting the disease identified 
was clinically representative58. Participants with OC identified from the GPRD represent a large 
cohort with a median 9 (IQR 3.7 – 22.7) months follow-up post diagnosis to enable meaningful 
survival analyses. In a subset of patients, linkage with the NCR enabled associations between 
statin use and mortality for the histological subtypes of OC; and linkage with the ONS database 
enabled OC-specific mortality to be examined. Prospective prescription records within the GPRD 
avoid recall bias compared to self-reported medication use. Measurement error of drug 
exposures is likely to be minimal given the accuracy of prescription records in the GPRD240. While 
the GPRD does not record purchased over-the-counter medications, exposure misclassification for 
statin use is unlikely as such purchases account for only 0.7% of total statin use in the UK246. While 
the GPRD records prescribed medications, exposure misclassification could foreseeably arise 
where patients did not adhere to treatment: while prescriptions are accurately recorded by the 
GPRD, drug adherence is not directly captured. However, exposure misclassification through both 
sources would be expected to attenuate associations and underestimate the associations 
Statins and oesophageal adenocarcinoma 
98 
observed in this study. For analyses of post-diagnosis statin use, the time-varying nature of drug 
exposures were accounted for and therefore avoided immortal time bias, which would have 
otherwise likely exaggerated associations. A form of selection bias, healthy survivor bias, could 
have influenced results for individuals who were prescribed their first statin after a substantial 
interval following diagnosis: this group would by definition have an improved prognosis as their 
risk of death due to the index cancer would be expected to diminish as the interval lengthened. 
However, this potential bias would seem unlikely to have influenced results overall as 90% of 
patients who were prescribed statins post-diagnosis, did so within 6 months (see figure 12).  
Analyses of OC-specific mortality censored for deaths due to other causes appropriately 
accounted for competing risk of death244, an approach of particular relevance given the 
established efficacy of statins in reducing cardiovascular-related mortality148-151. 
 
Importantly time-dependent exposure to aspirin use was adjusted for as it is a plausible 
confounder in the association between post-diagnostic statin use and mortality outcomes in this 
population. Aspirin, through inhibition of cyclo-oxygenase to reduce inflammatory mediators and 
modulate platelet function, could improve survival in patients with OAC, a malignancy driven by 
inflammation247, 248. Indeed, in an individual patient meta-analysis of eight RCTs, allocation to 
aspirin (likely prior to the diagnosis of OAC) was associated with a significant reduction in death 
due to OAC123. While residual confounding by over-the-counter aspirin use is possible, any bias 
would be expected to have a negligible effect on study validity: nearly all long-term aspirin use is 
captured by the CPRD249, the prevalence of aspirin use is low in this population, and any over-the-
counter use would be expected to be non-differential between survivors and non-survivors prior 
to death250.  
 
This study has several limitations. There were substantial amounts of missing data for treatment 
modality and cancer stage. Completeness of treatment modality approached that expected for 
surgery and radiotherapy but not chemotherapy for patients linked to the cancer registry. For 
example, for OAC patients the proportion receiving surgery, chemotherapy, and radiotherapy, 
respectively, was 33%, 24% and 15% and national audit data indicate the approximate expected 
proportions to be 35%, 47% and 12%251. While treatment modality and stage are important 
predictors of outcomes, it is not clear as to whether they operate as confounders in the 
association between statin use and mortality. As clinical staging and treatment modality are 
closely related, treatment modality could be regarded as a proxy for staging: with surgery 
expected to be most discerning from the three captured modalities. Therefore, sensitivity 
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analyses were conducted (outlined above), to explore whether treatment modality, and by 
extension cancer staging, could operate as confounders in the association between statin use and 
mortality. Effect sizes and the precision of the estimates were similar for post-diagnosis statin use 
in analyses which did and did not adjust for surgery, chemotherapy and radiotherapy; suggesting 
that unmeasured confounding by treatment modality or clinical stage was not operating.  
 
Reverse causation bias could theoretically operate in the association between post-diagnosis 
statin use and mortality. New users could represent a group with a more favorable prognosis, as 
determined by their GP, such that for these individuals prevention of cardiovascular disease 
(particularly primary prevention), a long-term outcome, is deemed a clinical priority, as opposed 
to adopting a more palliative approach. Although we cannot exclude this, our findings would 
suggest this mechanism of reverse causation bias is not a prominent explanation for the 
associations observed. First, of all statin users post-diagnosis, new statin users who were likely 
prescribed statins for primary prevention accounted for a minority (14%). Second, there was no 
significant interaction with statin use prior to diagnosis for the association between post-
diagnosis statin use and OC-specific and all-cause mortality. Third, restricting the whole cohort to 
those surviving greater than three months from diagnosis did not materially alter associations in 
the whole cohort (associations examined with linked data were likely underpowered to assess 
this). Restricting the cohort to those surviving longer periods would have been underpowered: 
the prognosis from OC overall is poor and the remaining cohort size would be too small to permit 
meaningful analyses. Fourth, one would expect reverse causation bias to operate in the same 
manner as for other medications exposures used in the treatment of cardiovascular diseases 
(assuming they do not cause harm): indeed significant associations were not observed (all p 
values > 0.05). Fifth, pre-diagnosis statin use, a measure of statin exposure which would be 
expected to be free of reverse causation bias, was associated with reduced all-cause mortality. 
Deeming patients continuously exposed to statins once a prescription was issued until the end of 
follow-up prevented another guise of reverse causation bias, whereby treatment decisions made 
at the end-of-life, such as withdrawing regular medications, ensured patients were correctly 
classified as exposed. Similarly, sensitivity analyses which ignored all new prescriptions in the final 
three months’ of follow-up, an exposure which may not plausibly influence outcomes but which 
could reflect a GP’s assessment of prognosis, did not materially alter the strength or significance 
of associations. 
 
Statins and oesophageal adenocarcinoma 
100 
The analyses may be susceptible to unmeasured confounding mediated by a healthy-user effect: 
statin users could represent a more health conscious group, whereby associated behaviors, either 
on the part of the patient or health-professional, may be associated with improved survival. For 
example, more health-conscious individuals may present and be diagnosed with an earlier stage 
of cancer; and GP have been reported to selectively under-prescribe lipid-lowering medications to 
obese patients or smokers252, both of which are associated with increased cancer-related 
mortality253, 254. However, contrary to this, statin users appeared less healthy: they were more 
likely to be overweight or obese, smoke and have diabetes or cardiovascular disease than non-
users - factors which independently predict mortality. Nevertheless, we attempted to minimize 
potential confounding from a healthy-user effect by including smoking, BMI, cardiovascular 
disease and concomitant medication use in multivariable analyses. Nevertheless, as with all 
observational studies, residual confounding is still possible. 
 
Use of propensity scores as an alternative method to the multivariable outcome model used in 
the present study to account for confounding deserve consideration.  A propensity score assigned 
to an individual is the probability of exposure status (in this case, post-diagnostic statin use) 
conditional all known confounders255. Propensity scores are most commonly estimated using 
multivariable logistic regression. The most common techniques for controlling for propensity 
scores are stratification, matching, weighting and adjustment. Adjustment is generally not advised 
as its validity is dependent on correctly specifying two models (used to derive the propensity 
score and the outcome model)255. Generally, the ability to control for confounding in traditional 
multivariable models and propensity score analyses is similar, with comparable effect sizes and 
precisions of estimates seen between the two when these methods are compared in the same 
dataset256-258. Nevertheless, propensity score analyses possess several advantages for treatment 
comparisons in epidemiological research. A major source of bias in pharmaco-epidemiology is 
confounding by indication/channeling bias/reverse causation bias: in the present study the 
probability of a GP initiating a statin after diagnosis of cancer is likely to be dependent on their 
assessment of a patients’ prognosis and their anticipated long-term benefit. A propensity score is 
well placed to account for the indications and contraindications of use of the drug (as they focus 
on treatment indications and in addition are able to control for a large number of covariates), and 
enable comparison (by matching for or within strata of propensity scores) of patients with similar 
propensity to receive treatment, to generate valid treatment estimates258. This is in contrast to 
traditional multivariable models which are unable to specify this. Valid treatment comparisons 
can be further refined with the use of “trimming” of the study population: restriction to 
observations in comparison groups with overlapping propensity scores, through exclusion of 
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subjects in exposed and non-exposed groups with non-overlapping scores, before onward 
matching or stratification255. Therefore, individuals treated or not treated contrary to expectation 
(with low or high propensity scores, respectively) are excluded. Theoretically, unmeasured 
confounders should explain these non-overlapping populations. Indeed, this technique in 
simulation studies has been shown to reduce unmeasured confounding by frailty, an unobserved 
variable which is difficult to capture with known variables259. It should be noted that trimming the 
study population reduces the generalizability of causal inferences made to the restricted 
population only255.  
 
Propensity score analysis could be effectively implemented in the future to determine 
associations between post-diagnostic statin use and mortality in patients with OC. The propensity 
scores for post-diagnostic statin initiation would include variables which comprehensively account 
for the indications and contra-indications for statin therapy, cardiovascular disease (including 
severity), concomitant cardiovascular disease medications (including aspirin and statin therapy), 
and available contributing variables to clinically applicable cardiovascular disease risk calculators 
(such as QRISK®2260) to account for primary prevention measured prior to OC diagnosis. This 
approach would also account for confounding by medication use at baseline (such as aspirin) and 
in addition, would implement time-dependent exposures for their initiation post-diagnosis. 
Furthermore, trimming the population with non-overlapping propensity could limit unmeasured 
confounding, potentially by reverse causation or channeling bias (particularly the unobserved 
aspects of clinical decision making in determining treatment initiation), a key threat to the validity 
of such work. Subsequent matching or stratification for propensity scores with a sufficiently 
narrow caliper would further reduce residual confounding within strata or matched pairs255. Such 
an approach could improve the validity of such treatment estimates in population in future 
research. 
 
An alternative, but equally valid approach to analysis of this cohort is the nested case-control 
study. In this setting, cases would be those participants with OC who had died during follow-up. 
Their date of death would be the assigned “index date” for their matched control(s) who would 
need to alive and undergoing follow-up at this time. Exposure data (including drug exposures) 
would be captured during fixed exposure windows measured prior to death (or index date), 
equally applied regardless of case/control status. Conditional logistic regression, with adjustment 
for the same factors listed in section 2.3, “covariates” (excluding matching factors) would 
generate odds ratios with 95% confidence intervals to estimate the association between post-
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diagnostic statin use and mortality in patients with OC. These odds ratios would be expected to 
closely estimate the hazard ratio derived from the Cox proportional hazard regression model of 
the full cohort290, 291. Furthermore, this approach will account for the time-dependent nature of 
drug exposures and hence avoid immortal-time bias261. Such a nested case-control analysis could 
be included as a sensitivity analysis in similar future research. 
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Conclusions 
In summary, post-diagnosis statin use was associated with large and significant reductions in OC-
specific and all-cause mortality, specifically in those with OAC. There was evidence of significant 
dose and cumulative dose-response relationships with pre-diagnosis statin use on all-cause 
mortality in patients with OC. These results require replication in other large cohorts and provide 
further evidence in support of the conduct of randomized controlled trials of statins as adjuvant 
agents in patients with OC. 
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3. Chapter 3 – A Feasibility Study of Adjuvant Statin Therapy in the 
Prevention of Post-Operative Recurrence of Oesophageal 
Adenocarcinoma 
3.1. Abstract 
Background 
Preclinical studies have demonstrated statins inhibit proliferation, promote apoptosis and limit 
invasiveness of oesophageal adenocarcinoma (OAC) cell lines. Observational research has 
demonstrated significant improvements in mortality associated with statin use after diagnosis of 
OAC. We aimed to determine the feasibility of assessing adjuvant statin therapy in patients with 
operable OAC in a phase III randomised controlled trial. 
Methods 
For this multi-centre, double-blind, parallel group, randomised, placebo-controlled trial, eligible 
patients were adults with OAC or Siewert type I/II adenocarcinoma due surgery. Participants were 
recruited from four UK centres and randomly assigned (1:1) to simvastatin 40mg or matching 
placebo by block randomisation, stratified by centre. Participants, clinicians and investigators 
were blinded to treatment allocation. Treatment started from the date of discharge following 
surgery and continued for up to one year. Feasibility assessments of recruitment, retention, drug 
absorption, adherence, safety, quality of life, generalisability, all-cause and disease-free survival 
were made. Trial registration: ISRCTN98060456. 
Results 
Between 23rd November 2014 and 22nd July 2016, 120 patients were assessed for eligibility, of 
which 32 (26.7%) were randomised. Of patients meeting eligibility criteria, 59.3% (32/54) were 
randomised. Patients allocated to simvastatin had significantly lower LDL cholesterol levels by 
three months (adjusted mean difference, -0.83 mmol/L, 95% CI -1.4 to -0.22, p=0.009). Median 
medication adherence for the preceding three months of follow-up at 3, 6, 9 and 12 months, 
respectively, was 83%, 94%, 99%, and 94%, with no significant differences in adherence between 
treatment groups. In total, 87.5% in the simvastatin group and 92.9% in the placebo group 
(p=0.626) experienced at least one adverse event. Completion of quality of life data was high 
(98.3% of questionnaire items) with no clinically significant differences observed between 
treatment groups. Cardiovascular disease (p=0.003), diabetes (p=0.003) and aspirin use (p=0.01) 
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were more prevalent in the non-randomised group compared with the randomised group. There 
were no significant differences between groups for overall (p=0.716) or disease-free survival 
(p=0.807). 
Conclusions 
This RCT supports the feasibility of assessing adjuvant statin therapy in a future phase III trial in 
patients with operable OAC. Feasibility estimates derived from this trial inform the design and 
conduct of a future study. 
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3.2. Introduction 
3.2.1. Background 
OAC is an important public health and clinical problem. The incidence has risen in the UK over 
recent decades by at least three fold262 and the overall 5-year survival rates are less than 20%263. 
Patients with OAC commonly present at an advanced stage of disease and are therefore often 
only amenable to palliative treatments264. Even of those suitable for potentially curative 
treatment, the outcomes are still often poor, with 5-year survival estimated at 45%114, and 
mortality predominantly attributed to recurrent disease113. Beyond current primary treatment 
modalities (oesophagectomy with or without peri-operative 
chemotherapy/chemoradiotherapy111), there are no established longer-term systemic therapies 
to reduce risk of recurrent disease. Consequently, there is an urgent need to assess potential 
novel therapies to improve current survival rates. 
There is emerging experimental and epidemiological evidence that statins (3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors), used in the primary and secondary prevention 
of cardiovascular disease, exert pleiotropic effects which are of relevance to cancer biology. 
Preclinical studies have demonstrated the effects of statin treatment on validated OAC cell lines, 
including inhibiting proliferation, promoting apoptosis and limiting invasiveness in a dose-
dependent manner179-182. By inhibiting HMG CoA reductase, statins decrease production of 
intermediates of the mevalonate pathway, including farnesyl pyrophosphate, which are required 
for the prenylation and consequent membrane localisation of key members of the RAS 
superfamily of GTPases, including RAS, RAC and RHO156, 245. Through inhibiting RAS farnesylation, 
statins deplete extracellular signal-related protein kinase (ERK) and protein kinase B/Akt, both of 
which promote cell survival and growth signal transduction in OAC cell lines179, 265. Statins also 
reduce, in a dose-dependent manner, intracellular adhesion molecule-1 (ICAM-1)180, a critical 
adhesion molecule involved in transendothelial tumour cell migration which promotes metastatic 
spread185, 186. 
A large observational study within the entire Danish population examined the effect of statin use 
pre-diagnosis on cancer specific survival in 295,925 patients diagnosed with cancer of any site189. 
In a sub-analysis of 4,398 cases of oesophageal cancer (including any histological subtype), statin 
use was associated with reduced cancer-related mortality (HR 0.81, 95% CI 0.69-0.95). 
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Furthermore, in a large pharmaco-epidemiological study, using the General Practice Research 
Database with linkage to the National Cancer Registry and Office of National Statistics Datasets, 
statin use after diagnosis of OAC (modelled as a time-dependent variable) was associated with 
significant reductions in cancer-specific mortality (HR 0.62, 95% CI 0.44-0.86)207.   
The emerging preclinical and epidemiological evidence justifies the conduct of randomised 
controlled trials to examine whether statins are efficacious adjuvant agents in patients with 
operable OAC. This proposed investigation is a feasibility study of adjuvant statin therapy in the 
prevention of post-operative recurrence of OAC, including adenocarcinoma of the gastro-
oesophageal junction (Siewert I/II lesions). This group of post-surgical patients has been selected 
as they have minimal disease burden, yet substantial risk of recurrent disease. This implies the 
presence of undetectable residual micro-metastatic disease at oesophagectomy. We hypothesise 
that adjuvant and maintenance therapy could have a more pronounced clinical effect in this 
group, as opposed to those with macroscopic unresectable disease at presentation.  Statins 
represent ideal agents to investigate as they are easily administered, inexpensive, well-tolerated 
and with an excellent safety profile at a population level148-151. 
3.2.2. Rationale 
Before launching a definitive phase III RCT to determine efficacy of adjuvant and maintenance 
statin therapy in patients with OAC on a curative surgical pathway, important questions remain 
regarding study feasibility. Although statins are commonly prescribed for cardiovascular disease 
prevention, it is not known whether patients would be willing to consider entering a trial for the 
indication of investigating their anti-cancer potential. Valid and precise estimates of recruitment 
and retention would be required to determine feasibility and aid planning of a future trial. 
Prevalence of statin use has increased dramatically, however it is not clear to what extent this 
would impact recruitment to a future trial. It is important to determine whether patients are 
willing to adhere to treatment for this indication. Although a lesser concern, it is not known 
whether statins are adequately absorbed in this patient group: vagotomy performed during 
oesophagectomy may lead to reduced small bowel transit and could theoretically limit statin 
absorption. A future trial would be expected to capture patient-reported outcomes, particularly 
quality of life, and it would therefore be important to establish completion rates.  
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3.2.3. Objectives 
The overarching aim of the STAT-ROC feasibility study was to determine the feasibility of 
assessing adjuvant statin therapy in patients with operable OAC in a future phase III randomised 
controlled trial. The following lists the objectives of the STAT-ROC feasibility study: 
 
1. Recruitment and retention: to determine the recruitment and retention rates of eligible 
participants.  
2. Absorption: to determine whether simvastatin is absorbed in patients following 
oesophagectomy.  
3. Adherence: to determine whether participants adequately adhere to the allocated trial 
medication.  
4. Safety: to determine a preliminary safety profile of simvastatin in this patient group.  
5. Quality of life: to determine completion rates of questionnaires and conduct exploratory 
comparisons in quality of life reported between simvastatin and placebo treated groups.  
6. Preliminary survival data: to estimate the effect of simvastatin 40mg following potentially 
curative surgery for OAC on disease-free and overall survival by one year post-randomisation. 
7. Generalisability: to compare the demographic and clinical characteristics between 
randomised and non-randomised patients screened for this trial who meet inclusion criteria 2-4 
(listed below). 
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3.3. Methods 
3.3.1. Trial design  
This study is a multi-centre, double-blind, parallel group, randomised, placebo-controlled trial to 
determine the feasibility of investigating adjuvant statin therapy in the prevention of post-
operative recurrence of OAC in a future phase III RCT. Patients with OAC who underwent 
potentially curative surgery were randomised to receive either simvastatin 40mg nocte or placebo 
on discharge from hospital for up to one year. Participants were be assessed at screening, 
baseline and at three monthly intervals after discharge following surgery. Participants were 
followed-up for one year if recruited prior to 31/10/15. For patients recruited between 31/10/15 
– 31/07/16, patients received at least 3 months’ follow-up until 31/10/16 at the latest. 
Assessments include measurements of recruitment and retention, absorption, adherence, safety, 
quality of life, disease-free and overall survival and generalizability. A summary of the study 
design is shown in figure 13. 
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Figure 13: Summary of study design 
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3.3.2. Participants 
Participants with OAC (including Siewert type I/II lesions) who underwent potentially curative 
surgery with either an oesophagectomy, oesophago-gastrectomy or extended total gastrectomy 
and whom survive to discharge from hospital following their operation. 
 
Inclusion criteria 
1. Participant was willing and able to give informed consent for participation in the trial. 
2. Male or female, aged 18 years or above. 
3. Diagnosed with OAC (including adenocarcinoma of the gastro-oesophageal junction 
[Siewert I/II lesions]) confirmed with both endoscopy and histology. 
4. Due to undergo potentially curative surgery with either an oesophagectomy, 
oesophago-gastrectomy or extended total gastrectomy and survive to discharge from 
hospital following their operation. 
 
Exclusion criteria 
1. Currently prescribed a statin as part of their routine clinical care. 
2. Were due to be prescribed a statin as part of their routine clinical care. Applicable to 
a participant who has agreed to statin therapy as recommended by their general 
practitioner (GP) for the primary or secondary prevention of cardiovascular disease.  
NB: patients who qualified for a statin but who choose not to be prescribed one for 
primary or secondary prevention of cardiovascular disease were still potentially 
eligible for this study. 
3. Hypersensitivity to simvastatin. 
4. Active liver disease or unexplained persistent elevations of serum transaminases (> 3x 
ULN). 
5. Severe renal insufficiency (estimated glomerular filtration rate [eGFR] less than 30 
mL/minute/1.73 m2). 
6. Creatine kinase (CK) > 5x ULN 
7. Female participants who were pregnant, lactating or planning pregnancy during the 
course of the trial. 
8. Concomitant drug prescription of potent CYP3A4 inhibitors planned for greater than 
one month during the study period (e.g. itraconazole, ketoconazole, fluconazole, 
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posaconazole, HIV protease inhibitors [e.g. nelfinavir], erythromycin, clarithromycin, 
telithromycin and nefazodone). 
9. Concomitant drug prescription planned for greater than 1 month during the study 
period of amiodarone, verapamil, diltiazem, amlodipine, ciclosporin, danazol or 
gemfibrozil.   
10. Acute porphyria. 
 
Research Setting and delivery 
This trial was conducted across four UK NHS sites: the Norfolk and Norwich University NHS 
Foundation Trust (NNUH), Nottingham University Hospitals NHS Trust (NUH), Mid Essex Hospital 
Services NHS Trust (MEHT), and James Cook University Hospital (JCUH) (South Tees Hospitals NHS 
Foundation Trust). Queen Elizabeth Hospital NHS Foundation Trust (QEH), Kings Lynn, Norfolk 
served as a single Patient Identification Centre (PIC) site for patients referred to NNUH. NNUH 
sponsored the study (ref: 2014GSURG01L[030114]). The research was hosted within respective 
departments of surgery at each NHS trust. The study was adopted by the UK Clinical Research 
Network Portfolio of studies and therefore received support from network-funded research 
delivery staff within division 1 (cancer). The Research Design Service East of England contributed 
to study design. Norwich Clinical Trials Unit (NCTU) supported all stages of delivery of the trial, 
including design, management, statistics, quality assurance and regulatory reporting. 
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3.3.3. Trial procedures 
Trial procedures including recruitment, randomisation, baseline and follow-up assessments are 
summarised in Figure 14. 
 
 
Figure 14: Flowchart of trial procedures 
Abbreviations: MDT, multi-disciplinary team; PIS, participant information sheet. 
 
Recruitment 
Participants were identified at the local upper gastro-intestinal (UGI) cancer multi-disciplinary 
team (MDT) meetings at each NHS site. Each participant was asked in the pre-operative period by 
their surgeon or oncologist (or a member of their clinical team) if they would consider 
participating in this study. They were issued an invitation letter and a Participant Information 
Sheet (PIS). A member of the research team saw them at a screening visit prior to surgery, which 
was usually scheduled on the day of their pre-operative assessment. During this visit participants 
were screened to determine eligibility (see appendix F for the screening log) and informed 
consent was sought. 
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A retrospective case review of all patients meeting inclusion criteria numbered 2-4 at each site 
was conducted. The data were collected using an anonymised form. The data captured consisted 
of: patient demographics, clinical characteristics including tumour characteristics, performance 
status and adjuvant therapies. This generated a reference population against which 
generalisability was assessed for the randomised study population. Patients who met inclusion 
criteria numbered 2-4 who did not obviously meet any exclusion criteria at pre-screening were 
approached.    
 
Informed consent 
Recruited participants personally signed and dated the latest approved version of the Informed 
Consent Form (ICF) which was observed and countersigned by a member of the research team 
before any trial specific procedures were performed (see appendix G). Information presented to 
the participants detailed the trial rationale; the exact nature of the trial; what it would involve for 
the participant; participant responsibilities; the implications and constraints of the protocol; the 
known side effects of simvastatin; the safeguards in place; and how blood tests were due to be 
processed. The information clearly stated the participant was free to withdraw from the trial at 
any time for any reason without prejudice to future care, and with no obligation to give the 
reason for withdrawal. The participants were allowed at least 24 hours to consider the 
information, and the opportunity to question the Investigator, their GP or other independent 
parties to decide whether to participate in the trial.  The member of the research team who took 
consent was familiar with the study and had the express authority to do so as detailed in the 
delegation log. Informed consent was sought during the screening visit. The original signed 
consent form was stored in the investigator site file. A copy of the signed informed consent was 
given to the participant, another was stored in the patient’s medical notes and a copy was e-
mailed to the NCTU. 
 
Screening and eligibility assessments 
Trial visit procedures are summarised in table 16. Participants were screened to ensure they 
fulfilled the inclusion criteria and did not meet any of the exclusion criteria. Some eligibility 
criteria required confirmation by laboratory tests, the results of which were available after 
patients had consented to the study. The research team wrote to the patient’s GP to determine 
whether they were either currently prescribed a statin or due to be prescribed one for the 
primary or secondary prevention of cardiovascular disease. Members of the research team, 
including designated research nurses/practitioners and clinicians, performed screening and 
eligibility assessments. The maximum expected duration between screening and randomisation 
was two months. The assessments were: 
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1) Screening medical records to determine application of inclusion and exclusion criteria 
2) Demographic information 
3) Medical history 
4) Drug history, including statin use 
5) Quality of life questionnaires: EORTC QLQ-C30 and disease specific Oesophagogastric 
OG25 module 
6) Height and weight 
7) Blood tests for safety: thyroid function tests (TFTs), creatine kinase (CK), liver function 
tests (LFTs), creatinine. Blood test for research: non-fasting LDL cholesterol. 
8) STAT-ROC feasibility study acceptance questionnaire or STAT-ROC feasibility study 
declined questionnaire (as appropriate) 
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Procedures Visits  
Screening Baseline Visit 1 Visit 2 Visit 3 Visit 4 
Pre-op Post-op 3 months 6 months 9 months 12 months 
Informed consent       
Demographics       
Medical history 
      
Concomitant medications 
      
Physical examination 
      
Eligibility assessment 
      
Randomisation       
Dispensing of trial drugs       
Assessment of adherence       
Blood tests for research  
      
Blood tests for safety 
      
EORTC QLQ-C30 and OG25 
      
STAT-ROC Acceptance or 
declined questionnaire 
      
STAT-ROC withdrawal 
questionnaire (if applicable) 
      
Adverse event assessments        
Clinical note review 
      
Table 14: Schedule of procedures 
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; QLQ, quality of life questionnaire;  
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Randomisation, allocation concealment, blinding and code-breaking 
Participants, clinicians, investigators and CTU staff were blinded to treatment allocation. 
Randomisation took place for consenting participants who satisfied the screening and eligibility 
assessments and whom were shortly to be discharged (within 1-5 days) from hospital following 
surgery for OAC. A computer generated randomisation code was produced by Ipswich Pharmacy 
Manufacturing Unit (PMU) and used to randomise participants in a 1:1 ratio to either simvastatin 
or placebo in blocks of six, stratified by NHS site. The final protocol deliberately did not stipulate 
the block size. The code stipulated the treatment allocation according to sequentially ordered 
four-digit subject number (starting from 0001). The unblinding code was sealed and stored at 
Ipswich PMU, NCTU and the NNUH pharmacy. Ipswich PMU produced identical sealed medication 
bottles which were individually labelled with corresponding subject numbers to preserve 
allocation concealment, and bottle numbers (from 1-12 corresponding to each month of 
treatment). Participants were sequentially allocated a subject number in the order they passed 
the baseline assessment. An Interactive Web Response System (IWRS) with password access 
limited to registered investigators, serially allocated the subject numbers to recruited patients. 
Confirmation e-mails were automatically sent to the user who performed allocation, the site 
principal investigator, site pharmacist and the trial co-ordinator to confirm the patient had been 
randomised. Prescription of the trial medication required the participant’s name, date of birth, 
hospital number, subject number and the bottle numbers to be dispensed. Ipswich PMU 
produced identical active and placebo tablets to preserve blinding. Participants, their healthcare 
providers, data collectors and outcome adjudicators were all blinded to treatment allocation. 
 
A mechanism was in place to facilitate treatment unblinding during the trial. Unblinding of the 
treating physician could only be justified in instances where knowing treatment allocation would 
alter the management of a severe adverse event. All suspected unexpected severe adverse 
reactions (SUSARs) would require unblinding and reporting as detailed below (under section x). 
Requests for unblinding should have been made via the trial co-ordinator or the CI to authorise 
this. In the case of out-of-hours emergency unblinding, the local PI or their delegate could log into 
the IWRS to reveal treatment allocation for a single participant. The IWRS which recorded the 
reason, date and time of the event, and identity of all recipients of the unblinding information to 
NCTU.  
 
Baseline assessment 
Baseline assessments were made while participants were an inpatient awaiting discharge 
following surgery. Provided there were no clinical contra-indications to receiving trial medication 
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and the participant was still willing to participate in the trial, they were randomised and hence 
allocated a subject number. To ensure sufficient medication supply, patients were prescribed four 
bottles each containing 31 tablets to ideally start on the day of discharge. Randomisation could be 
delayed by up to 31 days post discharge where a clinical contra-indication to starting the 
investigational medicinal product existed at the point of discharge but which may reasonably 
resolve to permit recruitment, such as renal impairment or awaiting the result of a barium 
swallow. Patients were asked to swallow the medication whole, in the evening. They were not 
permitted to crush the medication or open the capsules. Investigators were instructed to not 
inform participants of the reason for this: as it would risk unblinding.  
 
Follow-up assessments 
Participant follow-up began from the date of discharge from hospital following surgery with 
curative intent. Participants were invited to attend four follow-up assessments at 3, 6, 9 and 12 
months post-discharge for those recruited prior to 31/10/15. A substantial amendment (described 
below) permitted extension of the recruitment period from 31/10/15 to 31/7/16; while the last 
possible date of patient follow-up remained 31/10/16. For participants recruited during this time, 
visits were still arranged at these three monthly intervals. Provided a three monthly visit was 
within 14 days (from 17/10/16) inclusive of the end of the study (31/10/16), this visit served at 
the final visit. If a three monthly visit was prior to this 14 day period the final visit was be made on 
31/10/16 at the latest to maximise follow-up time. The IWRS calculated the target dates for each 
follow-up visit. Regardless of the period of recruitment (pre or post 31/10/15), the procedures for 
each visit were the same as detailed below:   
1. Confirmation of any clinical contra-indication to patient receiving trial medication 
2. Medical notes review to determine disease outcomes, including cancer recurrence 
3. Record concomitant medications 
4. Assessment of adverse events 
5. Physical examination for evidence of recurrence if not already diagnosed 
6. Quality of life: EORTC QLQ-C30 and disease specific Oesophagogastric OG25 module 
questionnaires 
7. Perform pill counts  
8. Specific drug safety assessments:  LFTs at 3 and 12 months as routine, CK if muscle 
symptoms developed and the trial medication was felt likely to be causal. Blood tests for 
safety did not need to be repeated at study visits if they have already been determined 
within the prior 14 days of the patient visit as part of the patient’s routine clinical care. 
9. Assessment of simvastatin absorption: blood tests (non-fasting LDL-cholesterol [frozen]),  
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10. Dispensing of trial drugs at 3, 6, and 9 months 
 
Follow-up assessments, where possible, were scheduled to coincide with hospital appointments 
as part of the participant’s usual care. Symptoms of muscle toxicity were managed using an 
algorithm devised from the elected Summary of Medicinal Product Characteristics (SmPC) for 
Simvastatin 40mg and relevant clinical guidelines (appendix H)266, 267. Date and cause of death 
were verified using Death certificates or the Office for National Statistics. Provided the participant 
still met eligibility, trial medication were dispensed at each of these visits (3 bottles each 
containing 31 tablets at the 3 and 6 month visit, and 2 bottles at 9 months), excluding the final 
assessment which was the end of study involvement for that participant. The definition of the end 
of trial was the date of the last follow up visit of the last participant (31/10/16). 
 
Discontinuation/withdrawal of participants from trial treatment 
Participants could withdraw from the trial at any time. In addition, investigators could discontinue 
a participant from the trial at any time if they considered it necessary for the following reasons: 
 Pregnancy, breast feeding or planning pregnancy during the course of the trial 
 Ineligibility (either arising during the trial or retrospectively having been overlooked at 
screening) 
 Significant protocol deviation 
 An adverse event which requires discontinuation of the trial medication (anticipated for > 
31 days) or results in inability to continue to comply with trial procedures 
 Withdrawal of consent 
 Loss to follow up 
Participants could be withdrawn from trial treatment on a temporary (defined as ≤ 31 days) or 
permanent basis. When trial medication was withdrawn participants were still invited for the 
usual scheduled follow-up visits to permit intention-to-treat and safety analyses. The reason(s) for 
withdrawal were recorded. Patients who voluntarily withdrew from the study were asked to 
complete the STAT-ROC feasibility study patient withdrawal questionnaire, although they were 
under no obligation to do so nor were they required to provide their reason(s). If the participants 
were withdrawn due to an adverse event, the investigator arranged for follow-up visits or 
telephone calls until the adverse event has resolved or stabilised. 
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Adherence 
Adherence was measured by pill counts recorded at each follow-up visit and corroborated at the 
end of the trial through LDL-cholesterol measurement (applicable only to the simvastatin treated 
group). In the MRC/BHF Heart Protection Study, simvastatin 40mg reduced LDL-cholesterol by 1.0 
mmol/L on average in intention-to-treat analyses regardless of pre-treatment non-fasting LDL-
cholesterol level268.  
 
For patients who had not already withdrawn treatment, adherence was encouraged at baseline 
and at each follow-up visit. Non-adherence was defined as intake of less than 80% of dispensed 
medications at each follow-up visit for the preceding three months. Reasons for non-adherence 
were sought which could be addressed in a future trial. Adherence was promoted through the 
following evidence-based approaches: 
i. Patient focused: Patient education on adherence, the potential importance of the 
results269 and to reduce perceptions of adverse events associated with statins270. 
Reinforcement by asking about adherence at each patient visit271. Acknowledge 
adherence verbally at follow-up visits272.  
ii. Health-professional focused: good communication skills with an empathic 
approach273. 
iii. Drug-focused: emphasis placed on the wide use and acceptable side-effect profile 
of simvastatin with a simple once daily dosing regimen274, 275. Medication will be 
supplied with clear information on dosing276. Encourage medication-taking with a 
daily event such as brushing teeth at night270.  
iv. System focused: Telephone call277 to remind and encourage adherence at 2 and 4 
weeks post-discharge. Minimise costs to the patient by reimbursing the financial 
costs of travel to follow-up visits278.  
 
Concomitant medication 
The following medications were contra-indicated and necessitated temporary withdrawal of the 
trial medication if planned for up to 31 days, or permanent withdrawal if planned for longer than 
31 days during follow-up: 
• Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, fluconazole, posaconazole, HIV 
protease inhibitors [e.g. nelfinavir], erythromycin, clarithromycin, telithromycin and nefazodone). 
• Ciclosporin, danazol, gemfibrozil, amiodarone, verapamil, diltiazem or amlodipine.   
If treatment with a contra-indicated medication was planned for more than 31 days the study 
team liaised with their general practitioner or hospital consultant to prescribe a suitable 
alternative if possible.  
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Procedure for processing blood tests  
Blood samples for research were centrifuged and serum was transferred to two cryovials at each 
site. Blood samples were frozen at -80°C and transferred on dry ice from participating centres to 
the NNUH Biochemistry department where they were be stored at -80°C. At the end of the trial 
one of the frozen samples from each time point from each participant was thawed at room 
temperature, mixed and centrifuged before being analysed for LDL cholesterol levels (a 
pharmacodynamic marker of statin absorption). The latest LDL cholesterol result was reported to 
the participant and their general practitioner. Blood tests for safety were processed in the usual 
way according to local hospital policy. Blood tests for research will be stored for a maximum of 
two years after the end of the trial. Samples were analysed at the end of study involvement for 
each participant (as opposed to during the study) to prevent unblinding. Participants were not 
expected to be disadvantaged by not knowing their non-fasting LDL cholesterol result until the 
end of the study as it would not be routinely measured as part of the standard clinical care of 
patients following potentially curative surgery for OAC. Furthermore, should participants have 
had their LDL cholesterol measured during the study for a non-trial indication and require 
treatment for high cholesterol they were aware to stop taking the trial medication in order to 
start treatment. 
 
Trial medication preparation 
Trial medication preparation was conducted by Ipswich PMU. Trial medications were simvastatin 
40mg (the investigational medicinal product[IMP]) and placebo. To achieve blinding simvastatin 
40mg capsules were manufactured by over-encapsulating simvastatin 40mg film coated tablets. 
These were identical in appearance to the placebo capsules. Opaque size 00 hard gelatine 
capsules were loaded into a capsule filling tray and the capsule tops were removed. For the active 
trial medication, one Simvastatin 40mg tablet (either PL 00289/1451 Teva UK Limited, Ridings 
Point, Whistler Drive, Castleford, WF10 5HX United Kingdom; PL 30306/0035 Actavis Group PTC 
ehf; and/or PL 17907/0127 Bristol Laboratories Ltd.) was placed into each empty capsule and 
subsequently Lactose monohydrate powder BP / Ph Eur (FrieslandCampina DMV BV, Veghel, The 
Netherlands) was added to the capsule until each lower shell was brim-full. For the inactive trial 
medication the capsule tops were removed and then filled to the brim with Lactose alone. The 
capsule tops were then refitted. For both active and inactive trial medication, the Lactose was 
sufficient to fully fill the capsule and in the case of the active medication, prevent movement of 
the enclosed tablet. Once processed, the bulk capsules were packaged into suitably labelled 
containers and quarantined until Quality Control checks had been performed. Thirty one capsules 
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were counted using a manual capsule counter and filled into each amber glass medicine bottle. 
One 0.5g Dilica Gel sachet was placed into each bottle and a child resistant cap tightly applied. 
 
The smallest generic brands of Simvastatin (listed above) were selected such that the smallest 
possible capsule shell would not distort once prepared. The overall closed dimensions of each trial 
capsule was 23.3 x 8.53mm, with a capsule volume of 0.91 mls. The supplied certificate of analysis 
of the gelatin shell stipulated disintegration in less than 15 minutes, and in-house testing showed 
dissolution in water at 37°C of less than 5 minutes. 
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3.3.4. Safety reporting 
Definitions 
The definitions of harm of the EU Directive 2001/20/EC Article 2 based on the principles of ICH 
GCP applied to this trial (see table 17).  
Adverse Event (AE) Any untoward medical occurrence in a participant to whom a medicinal 
product has been administered, including occurrences which are not 
necessarily caused by or related to that product. 
Adverse Reaction (AR) 
 
An untoward and unintended response in a participant to an investigational 
medicinal product which is related to any dose administered to that 
participant. 
The phrase "response to an investigational medicinal product" means that a 
causal relationship between a trial medication and an AE is at least a 
reasonable possibility, i.e. the relationship cannot be ruled out. 
All cases judged by either the reporting medically qualified professional or 
the Sponsor as having a reasonable suspected causal relationship to the trial 
medication qualify as adverse reactions. 
Serious Adverse Event (SAE) A serious adverse event is any untoward medical occurrence that: 
 results in death 
 is life-threatening 
 requires inpatient hospitalisation or prolongation of existing 
hospitalisation 
 results in persistent or significant disability/incapacity 
 consists of a congenital anomaly or birth defect. 
Other ‘important medical events’ may also be considered serious if they 
jeopardise the participant or require an intervention to prevent one of the 
above consequences. 
NOTE: The term "life-threatening" in the definition of "serious" refers to an 
event in which the participant was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it 
were more severe. 
Suspected Serious Adverse 
Reaction (SSAR) 
An adverse event that is both serious and, in the opinion of the reporting 
Investigator, believed with reasonable probability to be due to one of the 
trial treatments, based on the information about the IMP provided in the 
Summary of Product Characteristics (SmPC). 
Suspected Unexpected 
Serious Adverse Reaction 
(SUSAR) 
A serious adverse reaction, the nature and severity of which is not consistent 
with the information about the medicinal product in question set out in the 
SmPC for that product  
Table 15: Definitions of harm. Adapted from the EU Directive 2001/20/EC Article 2 
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Causality 
The strength of the causal relationship between the study medication and each adverse event 
was assessed using the following definitions: 
Unrelated: there is no evidence of any causal relationship 
Unlikely: there is little evidence to suggest there is a causal relationship (e.g. the event did not 
occur within a reasonable time after administration of the trial medication). There is another 
reasonable explanation for the event (e.g. the patient’s clinical condition or other concomitant 
treatment). 
Possible: There is some evidence to suggest a causal relationship (e.g. because the event occurs 
within a reasonable time after administration of the trial medication). However, the influence of 
other factors may have contributed to the event (e.g. the patient’s clinical condition or other 
concomitant treatments). 
Probable: There is evidence to suggest a causal relationship and the influence of other factors is 
unlikely. 
Definitely: There is clear evidence to suggest a causal relationship and other possible contributing 
factors can be ruled out. 
 
Capturing adverse event data 
Adverse events (AEs) were captured from the date of first successful administration of the trial 
medication until 31 days following last administration. AEs occurring following consent but prior 
to first trial medication administration were not recorded as patients were exposed to normal 
care during this time. This approach was approved by the ethics committee and the MHRA. The 
date of discharge was the earliest date from which adverse events could be recorded. The 
following information was recorded on an adverse event form: description, defined using the 
Common Terminology Criteria for Adverse Events (CTCAE) V4.0 term; seriousness, using the 
definitions provided above; severity, defined using the CTCAE grade (1-5, where 1 indicates mild 
symptoms, and 5 indicates death); date of onset and end date; assessment of relatedness to trial 
medication; and action taken (none, IMP temporarily stopped, IMP permanently stopped). AEs 
were routinely recorded and reviewed at each follow-up visit and between visits when brought to 
the attention of the investigators.  
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Reporting adverse events 
All SAEs that developed from first administration of the IMP to 31 days following last 
administration of the IMP (except those listed below) were recorded and reported to NCTU within 
24 hours of the investigator becoming aware of the event. SAEs which did not require reporting 
include admissions or death secondary to known complication of adjuvant chemotherapy (eg. 
neutropenic sepsis, symptomatic anaemia, venous thromboembolism, cardiotoxicity and 
diarrhoea) or due to index cancer (eg. dysphagia or gastro-intestinal bleeding due to local tumour 
recurrence, ascites, metastatic disease, deep vein thrombosis or pulmonary embolism) or surgery 
(pneumonia, empyema, acute respiratory distress syndrome, pulmonary embolism, pleural 
effusion, surgical conduit dysfunction, anastomotic leak, wound infection, wound dehiscence or 
oesophageal stricture) but were be recorded in adverse event forms. This express list of 
exceptions to reporting SAEs was devised to limit the workload of contributing sites and NCTU as 
there would be no additional expected benefit to promoting pharmacovigilance through reporting 
these.  For each reportable SAE, an SAE form was completed which included an assessment of 
causality and expectedness to determine whether the event was an SAE, SSAR or SUSAR.  
 
Expected adverse events with Simvastatin 
The Summary of Product Characteristics for simvastatin 40mg279 lists the following adverse events 
which have been reported during clinical trials in adults and post-marketing experience. In the 
Heart Protection Study of 20,536 patients aged 50-80 years with cardiovascular disease or 
diabetes, 10,269 treated with simvastatin 40mg daily and 10, 267 treated with placebo, the safety 
profiles were comparable between groups over the five years of the study268. Individual adverse 
events, which were reasonably causally related to simvastatin 40mg, were categorised as “rare” 
(>1/10 000, <1, 000). Discontinuation rates due to side effects were comparable (4.8% treated 
with simvastatin 40mg and 5.1% treated with placebo). Furthermore, a meta-analysis of 14 RCTs 
in the primary prevention (46 262 participants) and 15 RCTs in the secondary prevention (37 618 
participants) of cardiovascular diseases found a small minority of symptoms reported on statins 
were due to the drugs, and almost all would occur just as frequently on placebo280. Only new-
onset diabetes was significantly higher on statins than placebo with an absolute risk of 0.5%, 95% 
CI 0.1-1.0%. Serious adverse events and treatment withdrawals were similar in both intervention 
and controls arms.  
 
The sponsor elected one approved SmPC (Teva, Simvastatin 40mg, PL 00289/1453) as equivalent 
to the investigator’s brochure.  Table 18 summarises the expected AEs as documented in the 
SmPC: 
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Frequency of adverse event Adverse event 
Very common (> 1/10) None. 
Common (> 1/100 to < 1/10) None. 
Uncommon (≥ 1/1000 to < 1/100) Sleep disorders including insomnia, nightmares, 
depression, memory loss, sexual dysfunction, 
Diabetes Mellitus: Frequency will depend on 
the presence or absence of risk factors (fasting 
blood glucose ≥ 5.6mmol/L, BMI>30kg/m2, 
raised triglycerides, history of hypertension). 
Rare (> 1/10,000 to < 1/1000) Anaemia, headache, paresthesia, dizziness, 
peripheral neuropathy, peripheral 
polyneuropathy, constipation, abdominal pain, 
flatulence, dyspepsia, diarrhoea, nausea, 
vomiting, pancreatitis, hepatitis, rash, pruritus, 
alopecia, asthenia, hypersensitivity syndrome 
(angioedema, lupus-like syndrome, polymyalgia 
rheumatica, dermatomyositis, vasculitis, 
thrombocytopenia, eosinophilia, ESR increased, 
arthritis and arthralgia, urticaria, 
photosensitivity, fever, flushing, dyspnoea and 
malaise), increases in serum transaminases, 
elevated alkaline phosphatase, increase in 
serum CK levels, rhabdomyolysis (CK more than 
40 times the upper limit of normal plus 
evidence of end-organ damage). 
Very Rare (< 1/10,000) Insomnia, memory impairment, hepatic failure 
Not known (cannot be estimated from the 
available data) 
Depression, interstitial lung disease, tendonitis, 
tendinopathy sometimes complicated by 
tendon rupture, tendon rupture, erectile 
dysfunction. 
Table 16: frequencies of adverse events expected with Simvastatin 40mg 
Abbreviations: BMI, body mass index; ESR, erythrocyte sedimentation rate; CK, creatine kinase. 
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3.3.5. Statistical analysis 
A statistical analysis plan was finalised and approved by the trial steering committee before 
masking was broken and analysis undertaken. 
 
Flow of participants 
A consort flow diagram was constructed to document the flow of participants through this trial: 
through enrolment, intervention allocation, follow-up and data analysis281. The number “assessed 
for eligibility” only applied to those participants meeting inclusion criteria numbered 2-4, 
regardless of the subsequent outcome of inclusion criteria 1 or any of the named exclusion 
criteria. This definition was provided to all contributing sites to ensure consistency of this 
population. The number who “received allocated intervention” applied only to those who 
successfully administered at least one dose of the trial medication; it did not apply to those who 
received dispensed medication bottles but did not swallow any trial medication.  
 
Baseline characteristics 
The baseline characteristics of all randomised participants were presented stratified according to 
treatment allocation. For each characteristic the summary measure used was appropriate to the 
nature of the variable and its distribution.  
 
Outcomes and statistical analysis 
As this was a feasibility study, the outcome measures were viewed with equal primacy and hence 
were not divided into primary and secondary outcomes overall. However, to reduce the 
probability of type 1 error, the primary outcome measure for drug absorption was prespecified 
(see below). Full analyses were conducted by intention to treat (ITT) and included all randomised 
participants. Per-protocol analyses (a non-randomised observational comparison281) comprised 
two definitions depending on the outcome assessed, for drug absorption and survival (see below).  
 
1. Recruitment. Outcome defined as the randomisation of a trial participant. Three aspects 
of recruitment were calculated: i) the number of participants randomised per month per 
recruiting site; ii) the proportion of participants randomised from all those who met 
inclusion criteria 2-4 (regardless of exclusions) at pre-screening; and iii) the proportion of 
participants randomised from those not randomised who met all inclusion criteria except 
the first criterion (ie declined). These proportions were presented with 95% confidence 
intervals calculated using the binomial exact method. 
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2. Retention. Outcome defined as the last date of active participation in trial procedures 
including administration of trial medication. Withdrawal of participant included both 
complete withdrawal from the trial and withdrawal of treatment but still undergoing 
active follow-up, censored for recurrence and/or death (censored for recurrence first if 
later died during follow-up) as this is expected to be an outcome in the future phase three 
trial). This rate was presented with 95% confidence intervals calculated using the 
quadratic approximation to the Poisson log likelihood for the log-rate parameter. Kaplan-
Meier survival curves were plotted (right censored for patients with truncated follow-up 
[until 31/10/16 at the latest] and death) for the randomised population and by treatment 
group. Differences in withdrawal between groups were tested using the log-rank test. 
3. Absorption. The primary outcome was change in non-fasting LDL cholesterol at three 
months following discharge (visit 1), adjusted for LDL cholesterol measured at screening 
in the ITT population. The adjusted and unadjusted mean differences in LDL cholesterol, 
measured between treatment groups for visits 1-4 (3-12 months), were tabulated with 
95% confidence intervals and p-values. Adjusted comparisons were conducted using 
ANCOVA. Significance testing for the primary outcome was assessed at the 5% level, while 
analyses at the other time points were exploratory at 1% significance. Plots were 
constructed with the mean unadjusted LDL cholesterol for each group plotted against 
serial visits over time (Screening, V1, V2, V3 and V4). Sensitivity analyses using the 
method above were repeated for the per-protocol population, defined for this outcome 
as participants adherent to least 80% of dispensed medications in the preceding three 
months. Individual participants could therefore leave and re-enter periods of adherence 
(and vice versa); and consequently could intermittently populate the per-protocol 
populations.  
4. Adherence. Outcome defined as the proportion of medication consumed in the three 
months preceding the visit at which the pill count was performed. Median adherence 
(with interquartile range) were tabulated and presented using a range plot for all 
individuals included in the ITT population and according to treatment group, right 
censored for patients with truncated follow-up (until 31/10/16 at the latest), recurrence 
or death (whichever came first). Adequate adherence was defined as administration of at 
least 80% of trial medication in the three months preceding each follow-up visit. 
Estimates for adherence exceeding 105% for the preceding three months were 
considered implausible and were ignored. Estimates of adherence at all subsequent visits 
to implausible values were also ignored (as these were reliant on valid earlier estimates) 
for affected patients. 
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5. Safety. All reported adverse events were summarised according to treatment received 
and tabulated with frequencies (for the number of individuals with ≥ 1 adverse event) and 
percentages according to category of AE and worst grade experienced using CTCAE v4.0. 
The proportions of individuals with at least one adverse event were compared using the 
χ² test. Safety analyses were restricted to the trial population who successfully 
administered at least one dose of trial medication. 
6. Quality of life. Compliance for completing quality of life questionnaire items were 
tabulated for each study visit (n, %). Items on both the EORTC QLQ-C30 and OG25 were 
scored and scaled, and missing values were imputed, in line with the EORTC manual282. 
Difference in mean scores adjusted for values observed at screening were tabulated (with 
95% confidence intervals) for each follow-up visit stratified according to treatment 
allocation using ANCOVA. Plots were constructed with the mean scores for each group 
plotted against serial visits over time (Screening, V1, V2, V3 and V4). 
7. Exploratory survival comparisons. Overall survival was defined as time elapsed from 
discharge from hospital to death from any cause. Disease-free survival was defined as the 
time elapsed from discharge to the first time point at which one of the following events 
occurred: local recurrence, distal recurrence or death. Kaplan-Meier survival curves and 
the log-rank test, with Cox proportional hazards modelling (which estimated hazard ratios 
and 95% confidence intervals) compared treatment groups. OS and DFS were compared 
between groups for the intention-to-treat population only: the number of events in the 
per-protocol populations (defined for this outcome as including participants adherent to 
least 80% of dispensed medications by the first follow-up visit at 3 months) were too low 
(no deaths and one recurrence).  
8. Generalisability. Demographic and clinical characteristics were compared between 
randomised and non-randomised patients assessed for eligibility. Categorical data was 
compared using the χ² test, and continuous data were compared using the two sample t-
test or Mann-Whitney U as dictated by the distribution. 
 
Sample size calculation 
As this is was a feasibility study, a formal sample size calculation was not required. 
Nevertheless, a sample size of 24 represents the inflection point between the number of 
participants randomised in a 1:1 ratio and the precision of mean difference between both 
groups283 and would be expected to satisfy assessment of feasibility outcomes measured on a 
continuous scale. Therefore 24 was the minimum recruitment target for the trial. A sample of 
22 participants (11 per arm) had 80% power at the 5% level to detect a difference of 1 mmol/l 
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in LDL cholesterol, assuming a standard deviation of 0.8268. An upper recruitment target limit 
of 36 participants was aimed for and felt to be potentially feasible given the inclusion criteria 
and study population available as this would have enabled improved precision in the 
assessment of feasibility outcomes. All analyses were performed with STATA version 13 
(StataCorp LP, College Station, Texas, USA). 
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3.3.6. Trial oversight and quality assurance procedures 
Trial monitoring 
The aims of monitoring were to ensure that the trial was conducted and data generated, 
documented and reported in compliance with the protocol, good clinical practice (GCP) and the 
applicable regulatory requirements. Central monitoring was conducted by NCTU, with the option 
for on-site monitoring if required. There were three main aspects to trial monitoring as 
documented in a trial-specific working practice document (STAT-ROC quality management and 
monitoring plan): consent forms, patient safety and deliverability.  Patients were consented to 
enable the NCTU to hold a copy of the consent form for the trial to facilitate central data 
monitoring. Consent forms were monitored for all randomised patients to ensure the correct 
version number was used; both the participant and investigator (as named on the delegation log) 
had signed the form; the date of consent preceded the date of randomisation; and that consent 
was recorded electronically on the IWRS. Patient safety was monitored to ensure that all inclusion 
and exclusion criteria (the latter were designed to preserve patient safety) were documented in 
the CRF and IWRS; blood tests for safety were taken as per the study schedule and that results 
were in the required ranges for participation in the trial; and serious adverse event forms were 
completed correctly and reported to NCTU within 24 hours of the investigator become aware of 
the event. Regarding trial delivery, the number of participants screened and recruited per month 
per site were monitored. On-site monitoring could be triggered following concerns raised by the 
chief investigator, trial steering committee or trial management group, if sites were to generate 
high volumes of data queries, or if sites did not respond to queries within three weeks.  
 
Trial management group 
The trial management group (TMG) met at least monthly to discuss the general progress and day-
to-day running of the trial. The key members were the CI, trial co-ordinator, research practitioner, 
and all other STAT-ROC investigators. The TMG reviewed all AEs, CRF completion and data quality 
and dealt with all aspects of the quality control procedures.  
 
Trial steering committee 
A trial steering committee (TSC) was established to provide oversight for the trial, review the 
trial’s progress, conduct and new relevant information. Specifically, their remit covered advising 
the Trial Management Group on all aspects of trial conduct; decision making for the continuation 
of the trial; approving the protocol, substantial amendments and the statistical analysis plan; 
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reviewing the recommendations of the safety committee; and assessing the impact and relevance 
of any accumulating new external evidence which may inform the conduct of the trial. 
Membership included independent and non-independent representation. Independent 
representation included a chair, consultant clinical oncologist, consultant gastroenterologist, NIHR 
representative, two patient representatives, and sponsor representative. Non-independent 
members were the team of investigators. TSC meetings were held twice per year for the duration 
of the trial (four were held in total). 
 
Safety committee 
A Safety committee (SC) was established in place of a full data monitoring and ethics committee 
(DMEC) given the relatively small size of the trial (compared with a large phase three RCT) and the 
relatively low risk of the intervention in terms of safety. Membership included two consultant 
physicians independent to the trial with clinical trial experience and routine clinical experience of 
prescribing statins. The main responsibilities of the safety committee were to review each serious 
and non-serious adverse event recorded during the trial; provide an independent opinion on 
whether the AEs were in line with that expected from this patient cohort (given the disease of 
interest and expected concomitant treatments including surgery and chemo/radiotherapy) or 
were related to simvastatin exposure; discuss and attempt to resolve any issues with the CI; and 
make recommendation to the TSC for either continuation, temporary or permanent stopping of 
the trial on grounds of the emerging safety data. The TSC reviewed blinded data, however, could 
at their disposal, request unblinded data. Safety committee meetings were held twice per year for 
the duration of the trial (four were held in total).  
 
Ethical and regulatory considerations 
Ethical approval was first granted in 1st July 2014 (appendix B), and subsequently for a substantial 
amendment on 29th June 2015 (NRES Committee South Central – Oxford B; reference: 
14/SC/0247) (appendix C). Medicines and Healthcare products Regulatory Agency (MHRA) 
approval was first granted on 9th June 2014 (appendix D) and subsequently for a substantial 
amendment on 2nd July 2015 (reference: 13630/005/001-0002) (appendix E). The trial was 
registered with the European Clinical Trials Database (EudraCT Number: 2014-001318-24) and 
ISRCTN registry (ISRCTN98060456). 
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Role of the funding source 
This research was funded by a Doctoral Research Fellowship (DRF-2013-06-115) awarded by the 
National Institute of Health Research (NIHR), the Norfolk and Norwich University Hospital 
Gastroenterology research fund (Dr Hugh Kennedy) and Surgical research funds (Mr Edward 
Cheong). The funding sources and sponsor had no input regarding the design, conduct or 
interpretation of this study. This research represents independent research funded by the 
National NIHR. The views expressed are those of the investigators and not necessarily those of the 
NHS, the NIHR or the Department of Health. 
 
Substantial amendment 
This feasibility study was originally planned to be conducted at a single site: the Norfolk and 
Norwich University Hospital NHS Foundation Trust. Within two months of this site being 
activated, it became clear that recruitment would be insufficient to meet the minimum target of 
24 patients. NIHR, NCTU, sponsor, MHRA and ethical approval was sought to expand the study to 
three further NHS sites, extend recruitment from 31/10/15 to 31/7/16 with truncated follow-up 
for participants recruited after 1/11/15. The last date of follow-up was fixed at 31/10/16.  
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3.4. Results 
Recruitment 
Between 21st October 2014 and 22nd July 2016, 120 patients were assessed for eligibility (see 
figure 15). 88 were excluded in total, 54 for not meeting inclusion criteria (54 were current statin 
users and of these, two were also in receipt of contra-indicated medication [ciclosporin and 
amlodipine], and one had severe renal insufficiency); 22 declined to participate; and 12 patients 
assessed for eligibility during the recruitment period were excluded for other reasons (five 
patients originally on a curative surgical pathway progressed and were deemed unsuitable for 
curative resection; one patient died during neoadjuvant chemotherapy; two were pre-screened 
and provisionally met eligibility, however were not approached in time to gain consent prior to 
surgery; one patient consented to the trial however later required enteral feeding and would 
have been unable to take the trial medication; and three were pre-screened during recruitment 
but could not be approached as recruitment had completed at respective sites. 
 
Between 23rd November 2014 and 22nd July 2016, 32 patients with oesophageal or oesophago-
gastric junctional (Siewert type I or II) adenocarcinoma who underwent resection with curative 
intent were randomised to receive Simvastatin 40mg (n=16) or placebo (n=16) once daily from 
three UK NHS sites. Participants were followed-up until withdrawal from the trial, death, or one 
year from discharge from hospital following potentially curative surgical resection or 31st October 
2016, whichever came first. Of the 16 patients randomised to placebo, two never received the 
study intervention (one withdrew consent prior to receipt of medication and one patient did not 
receive their trial medication prior to discharge, which was subsequently lost triggering a protocol 
violation). Of the 16 randomised to Simvastatin, all received the trial medication.  
 
Participants recruited after 1st November 2015 underwent truncated follow-up for at least three 
months, affecting eight patients in the placebo arm and seven in the simvastatin arm. In total 12 
patients in the placebo arm, and 14 patients in the simvastatin arm had both a screening and 
three month LDL cholesterol measurement. Reasons for missing values in the placebo group 
were: one death before the three months; one withdrawal before three months; one sample was 
insufficient volume; and for one hypertriglyceridaemia prevented calculation of LDL cholesterol. 
Missing values for two patients in the simvastatin group were also due to hypertriglyceridaemia.  
 
The overall proportion of participants randomised from those assessed for eligibility (regardless of 
reasons for exclusion) was 26.7% (95% CI 19.0-35.5%) (32/120). The proportion of participants 
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randomised from those who met all inclusion criteria except the first one (ie. “participant is 
willing and able to give informed consent for participation in the trial”) was 59.3% (95% 45.0-
72.4%) (32/54).  
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Figure 15: Trial profile 
1These patients were also current statin users 
 
Table 19 shows the monthly recruitment rate for each NHS site. Of the four active sites, three 
recruited at least one patient. The overall cumulative monthly rate of recruitment was 3.01 (95% 
CI 2.59-3.48) participants per month. Variation in rate between centres was observed, the highest 
was seen at Mid Essex Hospital Services NHS Trust (recruitment completed of six allocated 
patients within 4.6 months), while no patients were randomised at South Tees Hospitals NHS 
Foundation Trust (of 16 assessed, six declined, eight were prevalent statin users, one progressed 
pre-op and one consented but was not randomised as their date of surgery was after recruitment 
to the study had closed).  
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  Recruitment 
time (months)  
Number 
recruited Rate (95% CI) Site 
Norfolk and Norwich University Hospital 18 21 1.16 (0.73-1.76) 
Mid Essex Hospital Services NHS Trust 4.6 6 1.31 (0.49-2.79) 
Nottingham University Hospitals NHS trust 9.3 5 0.54 (0.18-1.24) 
South Tees Hospitals NHS Foundation Trust 5.8 0 0 
Cumulative total 37.7 32 3.01 (2.59-3.48) 
Table 17: Monthly recruitment rate by contributing NHS site 
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Baseline characteristics 
 
Baseline characteristics are presented in table 20. Baseline demographic and clinical 
characteristics, and quality of life function and symptoms scales were well-balanced overall 
between groups. The mean age at randomisation was 62.7 (SD 12.3) years in the placebo group 
and 66.6 (SD 8.7) years in the simvastatin group. As expected, most randomised patients were 
male, had a significant smoking history, where of white European descent, had minimal co-
morbidity, were not aspirin users, and predominantly had a performance status score of zero. 
Mean non-fasting LDL cholesterol was similar between groups: 3.51 (SD 0.89) mmol/L in the 
placebo group, and 3.73 (SD 0.92) in the simvastatin group. The frequencies of individual tumour 
sites were similar between groups; for oesophageal, Siewert I and Siewert II tumours respectively 
there were seven, two and seven in the placebo group, and five four and seven in the simvastatin 
group. Most tumours were grade 2-3, based on biopsies taken at index. The majority of tumours 
were T3, (all were in the placebo group) with one T2, one T4 and two T4a tumours in the 
simvastatin group. Clinical N staging was broadly equivalent between groups. In both arms 15/16 
(93.8%) received neoadjuvant chemotherapy and one patient in the simvastatin arm received pre-
operative radiotherapy. VO2 max was similar between groups, it was 20.7 ml/kg/min (SD 3) in the 
placebo group, and 21.8 ml/kg/min (SD 3.1) in the simvastatin group. Most oesophagectomies 
were hybrid procedures (9/16 in the placebo group and 10/16 in the simvastatin group). The 
lymph node yield and number of positive lymph nodes were similar between groups. Nine 
patients in the placebo group and five in the simvastatin group had a positive resection margin. 
Post-operative length of stay was similar between groups: median 10 days (IQR 6-12.5) in the 
placebo group, and 9 days (IQR 6-12) in the simvastatin group. The proportions of in-hospital 
complications were similar between groups, with seven (44%) in the placebo group, and six (38%) 
in the simvastatin group. Mean global quality of life, function scores (role, emotional, cognitive, 
social and physical) and symptom scales (dysphagia, eating difficulties and reflux) were similar 
between treatment groups.   
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Variable 
Placebo 
(n=16) 
Simvastatin 
(n=16) 
Age at randomisation (years) 62.7 (12.3) 66.6 (8.7) 
Time from diagnosis to randomisation (days) 153.4 (31.8) 155 (40.8) 
Gender     
Male 13 (81.3) 12 (75) 
Female 3 (18.8) 4 (25) 
Smoking status     
Current 1 (6.3) 2 (12.5) 
Past 10 (62.5) 11 (68.8) 
Never 5 (31.3) 3 (18.3) 
Body mass index (kg/m2) 26.2 (4.1) 26.6 (4.7) 
Ethnic origin (European) 16 (100) 16 (100) 
Comorbid conditions     
Cardiovascular 0 1 (6.3) 
Diabetes 0 0 
Charleson co-morbidity index1     
0 15 (93.8) 14 (87.5) 
1 1 (6.3) 2 (12.5) 
Peri-operative aspirin use 0 0 
Performance status     
0 16 (100) 13 (81.3) 
1 0 2 (12.5) 
2 0 1 (6.3) 
LDL cholesterol (mmol/L) 3.51 (0.89) 3.73 (0.92) 
Tumour site     
Oesophageal 7 (43.8) 5 (31.3) 
Siewert I 2 (12.5) 4 (25) 
Siewert II 7 (43.8) 7 (43.8) 
Tumour grade     
Gx 2 (12.5) 1 (6.3) 
G1 0 0 
G2 5 (31.3) 8 (50) 
G3 9 (56.3) 6 (37.5) 
G4 0 1 (6.3) 
Clinical T stage     
2 0 1 (6.3) 
3 16 (100) 12 (75) 
4 0 1 (6.3) 
4a 0 2 (12.5) 
Clinical N stage     
0 2 (12.5) 5 (31.3) 
1 9 (56.3) 6 (37.5) 
2 4 (25) 4 (25) 
3 1 (6.3) 1 (6.3) 
Neoadjuvant chemotherapy     
Yes 15 (93.8) 15 (93.8) 
No 1 (6.3) 1 (6.3) 
Pre-operative Radiotherapy     
Yes 0 1 (6.3) 
No 16 (100) 15 (93.8) 
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Variable 
Placebo 
(n=16) 
Simvastatin 
(n=16) 
Chemotherapy response     
Complete 2 (14.3) 2 (13.3) 
Good 1 (7.1) 0 
Moderate 4 (28.6) 3 (20) 
Poor 4 (28.6) 0 
No response 3 (21.4) 7 (46.7) 
Unknown response2 2 (12.5) 1 (6.3) 
VO2 max (ml/kg/min) 20.7 (3) 21.8 (3.1) 
Oesophagectomy     
Open 4 (25) 2 (12.5) 
Hybrid 9 (56.3) 10 (62.5) 
Minimally invasive 3 (18.8) 4 (25) 
Lymph node yield, n (IQR) 26 (19-42) 21.5 (24.5-35) 
Positive lymph nodes, n (IQR) 1.5 (0-4.5) 1 (0-3) 
Vascular invasion     
Positive 9 (56.3) 5 (31.3) 
Negative 7 (43.8) 11 (68.8) 
Margin status     
R1 4 (25) 3 (18.8) 
R0 12 (75) 13 (81.3) 
Postoperative length of stay 10 (6-12.5) 9 (6-12) 
Any postoperative in-hospital complication 7 (43.8) 6 (37.5) 
Global Quality of life3 68 (20) 73 (10) 
QLQ-C30 function scores     
Role3 85 (16) 82 (25) 
Emotional3 82 (26) 79 (28) 
Cognitive3 92 (17) 81 (24) 
Social3 71 (31) 70 (31) 
Physical3 95 (10) 92 (16) 
OG25 symptom scales     
Dysphagia4 15 (26) 27 (36) 
Eating restrictions4 20 (25) 34 (35) 
Reflux4 13 (18) 24 (31) 
Table 18: Baseline characteristics of randomised participants 
Abbreviations: G, tumour grade; IQR, interquartile range; kg, kilograms; LDL, low-density lipoprotein; m, meters; SD, 
standard deviation; VO2 max, maximum volume of oxygen used 
Values presented as frequencies (%) and means (SD) unless otherwise stated. 
1Modified Charleson co-morbidity index (excludes solid tumours) 
2Percentages presented for unknown categories reflect overall proportion of missing data for the relevant covariate; 
while percentages presented for known categories refer to complete data only. 
3Global quality of life and functional scales: high score suggests a high level of functioning 
4Symptom scales: high score suggest worse symptoms 
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Retention 
The number and proportion of participants withdrawn from the trial (including withdrawing 
treatment with continued follow-up, and complete withdrawal from all trial related procedures) 
are presented in table 21. In total, for both treatment groups, one withdrew consent prior to 
receiving treatment, six discontinued the trial medication having received it: four reported 
difficulty swallowing the medication; one discontinued the medication and continued follow-up; 
one received a statin from their GP after randomisation, and one developed grade 3 transaminitis 
(discussed below, under safety) and treatment was discontinued by an investigator. 
 
Number withdrawn Proportion Reason 
3 9.4% Difficulty swallowing trial medication 
2 6.3% Withdrew consent (1 from trial, 1 for treatment only) 
1 3.1% General practitioner prescribed statin during follow-up 
1 3.1% Adverse event (transaminitis) 
Total:              7 21.9%   
Table 19: Reasons for withdrawal of treatment. 
 
The overall annual rate of withdrawal from the study was 0.36 (95% CI 0.17-0.76) (see table 22). 
The rate was highest in the first three months: 0.74 (95% CI 0.31-1.77); before falling between 
three to six months to 0.36 (0.09-1.46); thereafter there were no further losses to follow-up. 
Retention overall and stratified by treatment allocation are further summarised in figure 16. 
 
Follow-up Person-years Number withdrawn Rate (95% CI) 
0-3 months 6.8 5 0.74 (0.31-1.77) 
3-6 months 5.5 2 0.36 (0.09-1.46) 
6-9 months 4.2 0 0 
9-12 months 2.8 0 0 
Overall 19.3 7 0.36 (0.17-0.76) 
Table 20: Withdrawal rates for recruited participants, stratified by follow-up period 
Rates represent the annual rate of withdrawal 
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Figure 16: Kaplan-Meier plots of time to withdrawal (A) overall and (B) according to treatment allocation. 
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There were no significant differences in withdrawals between treatment groups (log-rank test = 
0.63). Aside from two withdrawals between month three to six, all other withdrawals happened 
within 27 days of randomisation.  
 
Absorption 
Participants allocated to simvastatin, compared to placebo users, had a significant mean 
difference in LDL cholesterol by three months, adjusted for values at screening of -0.83 (95% CI -
1.4 to -0.22), p = 0.009 (the primary outcome for this feasibility outcome) (see table 23). 
Exploratory analyses revealed significantly (at the 1% significance level) lower LDL levels at 6 and 
12 months. None of the adjusted per-protocol comparisons reached significance at the 1% level.  
 
 
Table 21: Comparison of non-fasting plasma LDL cholesterol by treatment group during follow-up according to 
intention-to-treat and per-protocol populations.  
Abbreviations: CI, confidence interval; LDL, low density lipoprotein; n, number. 
Mean scores adjusted for values at screening by ANCOVA. A negative difference implies that patients on Simvastatin 
have a lower LDL cholesterol than patients on placebo. 
 
Mean plasma LDL cholesterol for participants over the duration of the study according to 
treatment allocation are shown in figure 17. 
placebo Simvastatin
Visit n LDL (mmol/L) n LDL (mmol/L) p value p value
Intention-to-treat
3 months 13 3.00 (0.54) 15 2.20 (0.85) -0.80 (-1.36 to -0.24) 0.007 -0.83 (-1.4 to -0.22) 0.009
6 months 10 3.09 (0.63) 14 2.14 (1.01) -0.95 (-1.71 to -0.20) 0.016 -1.23 (-1.85 to -0.40) 0.004
9 months 8 2.89 (0.61) 12 2.17 (0.74) -0.72 (-1.39 to -0.05) 0.036 -0.79 (-1.47 to -0.11) 0.025
12 months 4 3.00 (0.28) 6 2.07 (0.47) -0.93 (-1.54 to -0.33) 0.008 -0.99 (-1.58 to -0.40) 0.007
Per-protocol
3 months 7 3.00 (0.60) 9 2.46 (0.96) -0.53 (-1.42 to 0.36) 0.224 -0.49 (-1.47 to 0.49) 0.300
6 months 8 3.09 (0.66) 12 2.09 (1.09) -1.00 (-1.91 to -0.09) 0.034 -1.16 (-2.01 to -0.32) 0.010
9 months 7 2.86 (0.66) 12 2.17 (0.74) -0.69 (-1.41 to 0.03) 0.058 -0.74 (-1.47 to -0.003) 0.049
12 months 3 3.07 (0.31) 5 2.02 (0.51) -1.05 (-1.85 to -0.24) 0.019 -1.16 (-1.96 to -0.35) 0.016
Unadjusted mean 
difference (95% CI)
Adjusted mean 
difference (95% CI)
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Figure 17: Plasma LDL cholesterol during follow-up according to treatment group for (A) the intention-to-treat and (B) 
per-protocol populations.  
Half error bars span from the average to the upper limit or lower limit of the 95% confidence interval. 
Statins and oesophageal adenocarcinoma 
145 
Adherence 
Overall adherence was lowest in the first three months of treatment (52% adherence, median 
adherence 83%, IQR 45-98) before improving at subsequent visits at six months (78% adherence, 
median 94%, IQR 83-100), nine months (100% adherence, median 99%, IQR 96-100) and 12 
months (75% adherence, median 89%, IQR 82-97) (see table 24 and figure 18). Adherence was 
similar in both statin and placebo treated groups.  
Visit 3 months     6 months   
Allocation n median % (IQR) ≥ 80%   n median % (IQR) ≥ 80% 
Placebo 13 77 (38-98) 6 (46)   10 94 (90-100) 8 (80) 
Simvastatin 14 85 (63-99) 8 (57)   8 92 (67-99) 6 (75) 
Overall 27 83 (45-98) 14 (52)   18 94 (83-100) 14 (78) 
                
Visit 9 months     12 months   
Allocation n median % (IQR) ≥ 80%   n median % (IQR) ≥ 80% 
Placebo 5 97 (96-99) 5 (100)   3 92 (78-98) 2 (67) 
Simvastatin 5 100 (99-100) 5 (100)   5 96 (85-100) 4 (80) 
Overall 10 99 (96-100) 10 (100)   8 94 (82-99) 6 (75) 
 
Table 22: Adherence to trial medication during follow-up. 
Abbreviations: IQR, interquartile range. 
Median percentage (IQR) adherence and the proportion adherent (n, %) to ≥ 80% of trial medication in the preceding 
three months. 
No implausible values for adherence (> 105%) were observed at three months. Values from three patients were ignored 
at six months (and thereafter), values from five patients were ignored at nine months (and thereafter) and none were 
ignored at 12 months. 
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Figure 18: Median percentage adherence to trial medication (A) overall and (B) according to treatment allocation, 
calculated at each trial visit for the preceding three months. 
Half error bars span from the median to the upper limit or lower limit of the interquartile range 
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Safety 
Over the course of follow-up there were 108 individual adverse events affecting 27 participants. 
In total 20 (18.5%) were SAEs, with 13 in placebo and seven in the simvastatin arm. There were no 
suspected Serious Adverse Reactions (SSARs) or Suspected Unexpected Serious Adverse Reactions 
(SUSARs). Of all individual AEs, prior to unblinding, 94 were assessed as unrelated to trial 
medication, 12 were assessed as unlikely related, and two were assessed to be possibly related 
(grade 3 transaminitis [ALT > 5 ≤ 20 times upper limit of normal], which was subsequently 
downgraded to grade 2 [ALT > 3 ≤ 5 times upper limit of normal] in the same patient (who had 
been allocated placebo). As expected, the most frequent AEs were gastrointestinal (36 unique 
gastrointestinal AEs, excluding recurrent AEs in the same patient), of which dysphagia (8/36, 
22.2%), abdominal pain (6/36, 16.7%), vomiting (6/36, 16.7%), diarrhoea (4/36, 11.1%), gastro-
oesophageal reflux (4/36, 11.1%) and nausea (4/36, 11.1%) were the most common.  
 
Table 25 shows the AEs according to CTCAE System Organ Class. There were no significant 
differences between treatment groups AEs categorised using this classification. Grade 1 (mild) 
myalgia was experienced by three patients, 1 receiving placebo and 2 receiving simvastatin, and 
was self-limiting and did not require discontinuation of trial medication. There were no cases of 
rhabdomyolysis. Severity of AEs (unique events for the worst grade experienced per patient) 
stratified by treatment (see table 26), showed no obvious differences between treatment groups 
(χ² test for distribution of severity according to treatment for any toxicity, p=0.639). The majority 
of grades reported were mild to moderate (34.0%, 29.8% and 31.9% respectively were grade 1-3 
in the placebo group; and 43.8%, 31.3% and 18.8% respectively were grade 1-3 in the simvastatin 
group. There was a single grade 4 AE in the placebo group (dyspnoea) and in the simvastatin 
group (pleural effusion). Grade 5 AEs refer to death (one in placebo group and two in simvastatin 
group). All were due to metastatic disease and were not judged to be related to trial medication. 
No requests for unblinding on grounds of patient safety were made during the study. The safety 
committee held four meetings in total, during which there no safety concerns with the trial.  
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Placebo 
Number of 
individuals 
with ≥ 1 (%) 
Simvastatin 
Number of 
individuals 
with ≥ 1 (%) 
  
    
    
CTCAE System Organ Class p value 
Blood 1 (7.1) 0 0.277 
Ear 1 (7.1) 1 (6.3) 0.922 
Gastrointestinal 11 (78.6) 9 (56.3) 0.196 
General disorders 3 (21.4) 5 (31.3) 0.544 
Infections 3 (21.4) 4 (25) 0.818 
Investigations 3 (21.4) 2 (12.5) 0.513 
Transaminitis 1 (7.1) 0 0.277 
Metabolism and nutrition 0 1 (6.3) 0.341 
Musculoskeletal 1 (7.1) 5 (31.3) 0.100 
Myalgia 1 (7.4) 2 (12.5) 0.626 
Neoplasms 1 (7.1) 0 0.277 
Nervous system 2 (14.3) 3 (18.8) 0.743 
Psychiatric 2 (14.3) 2 (12.5) 0.886 
Renal and urinary 1 (7.1) 1 (6.3) 0.922 
Respiratory 4 (28.6) 2 (12.5) 0.272 
Skin 1 (7.1) 1 (6.3) 0.922 
Vascular 2 (14.3) 1 (6.3) 0.464 
Any 13 (92.9) 14 (87.5) 0.626 
Table 23: Adverse events by treatment allocation 
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events. 
Proportions of individuals with at least one adverse event were compared using the χ² test. 
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Quality of life 
Completion of questionnaires was very high at each visit: 98.8% (1685/1705) at screening; 98.8% 
(1606/1625) at 3 months; 96.4% (1379/1430) at 6 months; 99.1% (1065/1075) at 9 months; 98.7% 
(543/550) at 12 months. Overall completion was 98.3% (6278/6385). Therefore 1.68% (107) 
values were imputed using EORTC guidelines. Table 27 and figures 20-21 shows the mean scores 
for global quality of life, QLQ-C30 function scores (role, emotional, cognitive, social and cognitive), 
and OG25 symptoms scales (dysphagia, eating restrictions and reflux) in placebo and simvastatin 
groups for each of the four follow-up visits and the mean difference between groups adjusted for 
scores at screening. Overall, adjusted differences between groups for each of these scores were 
small.  
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Quality of life measured at 3 months         
  Placebo Simvastatin Difference at 3 months 
  n mean (SD) n mean (SD) n 
adjusted mean 
(95% CI) 
Global QOL 14 61.9 (20.3) 15 63.5 (16.9) 28 0.43 (-0.06 to 0.91) 
QLQ-C30 function scores             
Role 14 65.5 (36.1) 15 70.8 (30.1) 29 0.53 (-0.09 to 1.14) 
Emotional 14 76.8 (24.9) 15 78.0 (19.1) 28 0.51 (0.27 to 0.75) 
Cognitive 14 76.2 (33.1) 15 80.2 (20.4) 28 0.70 (0.27 to 1.13) 
Social 14 67.9 (33.0) 15 67.7 (22.3) 28 0.31 (-0.05 to 0.66) 
Physical 14 76.2 (18.4) 15 79.6 (18.9) 29 0.37 (-0.15 to 0.90) 
OG25 symptom scales             
Dysphagia 14 12.7 (14.4) 15 17.0 (25.8) 28 0.10 (-0.17 to 0.36) 
Eating restrictions 14 34.5 (24.6) 15 37.4 (25.2) 28 0.13 (-0.19 to 0.44) 
Reflux 14 29.8 (30.8) 15 24.4 (22.6) 28 0.45 (0.04 to 0.86) 
              
Quality of life measured at 6 months         
  Placebo Simvastatin Difference at 6 months 
  n mean (SD) n mean (SD) n 
adjusted mean 
(95% CI) 
Global QOL 12 75.0 (15.9) 13 71.8 (18.2) 23 0.30 (-0.18 to 0.77) 
QLQ-C30 function scores             
Role 12 86.1 (15.6) 13 76.9 (28.5) 24 0.70 (0.12 to 1.28) 
Emotional 12 88.2 (17.2) 13 78.8 (24.2) 23 0.57 (0.38 to 0.77) 
Cognitive 12 84.7 (19.4) 13 74.4 (30.1) 23 0.97 (0.64 to 1.31) 
Social 12 91.7 (15.1) 13 74.4 (33.1) 23 0.42 (0.11 to 0.74) 
Physical 12 88.9 (15.7) 13 78.9 (22.2) 25 1.25 (0.55 to 1.95) 
OG25 symptom scales             
Dysphagia 12 6.5 (11.1) 14 8.7 (12.5) 25 0.02 (-0.21 to 0.25) 
Eating restrictions 12 24.3 (22.0) 14 28.6 (20.6) 25 0.28 (-0.06 to 0.62) 
Reflux 12 23.6 (25.1) 14 13.1 (23.7) 25 0.44 (0.02 to 0.87) 
              
Quality of life measured at 9 months         
  Placebo Simvastatin Difference at 9 months 
  n mean (SD) n mean (SD) n 
adjusted mean 
(95% CI) 
Global QOL 8 75.0 (10.9) 12 75.7 (12.5) 18 0.12 (-0.31 to 0.56) 
QLQ-C30 function scores             
Role 8 87.5 (19.4) 12 81.9 (25.1) 19 0.77 (0.15 to 1.39) 
Emotional 8 84.4 (22.5) 12 78.5 (22.0) 18 0.50 (0.31 to 0.69) 
Cognitive 8 87.5 (19.4) 12 81.9 (21.9) 18 0.41 (-0.02 to 0.84) 
Social 8 93.8 (17.7) 12 81.9 (26.1) 18 0.05 (-0.38 to 0.47) 
Physical 8 93.3 (6.2) 12 84.4 (15.4) 19 0.67 (0.15 to 1.20) 
OG25 symptom scales             
Dysphagia 7 7.9 (12.4) 12 7.4 (10.9) 18 0.07 (-0.17 to 0.32) 
Eating restrictions 7 16.7 (17.3) 12 25.7 (19.6) 18 0.21 (-0.15 to 0.55) 
Reflux 7 16.7 (16.7) 12 23.6 (21.9) 18 0.53 (0.22 to 0.83) 
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Quality of life measured at 12 months         
  Placebo Simvastatin Difference at 12 months 
  n mean (SD) n mean (SD) n 
adjusted mean (95% 
CI) 
Global QOL 4 83.3 (0) 6 75 (13.9) 9 0.20 (-0.81 to 1.22) 
QLQ-C30 function scores             
Role 4 87.5 (8.3) 6 77.8 (25.1) 9 1.64 (0.72 to 2.57) 
Emotional 4 97.9 (4.2) 6 75.0 (19.0) 9 0.45 (0.14 to 0.75) 
Cognitive 4 95.8 (8.3) 6 77.8 (31.0) 9 1.40 (0.81 to 1.99) 
Social 4 100 (0) 6 83.3 (18.3) 9 0.26 (-0.09 to 0.62) 
Physical 4 95 (6.3) 6 81.1 (22.9) 9 6.17 (2.53 to 9.80) 
OG25 symptom scales             
Dysphagia 4 2.8 (5.6) 6 1.9 (4.5) 9 0.28 (-0.30 to 0.86) 
Eating restrictions 4 6.3 (8.0) 6 22.2 (16.4) 9 0.08 (-0.77 to 0.94) 
Reflux 4 12.5 (16.0) 6 19.4 (19.5) 9 -0.71 (-2.33 to 0.90) 
 
Table 25: Global quality of life, function and symptoms scores by treatment group measured during follow-up. 
Global quality of life and functional scales: high score suggests a high level of functioning. Symptom scales: high score 
suggest worse symptoms. Difference in mean scores adjusted for values at screening by ANCOVA. For global quality of 
life and functional scales a positive difference implies that patients on Simvastatin have less deterioration than patients 
on placebo. For symptom scales a positive difference implies that patients on Simvastatin have more deterioration than 
patients on placebo. For adjusted difference, n is the number of observations included in the model. 
 
 
 
Figure 19: Mean unadjusted scores for global quality of life and function during following up by treatment group.Table 
26: Global quality of life, function and symptoms scores by treatment group measured during follow-up. 
Global quality of life and functional scales: high score suggests a high level of functioning. Symptom scales: high score 
suggest worse symptoms. Difference in mean scores adjusted for values at screening by ANCOVA. For global quality of 
life and functional scales a positive difference implies that patients on Simvastatin have less deterioration than patients 
on placebo. For symptom scales a positive difference implies that patients on Simvastatin have more deterioration than 
patients on placebo. For adjusted difference, n is the number of observations included in the model. 
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Figure 20: Mean unadjusted scores for global quality of life and function during following up by treatment group.  
Higher scores suggest better quality of life and functioning. Half error bars span from the mean to the upper limit or lower 
limit of the 95% confidence interval. 
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Figure 21: Mean unadjusted scores for symptom scales during following up by treatment group.  
Higher scores suggest worse symptoms. Half error bars span from the mean to the upper limit or lower limit of the 95% 
confidence interval. 
 
 
Figure 21: Kaplain-Meier estimates of overall survival (A) and disease-free survival (B) by treatment allocation in the intention-
to-treat population.Figure 22: Mean unadjusted scores for symptom scales during following up by treatment group.  
Higher scores suggest worse symptoms. Half error bars span from the mean to the upper limit or lower limit of the 95% 
confidence interval. 
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Survival 
During follow-up four participants developed distal recurrent disease (two in both placebo and 
simvastatin groups) and of these, three died (one in the placebo and two in the simvastatin 
group). There were no local recurrences in either treatment group. Median overall and disease-
free survival was not reached. There was no significant difference between groups for overall 
survival (HR 1.56, 95% CI 0.14-17.3, p=0.716) or disease-free survival (HR 0.79, 95% CI 0.11-5.61, 
p=0.807) (see figure 22). Clinical examination (as part of research visits) did not detect recurrence 
in advance of diagnosis by the clinical team.  
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Figure 22: Kaplain-Meier estimates of overall survival (A) and disease-free survival (B) by treatment allocation in the 
intention-to-treat population. 
Hazard ratios and 95% confidence intervals estimated with cox proportional hazards regression.  
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Generalisability 
 
No significant differences were found between non-randomised and randomised patient 
populations for age at diagnosis, gender, smoking status, BMI, tumour site, tumour grade, clinical 
staging or pre-operative radiotherapy. As expected there were significant differences between 
treatment groups for cardiovascular diseases (28.4% in non-randomised and 3.1% in the 
randomised group, p=0.003), diabetes (22.5% in the non-randomised population, and no patients 
with diabetes in the group, p=0.003) and aspirin use (17.9% in the non-randomised group, and no 
patients in the randomised group, p=0.010). There were also significantly more patients (p=0.037) 
with a lower ECOG performance status (indicating better performance status) in the randomised 
group compared to the non-randomised group (87.5% in the randomised group and 63% in non-
randomised had a score of 0). Significantly more (p=0.035) patients underwent neoadjuvant 
chemotherapy in the randomised group (93.8%) than in the non-randomised group (76.7%). 
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  non-randomised 
(n=88) 
randomised 
(n=32) 
  
Variable p-value 
Age at diagnosis, years  67.8 (8.9) 64.0 (10.8) 0.059 
Gender       
Male 77 (88.5) 25 (78.1) 0.151 
Female 10 (11.5) 7 (21.9)   
Smoking status       
Current 13 (16.5) 4 (12.5) 0.485 
Past 42 (53.2) 21 (65.6)   
Never 24 (30.4) 7 (21.9)   
Body mass index (kg/m2) 27.6 (5.2) 26.4 (4.4) 0.245 
Comorbid conditions       
Cardiovascular 25 (28.4) 1 (3.1) 0.003 
Diabetes 18 (22.5) 0 0.003 
Peri-operative aspirin use 15 (17.9) 0 0.010 
Performance status       
0 53 (63.9) 28 (87.5) 0.037 
1 27 (32.5) 3 (9.4)   
2 3 (3.6) 1 (3.1)   
Unknown1 5 (5.7) 0   
Tumour site       
Oesophageal 42 (50.0) 12 (37.5) 0.458 
Siewert I 11 (13.1) 6 (18.8)   
Siewert II 31 (36.9) 14 (43.8)   
Unknown 4 (4.5) 0   
Tumour grade       
G1 1 (1.3) 0 0.342 
G2 41 (51.9) 13 (46.4)   
G3 37 (46.8) 14 (50)   
G4 0 1 (3.6)   
Unknown1 9 (10.2) 4 (12.5)   
Clinical T stage       
1 3 (3.5) 0 0.080 
2 15 (17.9) 1 (3.1)   
3 63 (75.0) 28 (87.5)   
4 3 (3.6) 3 (9.4)   
Unknown1 4 (4.5) 0   
Clinical N stage       
0 38 (45.8) 7 (21.9) 0.077 
1 22 (26.5) 15 (46.9)   
2 16 (19.3) 8 (25.0)   
3 7 (8.4) 2 (6.3)   
Unknown1 5 (5.7) 0   
Neoadjuvant chemotherapy       
Yes 66 (76.7) 30 (93.8) 0.035 
No 20 (23.3) 2 (6.3)   
Unknown1 2 (2.3) 0   
Pre-operative radiotherapy       
Yes 5 (6.0) 1 (3.1) 0.531 
No 78 (94) 31 (97.9)   
Unknown1 5 (5.7) 0   
Table 27: Comparison of demographic and clinical variables between the non-randomised and randomised patient 
populations. 
Abbreviations: G, tumour grade; kg, kilograms; m, meters; SD, standard deviation; maximum volume of oxygen used. 
Values are frequencies (%) or means (SD) unless otherwise specified. 
1Percentages presented for unknown categories reflect overall proportion of missing data for the relevant covariate; 
while percentages presented for known categories refer to complete data only. 
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3.5. Discussion 
This multi-centre, double-blind, parallel group, randomised, placebo-controlled trial reported 
outcomes for 32 participants randomised to simvastatin 40mg or placebo to determine the 
feasibility of adjuvant statin therapy in patients with operable OAC in a future phase III trial. 
Overall, 26.7% of patients assessed for eligibility were randomised. Of patients assessed for 
eligibility who did not meet any exclusions 59.3% were randomised. Across four sites, overall 
three participants were recruited per month (3.01, 95% CI 2.59-3.48). In total, seven participants 
withdrew during the course of the trial: three had difficulty swallowing the trial medication, two 
withdrew consent, one was started on a non-trial statin by their general practitioner, and one 
patient was withdrawn following an adverse event (transaminitis). The overall annual rate of 
withdrawal was 0.36 (95% CI 0.17-1.77). The rate of withdrawal was highest in the first three 
months, followed by the next three months, with no withdrawals thereafter. Patients allocation to 
simvastatin had significantly lower LDL cholesterol levels than the placebo group by three months 
(adjusted mean difference -0.83 mmol/L, 95% CI -1.4 to -0.22, p=0.009) in the intention-to-treat 
population, indicating drug absorption, a significant pharmacodynamic effect and suggesting drug 
adherence. Drug adherence was poorest in the first three months of follow-up (52% took at least 
80% of administered medications), and improved to acceptable levels thereafter. The majority of 
adverse events recorded during follow-up were expected given the patient cohort, and most were 
attributable to the underlying malignancy, surgery or oncological treatments. There were no 
statistically significant or clinical significant differences in the adverse event profile between 
treatment groups. Completion rates of quality of life questionnaires (QLQ-C30 and OG25) were 
very high over the course of the study (98.3% of individual items were completed overall). 
Although there were some statistically significant differences in quality of life scores between 
groups for certain domains at certain time-points, absolute differences were small and there were 
no clinically significant differences between groups. The absolute number of deaths (three) and 
recurrences (four) for the cohort were low. As expected, there were no significant differences 
between groups for overall survival or disease free survival. No systematic differences between 
the randomised and non-randomised groups were found for certain demographic characteristics 
(age, gender, smoking, BMI) or tumour characteristics (tumour stage or grade).   
 
Trial interpretation 
Recruitment and retention. This trial demonstrated that patients were willing to enter the trial 
and be randomised to simvastatin or placebo. The trial also demonstrated that patients’ 
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consultants (all oesophago-gastric surgeons) were willing to approach and enrol their patients in 
the trial. The proportion of patients randomised from those assessed for eligibility and from those 
meeting inclusion criteria was favourable. The recruitment rates across all sites should be seen as 
a valid and relatively precise estimate of anticipated recruitment rates for a future trial. The main 
caveat is that initiation rates of statins varies by geographic location284, and adjustment for 
projected statin prevalence across regions would be required for planning anticipated recruitment 
nationally. Comparison of recruitment rates between centres should be interpreted in light of the 
precision of the estimates, a function of duration of follow-up and absolute numbers of 
participants recruited. The rates calculated for the Norfolk and Norwich University hospital, with 
the longest period of follow-up and highest number recruited were predictably the most precise, 
while estimates rates at other centres lacked precision and should be interpreted with less 
certainty. Rates of withdrawal were highest in the first three months of follow-up, mainly 
contributed to by difficulties in swallowing trial medication. Participants who continued to 
participate between three-six months, and more so thereafter were more likely to be retained. 
There is uncertainty about the precise rate of withdrawal overall and particularly stratified by 
period of follow-up (and diminishes further over time) as person-time at risk was limited. This 
data provides strong impetus to manufacture bespoke, more easily swallowed (and ideally 
suitable for crushing) trial medication for a future trial. As a result, there may be difficulties in 
generalising these rates of withdrawal to a future phase III RCT for which, production of smaller 
trial medications could be justified. Despite the inherent uncertainty in estimates of retention, the 
current data are reassuring and would support trial feasibility. 
 
Baseline characteristics. The baseline characteristics were generally well balanced overall. 
Caution needs to be made in interpreting proportions for individual characteristics within 
treatment groups as the denominator for each group was 16. Therefore discrepancies of small 
numbers of patients between categories, expected by chance, dramatically alter percentages. It is 
important that such discrepancies are not over-interpreted. Well balanced characteristics (both 
observed and non-observed) are essential for a future phase III trial, though are of lesser 
importance for interpreting the feasibility of a future trial.   
 
Absorption. A significant reduction in non-fasting LDL cholesterol between randomised treatment 
groups at three months in the ITT population provides good evidence to infer that simvastatin 
40mg is absorbed sufficiently to produce a pharmacodynamic effect. Reductions in LDL 
cholesterol were consistent with those observed in the MRC/BHF Heart production study (mean 
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difference overall -1.0 mmol/L, standard error 0.02)285. Exploratory analyses conducted at 
remaining time points in the ITT population at the 6 and 12 months were significant at the pre-
specified 1% level, indicating longer term absorption over the course of the trial. Highly significant 
differences in LDL cholesterol between groups would be expected to be a function of drug 
absorption, drug potency (sufficient to exert a pharmacodynamics effect) and overall drug 
adherence. While it is possible to infer that adherence was sufficient to permit an observable 
difference in LDL cholesterol between groups, it is not possible to quantify adherence further 
based on these results. Per-protocol analyses lacked precision and did not meet significance 3 
months. Per-protocol analyses were underpowered given the assumptions set out in the power 
calculation to detect significant differences were they to exist. The per-protocol analysis should 
therefore not be seen as evidence that statins do not lower LDL cholesterol, instead that results 
were inconclusive for this population.  
 
Adherence. Adherence as determined using pill counts demonstrated poorest adherence in the 
first three months, followed by greatly improved adherence thereafter. At least 75% of the cohort 
adhered to at least 80% of the trial medication thereafter. Adherence data is only applicable to 
the first year of treatment, it is not possible to draw further inferences on longer term follow-up, 
such as that which would be expected from a full trial. Patterns of adherence were very similar 
between treatment groups. Furthermore, interpretation should also consider the known 
limitations of pill counts, as they can overestimate adherence (discussed below)286. Nevertheless, 
the data from pill counts taken together with the comparison of LDL cholesterol between groups 
would suggest adherence is sufficient to not obviate a future trial. 
 
Safety. There was no evidence to suggest an adverse safety profile in this patient population with 
statin use, either in terms of the absolute numbers of AEs nor in terms of their severity. Particular 
AEs of interest with statins are rhabdomyolysis, deranged live function tests, rash and depression. 
Comparisons involved small numbers of AEs and this analysis would unlikely be adequately 
powered to detect even modest differences between groups. Although there is no plausible 
reason to suggest the adverse event profile should be different in this cohort, this has not 
previously been determined and favourable safety profile would support the feasibility of a future 
trial. There are no known interactions with current chemotherapy regimens and statins.  
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Quality of life. Completion of both the QLQ-C30 and OG25 questionnaires was very high overall 
(98.3%) and at each follow-up visit. Importantly this demonstrates the feasibility of assessing 
quality of life in a future phase III RCT. This study was not intended (nor originally powered) to 
detect significant differences between groups. Statistically significant differences were observed 
(as demonstrated in the table by non-overlapping 95% CIs, p values not shown) for emotional and 
cognitive functional domains, and reflux, during follow-up. This is most plausibly the result of 
multiple testing and the product of calculating quality of life scales following linear transformation 
of raw scores; scores can in practice only occupy limited values and not each potential value from 
0-100. It is reassuring the absolute differences between scores were not clinically significant: most 
differences which reached statistical significance were less than two, and a value of eight points 
difference has previously been deemed to be of clinical importance in a landmark oesophageal 
cancer trial287. The mean and standard deviations for function scores and symptom scales can be 
used to inform sample size calculations for future trials where patient reported outcomes are 
used the primary outcome. 
  
Preliminary survival data. Estimates of overall and disease free survival were very imprecise. This 
is attributable to the limited numbers of events and short durations of follow-up for participants 
(particularly with truncated follow-up). This would be consistent with previous trials and 
observational data, few events would be expected with minimal follow-up25, 39, 288.  
 
Generalisability. Comparisons between randomised and non-randomised groups provide strong 
evidence for systematic differences between groups for cardiovascular disease (p=0.003), 
diabetes (p=0.003) and aspirin use (p=0.01). This is expected as the trial eligibility precludes statin 
users, which are indicated in patients with these conditions, similarly with shared indications for 
aspirin use. Statin use was associated with greater co-morbidity (presence of any cardiovascular 
comorbidity and/or diabetes, 84.6% for statin users vs 15.4% for non-statin users, p<0.001) and 
more advanced age (mean 63.1 [SD 10.0] for statin users vs. 71.5 [SD 6.8] for non-statin users, 
p<0.001) and may explain poorer ECOG performance status scores, and lower use of neoadjuvant 
chemotherapy and radiotherapy in the non-randomised population. It should also be noted that 
not all patients in the non-randomised group proceeded to surgery (five progressed and were 
deemed unsuitable for curative resection and one patient died during neoadjuvant 
chemotherapy), and of statin users and patients who declined involvement, the proportions who 
ultimately underwent resection is not known.  
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Comparison with previous trials 
This is the first RCT to determine the feasibility of assessing post-operative statin therapy in 
patients with OAC in a future phase III. The effect of simvastatin 80mg has been assessed in 
patients undergoing oesophagectomy in a single-centre RCT (conducted in Belfast, Northern 
Ireland) previously289. The aim of this study was to determine effect of simvastatin 80mg (versus 
placebo) when administered four days preoperatively and seven days post-operatively on 
pulmonary dead space (primary endpoint determined using volumetric capnography) to 
determine the potential of high dose statin therapy in preventing acute lung injury. No significant 
differences were found between groups. Similarly to STAT-ROC, prevalence of statin use was high 
(31/63 excluded were prevalent statin users). The Add-Aspirin trial, a study most readily 
comparable to STAT-ROC in design, is currently underway290. This is a phase III RCT assessing the 
effects of aspirin on disease recurrence and survival after primary therapy in four cohorts of non-
metastatic solid tumours (breast, colorectal, gastro-oesophageal and prostate). Aside from the 
intervention (a routinely prescribed medication for cardiovascular disease prevention for which 
there is compelling evidence of cancer chemo-preventive effects123), key distinctions are the 
inclusion of squamous cell carcinomas and gastric tumours (in addition to OAC) in the gastro-
oesophageal cohort; the exclusion of R1 resections; exclusion of patients with risk factors for 
gastrointestinal toxicity; and the use of a run-in period of eight weeks to assess toxicity and 
adherence prior to randomisation and dose escalation from 100mg to 300mg if under 75 years of 
age. Published trials have assessed the effect of allocation to statins on cancer-related outcomes 
in solid tumours previously197, 211-216; including gastric cancer211, 212, colorectal cancer197, pancreatic 
cancer213, breast cancer215 and lung cancer216. It is difficult to draw direct comparison with these 
studies which included predominantly patients with advanced disease and duration of statin 
therapy was short. Of relevance, there was no evidence to suggest a clinically significant increase 
in toxicity with statin allocation. 
 
Strengths and limitations 
This study has a number of strengths. First, we were able to assess the “real world” feasibility of a 
future phase RCT study in the setting of a multi-centre trial, to provide valid estimates of 
feasibility parameters. Feasibility estimates from multiple sites are more likely to be applicable to 
a future multi-centre RCT than from a single centre alone. Second, this trial has established the 
prevalence of statin use in the target trial population, a notable risk to study feasibility. This data 
is informative for assessing trial feasibility and to enable planning of expected recruitment. Third, 
recruitment exceeded the minimum target (of 24 patients) with 32 patients in total. This has 
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enabled assessment of the feasibility outcomes with greater precision. This is important for 
planning a future trial, where precise estimates of recruitment can be used to plan the number 
and size of recruiting oesophago-gastric centres required.  Fourth, this trial has provided valuable 
information to devise strategy to improve retention in a future trial, particularly a strong impetus 
to manufacture smaller trial medication which can be easily swallowed and potentially crushed. 
Data from this feasibility study can be used to justify the cost of manufacturing a bespoke placebo 
(for a generic statin brand) to funding bodies, which would be expected to exceed the cost of 
over-encapsulation. Fifth, we were able to establish that trial procedures were acceptable at 
different sites to clinicians, research staff and patients. Sixth, we established effective central 
trial-specific procedures at NCTU which would be expected to form the basis of procedures for a 
definitive trial: a high-level risk assessment (to consider the trial risks and risk reduction strategies 
relating to the safety of trial participants; study design; and project management and 
governance); a safety management plan (detailing safety oversight in the trial, trial specific 
procedures to preserve the safety of participants and serious adverse event reporting 
procedures); and a quality management and monitoring plan (a bespoke approach to quality 
assurance and a detailed central monitoring plan). 
 
This study has a number of limitations. First, patient follow-up was limited for patients recruited 
after 1/11/15 due to truncated follow-up. Assessment of outcomes of interest beyond 6 months 
are therefore limited. This particularly applies to the endpoints of retention, overall survival, 
disease-free survival, measures of adherence and measurement of quality of life. While 
assessments of these to 12 months were possible, estimates were imprecise as a result. This will 
have contributed to the relatively few recurrences and deaths captured. Longer follow-up with 
more events could have enabled more informative estimates of overall survival and disease-free 
survival which could have been used to inform a sample size calculation for a future trial. Second, 
despite use of the smallest available simvastatin tablets and smallest possible gelatin capsules to 
preserve blinding, the trial medication were deemed relatively large (measuring 23.3 x 8.53mm). 
To aid comparison, the largest available gelatin capsules, size 000, measure 26.1 x 9.91mm. Of the 
patients who withdrew trial medication, difficulty swallowing the tablets was the most commonly 
cited reason. Although this trial estimated retention, this is unlikely to be applicable to a future 
trial where manufacture of an easily-swallowed bespoke placebo would be justified and viable. 
This makes estimates of retention less certain, and hence require further assumptions be made 
for a future trial. Third, this study estimated feasibility for up to one year’s follow-up only. 
Feasibility beyond this time point have not been established. This does not preclude planning a 
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future trial, but necessitates sound assumptions on longer-term adherence to trial-related 
procedures.   
 
An application for funding a phase 3 RCT has been made to the NIHR Efficacy and Mechanism 
Evaluation programme based on the results of the STAT-ROC feasibility study. 
 
Conclusions 
This multi-centre, double-blind, parallel group, randomised, placebo-controlled trial has 
demonstrated the feasibility of assessing adjuvant statin therapy in patients with operable OAC in 
future phase III trial. Estimated recruitment and retention rates, adherence to medication, drug 
absorption, adverse events, and patient completion of trial-related procedures support the 
conduct and inform the design considerations for a future trial.  
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4. Chapter 4 – Statins in the prevention of oesophageal adenocarcinoma: 
nested case-control analysis 
4.1. Abstract 
Background 
There are no current non-endoscopic evidence-based approaches to reduce the risk of malignant 
progression in patients with non-dysplastic Barrett’s oesophagus (BO), the only known precursor 
to oesophageal adenocarcinoma (OAC). Statins exert plausible anti-carcinogenic mechanisms and 
are attractive potential chemoprotective agents. There is uncertainty in current estimates for 
associations between statin use and malignant progression in BO populations. This study aimed to 
investigate whether statin use is inversely associated with either high-grade dysplasia (HGD) or 
OAC in a BO population.  
Methods 
Participants diagnosed with BO with follow-up from 1st January 2000 to 13th June 2013 were 
identified from two contributing centres of the UK National Barrett’s Oesophagus Registry 
(UKBOR). Patients with incident or prevalent OAC were matched with up two controls with non-
dysplastic BO and no evidence of progression, for gender, centre and date of birth. Duration of 
follow-up was matched within each case-control set. Data on relevant exposures were extracted 
from patient records. Statin use was measured between 6 months to 5 years prior to the date of 
diagnosis of each case and the equivalent index date in matched controls. 
Results 
In total, 79 cases with HGD/OAC were matched to 138 controls with non-dysplastic BO. Statin use 
was equally prevalent (17.7%) in cases and matched controls. Statin use was not significantly 
associated with malignant progression in either unadjusted (OR 1.13, 95% CI 0.53-2.41) or 
adjusted analyses (OR 0.69, 95% CI 0.23-2.02). Dose and duration response relationships, defined 
with categories of mean statin dose (p for trend=0.758), cumulative dose (p for trend=0.289) and 
cumulative duration (p for trend=0.216) were all non-significant. Prevalence of statin use and the 
number of included participants were lower than required to meet the assumptions of the sample 
size calculation. 
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Conclusions 
No significant associations were demonstrated between statin use and risk of malignant 
progression in a BO population registered with UKBOR. This study was underpowered and 
therefore at risk of type 2 error. 
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4.2. Introduction 
 
4.2.1. Background 
Barrett’s oesophagus (BO) is the only known premalignant lesion to oesophageal adenocarcinoma 
(OAC). This is the most common histological subtype of oesophageal malignancy in the west, an 
aggressive malignancy with a poor prognosis4, 5. Endoscopic surveillance is practiced to identify 
and treat dysplastic and early cancerous lesions, to improve long-terms outcomes of patients at 
risk of progression. There has been considerable interest in the potential for chemoprevention as 
a future strategy. The results of the AspECT trial (Study of Aspirin and Esomeprazole 
Chemoprevention in Barrett's Metaplasia) are eagerly awaited and could change practice in the 
future291. There is considerable interest in the potential for statins, currently used in the primary 
and secondary prevention of cardiovascular diseases, to reduce the risk of malignant progression 
in BO populations3.  
 
In vitro studies have demonstrated the effects of statins in validated OAC-cell lines, with resultant 
inhibition of proliferation and promotion of apoptosis, in a dose-dependent manner179-182. The 
functional relevance of inhibiting the mevalonate pathway, has been demonstrated as likely 
causal, mediated through depletion of downstream isoprenoid intermediates which permit 
propagation of growth-signalling pathways, which are of relevance to Barrett’s carcinogenesis179.  
 
Seven previous observational investigations have determined associations between statin use and 
risk of malignant progression in BO populations188, 221-226. Unfortunately, most studies were at 
substantial risk of bias, likely mediated by immortal-time bias222, 224, time-window bias (discussed 
below)188, 221, 222, and confounding222-224, 226. Furthermore, the definition of statin exposure in some 
studies inadequately considered temporal associations188, 221, 223-226. It is therefore difficult to draw 
strong conclusions from the existing epidemiological literature. 
 
4.2.2. Aims and Objectives 
The overarching aim of this study was to examine associations between statin use and risk of 
malignant progression to HGD/OAC in a nested case-control study conducted within two of the 
largest contributing centres to the United Kingdom Barrett’s Oesophagus Registry. Specific 
objectives were: 
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1. To determine associations between statin use and risk of HGD/OAC with adjustment for 
plausible confounders, in particular BMI and relevant common drug exposures (acid 
suppressive medications, NSAIDs, and aspirin). 
2. To determine whether dose and duration-response relationships exist. 
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4.3. Methods 
 
4.3.1. Study population and data source 
This study was conducted using the United Kingdom National Barrett’s Oesophagus Registry 
(UKBOR), the world’s largest BO registry292. This resource was established in 1996 as joint 
initiative of the Oesophageal Section of the British Society of Gastroenterology and the European 
Cancer Prevention Organisation. It is currently administered by the University Department of 
Surgery, Royal Free Hospital, London. The aims of the registry are to determine the descriptive 
epidemiology of BO and identify risk factors for malignant progression. In total 12, 500 patients 
with BO have been registered by gastroenterologists from 46 UK centres. Of these, a core dataset 
of approximately 3000 patients with detailed demographic, endoscopic and clinical data, has been 
constructed; and is suited to analytical epidemiology, including pharmacoepidemiology293. In this 
subset, routinely available medical data have been extracted from medical records, including 
endoscopic reports (including date of endoscopy and endoscopic findings), linked histology 
records, demographic information (age, gender, ethnicity) and other clinical covariates (smoking, 
alcohol history and co-morbidity). This study was conducted using patients identified from 
Rotherham General Hospital and Wexham Park NHS foundation trusts, research-active sites which 
contribute to this detailed subset. For cases and controls selected for this study further collection 
of pseudo-anonymous data from hospital records was required to capture detailed time-
dependent medication exposures and other covariates required. Data sources for medication 
exposures within medical notes were inpatient prescription charts, general practitioner referral 
letters (including copied repeat prescription scripts where available), any correspondence, or 
hand written inpatient or outpatient records. Ethical approval for existing consented UKBOR 
participants was provided by the registry’s existing ethics approval (The London Multi-centre 
research Ethics Committee, MREC/02/2/5). For additional cases not previously registered with 
UKBOR from Rotherham General Hospital (having not previously declined participation with 
UKBOR), separate study-specific approval was granted to extract pseudo-anonymous data from 
their medical records (Brent Research Ethics Committee, 16/LO/1741) (appendix I).   
 
4.3.2. Case-control definitions 
We used a nested case-control analysis of a cohort dataset to investigate the association between 
statin use and risk of HGD/OAC in patients with non-dysplastic BO. Men and women who 
developed HGD or OAC, diagnosed between 1st January 2000 and 13th June 2013 (cases), were 
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identified centrally from UKBOR. Pseudo-anonymous data were provided by Rotherham General 
Hospital for additional cases not previously registered with UKBOR. Both incident (HGD or OAC 
diagnosed greater than one year since diagnosis of non-dysplastic BO) and prevalent (HGD or OAC 
diagnosed within one year of BO or without a previous BO diagnosis) cases were included. 
Prevalent cases were included as the expected number of incident cases was expected to 
preclude sample size considerations. The date of diagnosis of HGD or OAC first recorded from 
correlation of endoscopic and histology reports was the index date. Patients low-grade dysplasia 
at baseline or follow-up were excluded. Each case was matched with up to two patients with non-
dyplastic BO (controls) according to gender, date of birth (+/- 2 years), and centre. The same index 
date for each case was assigned to each of the matched controls, who were required to have no 
evidence of malignant progression at this time (with non-dysplastic BO on histology following a 
subsequent surveillance endoscopy).  
 
Compared with a full cohort analysis, a nested case-control analysis is an efficient study design 
which permits time-consuming and expensive data extraction of covariate information to be 
limited to only the selected cases and controls294. The calculated odds ratios from a nested case-
control analysis should closely estimate unbiased rate ratios derived from a proportional hazards 
model of a full cohort with minimal or no loss of precision295, 296. Furthermore the matching 
procedure is a recognized method to account for the time-varying nature of drug exposures with 
fixed exposure definitions applied equally prior to the index date for both cases and controls for 
each risk set, therefore avoiding immortal time bias261. 
 
 
4.3.3. Statin prescription and categorisation 
“Ever use” of statins was defined as at least one entry of statin use made in the hospital notes 
between 6 months to 5 years prior to the index date. “Regular use” was defined as at least two 
records, separated in time by at least 30 days, in the same time window defined above. Mean 
daily dose and cumulative statin dose were calculated for individuals where dosage was recorded 
during this time window using the defined-daily dose (DDD) categories. Median DDDs determined 
the category thresholds for both mean and cumulative statin dose analyses. Cumulative statin 
durations during this time period were determined.  
4.3.4. Covariates 
Potential confounders were extracted for time periods preceding the index date, including: 
smoking status (ever or never smoked); body mass index (BMI) (kg/m2) recorded closest to 5 years 
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prior to the index date, and other medications (aspirin, non-aspirin NSAIDs, proton pump 
inhibitors [PPIs], histamine receptor antagonists [H2As] were extracted using the same definitions 
as for statin use (separately ever and regular use).  
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4.3.5. Statistical analysis 
Baseline characteristics, excluding matching demographics (age, gender and centre), were 
compared between cases and their matched controls. For controls, means and percentages were 
weighted by the inverse number of controls (with complete data for the variable of interest) 
matched to each case. This ensured proportions were comparable between sets. To ensure 
unbiased comparisons between prior exposures, follow-up was restricted to the shortest duration 
of the present case and matched control(s) for each set. Follow-up therefore varied between sets 
but was controlled for within sets. This approached was used as it was not possible to match for 
follow-up as part of the matching procedure, which in turn determined which medical notes were 
to be interrogated. While maintaining adherence to the restrictions defined above, all medication 
exposures were measured between 6 months to a maximum of 5 years prior to the date of 
diagnosis of the cases and the index date for controls. Equal follow-up between cases and 
controls (in this case within sets) is important to avoid “time-window bias”297. In the context of 
case-control studies this bias can arise if differential follow-up periods between cases and controls 
occur are not adequately accounted for. Differential follow-up would naturally be expected as 
follow-up is function of disease course, where progressors would be expected to have shorter 
prior follow-up than non-progressors. This bias has been responsible for producing spurious 
protective associations between statin use and lung cancer297, 298. 
 
Nested case-control analyses were performed using conditional logistic regression, to investigate 
the association between statin use and malignant progression according to each definition of 
statin use (ever, regular use, and according to mean dose, cumulative dose and cumulative 
duration of use). Participants not prescribed statins in the 6 months to 5 years preceding the 
index date were used as the reference group, to calculate odds ratios (ORs) with 95% confidence 
intervals (95% CI). Age, gender and calendar period were controlled for using the matching 
procedure. Analyses were adjusted for smoking, BMI, aspirin, NSAIDs, PPIs and H2As. A test for 
trend was applied across dose and duration categories.  All analyses were performed with STATA 
version 13 (StataCorp LP, College Station, Texas, USA). 
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4.4. Results 
Participants 
In total, 2, 543 patients were registered with UKBOR from two of the largest contributing centres: 
Rotherham General Hospital NHS foundation trust (n = 1, 396) and Wexham Park NHS Foundation 
Trust (1, 147) (figure 23). From this cohort, 967 were excluded (671 with BO had no endoscopic 
follow-up after 1/1/2000; 139 with HGD/OAC were diagnosed prior to this date; and 157 were 
excluded with LGD at baseline or follow-up). The nested cases-control study was drawn from 123 
patients with HGD/OAC and 1, 453 patients with non-dysplastic BO. It was not possible to match 
controls to 13 of the cases, and in total 1243 controls were not selected by the matching 
procedure. The medical records were unobtainable for particular cases and/or their matched 
controls leading to the exclusion of 103 participants: matched sets were retained provided 
medical notes were obtainable for at least one case and one matched control. The final study 
population included 79 cases and 138 controls. The 79 cases comprised 24 with HGD and 55 OAC. 
In total, 19 (24.1%) cases were incident (known diagnosis of BO at least one year prior to 
diagnosis). The majority of study participants were selected from Rotherham General Hospital 
NHS foundation trust (n=211, 76 cases and 135 controls), a more contemporaneous cohort; and 
the minority were from Wexham Park NHS Foundation Trust (n=6, 3 cases and 3 controls). 
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Figure 23: Flow chart of study participants 
Abbreviations: BO, Barrett’s oesophagus; HGD, high-grade dysplasia; LGD, low grade dysplasia; OAC, oesophageal 
adenocarcinoma. 
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Baseline characteristics 
Baseline characteristics of study participants are summarised in table 30. Median follow-up prior 
to the index date was 3.5 years (IQR 0.4-6) for cases and was 3.9 years (IQR 2-5.6) for the controls. 
Age and gender were controlled for using the matching procedure. The mean age of cases was 
67.9 years (SD 10.7) and 68 (86.1%) were male. In total, 66.2% of cases and 55.8% of controls 
were smokers (percentages and means weighted by the inverse number of controls per case). For 
BMI, 32.3% and 33.9% of cases and 26.7% and 35% of controls respectively were in the 
overweight (BMI ≥ 25 to < 30 kg/m2) or obese category (BMI ≥ 30 kg/m2). 38 (48.1%) cases were 
known to have a diagnosis of BO. The median (maximal) length of BO in cases with known BO was 
4.5cm (IQR 3-7), and in controls was 4cm (IQR 2.5-5). Intestinal metaplasia was observed in 39.2% 
of cases and 37.7% of controls. Statin use was observed in 25.3% of cases and 22.8% of controls. 
Aspirin use was observed in 21.8% of cases and 24.7% of controls. NSAID use was observed in 
5.1% of cases and 13.3% of controls. H2A use was observed in 7.6% of cases and 6.3% of controls. 
PPI use was observed in 39.2% of cases and 67.1% of controls. Crude unadjusted odd ratios for 
risk of HGD/OAC, calculated prior to restricting follow-up within sets, demonstrated no significant 
associations for smoking status (OR 1.57, 95% CI 0.85-2.88, p=0.148), BMI (OR 0.65, 95% CI 0.30-
1.43, p=0.286 for BMI ≥ 25 to < 30 kg/m2; OR 1.00, 95% CI 0.45-2.24, p=0.994 for BMI ≥ 30 kg/m2), 
intestinal metaplasia (OR 1.18, 95% CI 0.66-2.11, p=0.587), statin use (OR 1.28, 95% CI 0.66-2.48, 
p=0.462); aspirin use (OR 0.89, 95% CI 0.45-1.75, p=0.734) or H2A use (1.21, 95% CI 0.43-3.43, 
p=0.718). Known associations with HGD/OAC were demonstrated in unadjusted analyses for 
length of the Barrett’s segment (OR 1.22, 95% CI 1.02-1.47, p=0.031, per 1cm increase), NSAID use 
(OR 0.27, 95% CI 0.08-0.99, p=0.049) and PPI use (OR 0.32, 95% CI 0.17-0.60, p<0.001). 
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Characteristics 
Cases 
(n=79) 
Controls 
(n=138) 
Crude odds ratio 
(95% CI) 
Median (IQR) duration of follow-up 
(years) 3.5 (0.4-6.0) 3.9 (2.0-5.6) - 
Age (years) mean (SD)1 67.9 (10.7) 67.9 (10.3) - 
Male sex, n (%)1 68 (86.1) 119 (86.1) - 
Smoking status       
Never 25 (33.8) 57 (44.2) 1.00 (reference) 
Ever 49 (66.2) 73 (55.8) 1.57 (0.85-2.88) 
Unknown2 5 (6.3) 8 (5.8) 1.35 (0.32-5.77) 
Body mass index (kg/m2)       
< 25 21 (33.9) 34 (26.7) 1.00 (reference) 
≥ 25 to < 30 20 (32.3) 53 (43.3) 0.65 (0.30-1.43) 
≥ 30 21 (33.9) 35 (30.0) 1.00 (0.45-2.24) 
Unknown2 17 (21.5) 16 (11.6) 2.03 (0.80-5.14) 
Known Barrett's, n (%) 38 (48.1) 138 (100) - 
Median (IQR) length of Barrett's (cm) 4.5 (3-7) 4 (2.5-5) 1.22 (1.02-1.47)3 
Intestinal metaplasia, n (%) 31 (39.2) 52 (37.7) 1.18 (0.66-2.11) 
Statin use, n (%) 20 (25.3) 30 (22.8) 1.28 (0.66-2.48) 
Aspirin use, n (%) 17 (21.5) 32 (24.7) 0.89 (0.45-1.75) 
NSAID use, n (%) 4 (5.1) 18 (13.3) 0.27 (0.08-0.99) 
PPI use, n (%) 31 (39.2) 92 (67.1) 0.32 (0.17-0.60) 
H2A use, n (%) 6 (7.6) 9 (6.3) 1.21 (0.43-3.43) 
Table 28: Baseline characteristics of HGD/OAC cases and matched controls 
Abbreviations: H2A, histamine receptor blocker; IQR, interquartile range; NSAID, non-steroidal anti-inflammatory drugs; 
PPI, proton pump inhibitor.    
1Matching variables (along with centre).     
For controls, means and percentages were weighted by the inverse number of controls (with complete data for the 
variable of interest) matched to each case.       
2Percentages presented for unknown categories reflect overall proportion of missing data for the relevant covariate; 
while percentages presented for known categories refer to complete data only. 
3per cm.    
Medication use defined as any use between 6 months - 5 years prior to index date. 
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Statin use and risk of high-grade dysplasia/adenocarcinoma 
The association between statin use and HGD/OAC is shown in table 31. Statin use measured 
between 6 months to 5 years prior to diagnosis or (index for the matched cases) was observed in 
17.7% of cases and 17.7% (percentage weighted by the inverse number of controls per case) of 
controls. These proportions are discrepant to those presented in table 30 and is a product of the 
restricted follow-up windows within sets. Any documented exposure to statins (ever use) was not 
significantly associated with HGD/OAC in either unadjusted (OR 1.13, 95% CI 0.53-2.41, p=0.747) 
or adjusted (0.69, 95% CI 0.23-2.02, p=0.492) analyses. Regular statin use (defined as a record of 
at least two records of statin use between 6 months to 5 years prior to date of diagnosis or index) 
was not significantly associated with HGD/OAC in either unadjusted (OR 1.11, 95% CI 0.42-
2.75,p=0.816) or adjusted (OR 0.68, 95% CI 0.17-2.65, p=0.576) analyses. 
 
Table 29: Statin use and risk of high-grade dysplasia/oesophageal adenocarcinoma 
Follow-up prior to index date matched within sets 
For controls percentages were weighted by the inverse number of controls matched to each case. 
1Adjusted for body mass index, smoking status, use of aspirin, NSAIDs, proton pump inhibitors and histamine receptor 
antagonists 
2At least two records documented at least 30 days apart 
 
 
 
 
No statin use 65 (82.3) 116 (82.3) 1.00 (reference) 1.00 (reference)
Ever use between 0.5-5 years 14 (17.7) 22 (17.7) 1.13 (0.53-2.41) 0.69 (0.23-2.02)
Regular use between 0.5-5 years2 10 (13.3) 14 (12.0) 1.11 (0.45-2.75) 0.68 (0.17-2.65)
No (%) of 
cases 
(n=79)
No (%) of 
controls 
(n=138)
Unadjusted odds 
ratio (95% CI)
Adjusted odds ratio 
(95% CI)1Statin exposure prior to index
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Dose and duration-response analyses 
No significant associations were observed for dose-response analyses (see table 32) in which 
categories of statin use were defined according to the mean DDD documented between 6 months 
to 5 years prior diagnosis of the cases or index date of the controls (adjusted analyses, for mean 
DDD < 0.82: OR 0.36, 95% CI 0.08-1.62; for DDD ≥ 0.82: OR 1.05, 95% CI 0.24-4.53; P for 
trend=0.758).  ORs decreased with increasing cumulative dose categories of statins use, however 
were individually non-significant (adjusted analyses, for cumulative DDD < 749: OR 0.85, 95% CI 
0.20-3.65; for DDD ≥ 749: OR 0.38, 95% CI 0.07-2.07) and there was no significant trend across 
categories (P for trend=0.289). Similarly, ORs decreased with increasing duration of statin use, 
though were individually non-significant (adjusted analyses, for durations < 3 years: OR 1.38, 95% 
CI 0.36-5.29; for durations ≥ 3 years: OR 0.23, 95% CI 0.05-1.38) and there was no significant trend 
across categories (P=0.216). 
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No statin use 65 (82.3) 116 (82.3) 1.00 (reference) 1.00 (reference)
Mean daily dose of statin
< 0.82 DDD2 5 (7.1) 11 (12.1) 0.74 (0.25-2.19) 0.36 (0.08-1.62)
≥ 0.82 DDD2 8 (10.3) 8 (5.5) 1.83 (0.63-5.29) 1.05 (0.24-4.53)
P for trend 0.494 0.758
Cumulative dose of statin
< 749 DDD3 7 (9.0) 9 (10.4) 1.21 (0.43-3.43) 0.85 (0.20-3.65)
≥ 749 DDD3 6 (7.7) 10 (7.0) 1.07 (0.34-3.37) 0.38 (0.07-2.07)
P for trend 0.791 0.289
Cumulative duration
< 3 years 9 (11.4) 11 (10.1) 1.53 (0.56-4.17) 1.38 (0.36-5.29)
≥ 3 years 5 (6.3) 11 (9.3) 0.80 (0.27-2.41) 0.26 (0.05-1.38)
P for trend 1.000 0.216
Statin exposure prior to index
No (%) of 
cases (n=79)
No (%) of 
controls (n=138)
Unadjusted odds 
ratio (95% CI)
Adjusted odds 
ratio (95% CI)1
Table 30: Mean dose, cumulative dose and cumulative duration of statin use and risk of high-grade 
dysplasia/oesophageal adenocarcinoma 
Abbreviations: DDD, defined daily dose. 
Follow-up prior to index date matched within sets 
For controls percentages were weighted by the inverse number of controls matched to each case. 
Missing dosage data affected one case and three controls.  Percentages presented for known dosage categories refer to 
complete data only. 
Cumulative dose and duration excludes the 6 month period preceding the index date 
1Adjusted for body mass index, smoking status, use of aspirin, NSAIDs, proton pump inhibitors and histamine receptor 
antagonists 
20.82 DDD cut off selected as the median daily dosage value in whole cohort. 0.82 DDD is equivalent to 25mg 
simvastatin or 16mg of atorvastatin (these do not correlate with dispensed doses).   
3749 DDD cut off selected as the median cumulative dosage value in whole cohort. 749 DDD is equivalent to 22, 470mg 
simvastatin or 14, 980mg of atorvastatin 
 
 
Table 31: Mean dose, cumulative dose and cumulative duration of statin use and risk of high-grade 
dysplasia/oesophageal adenocarcinoma 
Abbreviations: DDD, defined daily dose. 
Follow-up prior to index date matched within sets 
For controls percentages were weighted by the inverse number of controls matched to each case. 
Missing dosage data affected one case and three controls.  Percentages presented for known dosage categories refer to 
complete data only. 
Cumulative dose and duration excludes the 6 month period preceding the index date 
1Adjusted for body mass index, smoking status, use of aspirin, NSAIDs, proton pump inhibitors and histamine receptor 
antagonists 
20.82 DDD cut off selected as the median daily dosage value in whole cohort. 0.82 DDD is equivalent to 25mg 
simvastatin or 16mg of atorvastatin (these do not correlate with dispensed doses).   
 
 
 
Statins and oesophageal adenocarcinoma 
181 
4.5. Discussion 
This nested-case control analysis, using data from two contributing centres of the UK National 
Barrett’s Oesophagus Registry, demonstrated non-significant inverse associations between statin 
use and risk of malignant progression to HGD/OAC in patients with non-dysplastic Barrett’s. Effect 
sizes, and their precision, were not materially altered when the exposure definition considered 
associations for regular use instead. There was no significant evidence to support dose-response 
relationships (with exposures categorised according to mean statin dose, or cumulative dose) or 
duration-response relationships.  
Comparison with previous epidemiological studies 
There are seven previously published epidemiological investigations which examine associations 
between statin use and risk of HGD and/or OAC in populations with BO188, 221-226, each with 
distinctive population and design characteristics. In total, four used population-based healthcare 
datasets188, 222, 225, 226, and three were hospital-based221, 223, 224. The present study is hospital-based, 
both in terms of ascertainment of case/control status and exposure variables. In six studies, cases 
were known to have a prior diagnosis of BO188, 222-226, while in one, 94% of cases presented de 
novo (prevalent cases)221. This is a key feature which distinguishes our study from previous work 
(discussed below). Of the previous hospital-based studies, two were conducted at a single 
centre221, 223. For the outcome of interest, two studies considered HGD/OAC224, 226, three 
considered OAC188, 221, 223 and two considered a composite diagnosis of OC (with no distinction 
according to histological subtype)222, 225. Choice of outcome is very likely a function of 
ascertainment from available data sources. Our study used HGD/OAC as a composite outcome 
given the availability of histology data. Five considered both relevant patient characteristics (such 
as gender and age) and potential drug exposures as relevant confounders in either the matching 
procedure or in adjusted analyses188, 221, 223-225, while two did not (both population-based 
cohorts)222, 226, and would expected to be at greater risk of confounding. Five adjusted for BMI188, 
221-223, 225, and two did not223, 226. Our study adjusted for body mass index, smoking status, use of 
aspirin, NSAIDs, proton pump inhibitors and histamine receptor antagonists. One study adjusted 
for number of gastroscopies prior to index, to account for confounding by healthy user status (and 
in doing so significant inverse associations persisted)188. Our study did not make the same 
adjustment as only 19 cases (24.1%) had been diagnosed with BO more than one year previously. 
Two studies were at risk of immortal-time bias222, 224, which was subsequently adequately 
addressed in one230, while five adequately addressed time-dependent exposures through analysis 
or study design188, 221, 223, 225, 226. Six studies considered in the exposure definition of statin use up 
until the point of diagnosis of the case or index date of the control (for case-control studies)188, 221, 
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223-226, while one excluded measurement during the year preceding cancer diagnosis (however did 
not apply the same to controls)222. Unlike our study, three studies were at risk of time-window 
bias188, 221, 222. The prevalence of statin use varied between studies: in case-control studies, 
between 26-40% in cases and 25.5-54% in controls188, 221, 222, 226; and in cohorts overall between 
13.6-36.7% 223-225. In our study, the prevalence was 17.7% in cases and controls. 
 
In the context of BO literature in which estimates of exposure and their associations with 
malignant progression are made, it is reasonable to draw direct comparisons between studies 
which use different measures of effect size (ORs, RR, HRs): incidence rates of progression in non-
dysplastic BO populations are low36, and therefore estimates can be seen to approximate one 
another. Absolute effect sizes from studies which reported significant associations were 
consistent with one another: OR 0.65 (95% CI 0.49-0.91)188; 0.57 (95% CI 0.28-0.94)221; HR 0.61 
(95% CI 0.45-0.83)225; as were those from studies which did not reach statistical significance: HR 
0.55 (95% CI 0.23-1.29)224; HR 0.68 (95% CI 0.30-1.54)223; HR 0.82 (95% CI 0.43-4.56)222; OR 0.5 
(95% CI 0.1-1.7)226. The absolute adjusted effect size from our study for the primary is consistent 
with these previous studies analysis (OR 0.69, 95% CI 0.23-2.02), and there is a considerable area 
of overlap of the confidence intervals with all estimates from previous studies. There is, however, 
considerable uncertainty in our estimates: the 95% confidence interval spans one, and is 
potentially consistent with up to a 77% reduction and 202% increase in odds of HGD/OAC. 
Therefore the results from our study do not conclusively establish either a harmful, absent or 
protective association.  
 
Plausible explanations for some studies demonstrating significant and while others demonstrated 
non-significant inverse associations are potentially explained by differences in study design, 
sample size, prevalence of statin use in the studied population, periods of study conduct (earlier 
periods are associated with lower prevalence of statin use), ascertainment and definition of statin 
exposure, and choice of covariates adjusted for. To date there have been no RCTs in populations 
of BO to examine whether statin use affects subsequent risk of malignant progression.  
 
Biological mechanisms 
Previous preclinical studies have demonstrated the effects of statin treatment on validated OAC 
cell lines, including inhibiting proliferation, promoting apoptosis and limiting invasiveness in a 
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dose-dependent manner179-182. Inhibition of the mevalonate cascade and subsequent depletion of 
its downstream products, have been shown to be of functional relevance to these observations179. 
Depletion of intermediates, particularly farsenyl pyrophosphate, an isoprenoid responsible for 
farnesylation (lipidation) and hence membrane tethering of the RAS superfamily of GTPases, 
reduces activity of downstream growth signalling cascades, extracellular signal regulated kinase 
(ERK) and protein kinase B (Akt) pathways, which have been shown to be active in BO and OAC179, 
299. Statins also exhibit pro-apoptotic effects in non-malignant BO cells183. Mutant p53 defines the 
boundary between non-dysplastic BO and HGD, and is the most commonly recurrently mutated 
gene in OAC77; in other settings has demonstrated gain-of-function properties to upregulate 
transcription of mevalonate pathway enzymes to sustain malignant proliferation77, a viable target 
which can readily be inhibited by statins. However, whether these observations translate into 
clinically relevant chemopreventive actions in BO populations is not clear. While it is difficult to 
draw direct comparison from experimental data in predominantly malignant cell lines to 
premalignant contexts; and although the results of our study are inconclusive, the weight of 
previous observational evidence (its inherent limitations notwithstanding) does suggests inverse 
associations between statin use and risk of progression, which would be consistent with the 
emerging preclinical data. 
 
Strengths and limitations 
This study has a number of strengths. Patient demographic and clinical characteristics were 
consistent with other BO populations, and unadjusted associations between length of BO 
segment, NSAID and PPI use, would suggest the disease is clinically representative225, 300, 301. Unlike 
previous observational work222, 224, 226, we were able to adjust for BMI and other medication 
exposures which could plausibly confound associations. The nested case-control dataset was 
constructed from the cohort-study dataset by sampling controls at random from the risk sets who 
were being followed-up and had not progressed by the date of diagnosis of the case. Therefore, 
calculated odds ratios were precisely controlled for calendar time. This is important as calendar 
time could otherwise plausibly confound associations: statin use has become increasingly 
prevalent in the UK population during the study period (simvastatin prescriptions increased 300%, 
from 12.7 to 37.8 million annual prescriptions from 2004 to 2014302) and patients with non-
progressing BO would be expected to live longer than progressors, and hence more likely survive 
to time periods with increasing prevalence of statin use. Extraction of medication exposure data 
from medical records, as opposed to interviewing participants, prevented recall bias and enabled 
exposures to be captured during a defined time window, enabling their time-dependent nature to 
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be accounted for. While it was not possible to blind investigators conducting extraction from 
notes, algorithms for dataset construction uniformly defined drug exposure status measured prior 
to the index date, independent to participant case/control status. To ensure maximum follow-up 
data, ideally duration of follow-up should have been controlled for by the matching procedure. 
However, the duration of follow-up of each participant prior to matching was not known (it was 
not feasible to establish). Nevertheless, this study controlled for follow-up by ensuring exposure 
windows were matched exactly within sets. This was likely at the expense of measurement error: 
documented exposures captured prior to restricting exposure windows were ignored. It is 
therefore likely that some statin users (recorded more than five years prior to diagnosis for the 
cases or index date for the controls) were considered non users. Such measurement error would 
be expected to non-differential and apply equally to both cases and controls. The consequence of 
not measuring prior exposures equally could have resulted in time-window bias, and in other 
aetiological studies has been shown to produce “illusory” protective effects between statin use 
and other malignancies297. Importantly, aspirin use was adjusted for as it is likely to be an 
important confounder: aspirin users are more likely to be statin users (given the shared treatment 
indications of these medications), and aspirin use is independently associated with a reduced risk 
of malignant progression in patients with BO303. Inhibition of cyclo-oxygenase-2 enzyme is 
proposed as the predominant mechanism through which aspirin exerts its chemopreventive 
effects in this population304. This mechanism is largely distinct (and hence independent) to that 
exerted by statins from the existing experimental evidence summarized above. While, there is 
some evidence in OAC cell lines that statins inhibit COX-2 expression182, the functional relevance 
of this observation has not been assessed. The effects of combined statin and COX-2 inhibition 
(with a selective COX-2 inhibitor) are additive, in OAC cell lines, which again underscores an 
independent mechanisms of action179.  
This study has a number of limitations. The main limitation is the final sample is likely 
underpowered to optimally examine associations. Assumptions from the power calculation were 
not met, both in terms of the included numbers (actual: 79 cases and 138 controls, required: 200 
cases and 400 controls), but also in terms of the prevalence of statin use (actual 17.7% in both 
cases and controls, required: 20% in cases and 35% in the controls). Despite original counts of 262 
patients with HGD/OAC and 2281 registered with UKBOR from the included centres, after 
excluding all cases diagnosed prior to 1/1/2000 (n=139) and not being able to obtain medical 
records for selected cases/controls and/or their matched counterparts, it was not possible to 
meet the study’s sample size requirements. Data from the remaining 44 NHS sites which have 
previously collaborated with UKBOR, were largely historical and did not cover the time period 
required by the study.  
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It is unclear whether use of prevalent OAC cases could violate a key premise of the case-control 
study design: it is assumed, but not known, whether controls are truly randomly selected from the 
same well-defined at-risk base population as all cases. While we are confident that incident cases 
of OAC (diagnosed at least 1 year after diagnosis of BO) are drawn from the same baseline 
population, it is assumed, but not known whether the same applies to prevalent cases (either 
diagnosed within 1 year of diagnosis of Barrett’s oesophagus or without prior history of Barrett’s 
oesophagus). While it is widely accepted that OAC arises from BO (either previously diagnosed or 
undiagnosed), it is obviously not possible to corroborate that OAC our prevalent cases were truly 
preceded by undiagnosed BO. While our approach of using both incident and prevalent OAC cases 
is well-established and consistent with prominent published case-control studies in the 
aetiological BO literature221, 305, 306, emerging evidence indicates caution should be applied in the 
interpretation of such studies307. A recent case-case comparison study using the Surveillance, 
Epidemiology and End Results (SEER) Medicare database demonstrated large and significant 
differences for patients with OAC known and not known to have prior BO. Patients with known 
prior BO compared to patients without were older, attained higher educational level, higher 
burden of co-morbidity, more physician visits in the two years prior to diagnosis, favourable 
cancer staging, lower cancer grade, smaller tumour size, more likely to undergo surgery, and 
longer survival. Regardless of whether these observations are due to differences in underlying 
biology or selection bias, this raises the possibility of the premise of the case-control study 
detailed above as potentially being violated, and therefore risking selection bias. However, it is 
not clear whether this would affect associations between exposure and outcome.  
The use of routinely collected data on medication exposures from hospital notes presents several 
potential limitations. Unlike automated records for filled prescriptions electronically captured in 
large primary care datasets, such the Clinical Practice Research Datalink, this study relied upon 
the use of routinely collected medication data documented in medical notes. Therefore entries in 
the notes typically require a hospital visit and for the health professional to document the full list 
of patient medications. It is therefore almost certain that capture of medication use over time in 
medical notes is an incomplete record of all dispensed and over-the-counter medications and will 
be a function of the setting of interaction (out-patient or emergency attendance) and will be 
expected to be dependent on the specialty. The extent of medication history documentation is 
likely to be context specific: for example, at a cardiology clinic appointment or full medical 
admission the physician would be expected to detail a more thorough medication history than for 
example an ophthalmology appointment or accident and emergency attendance where generally 
such information may be of lesser importance. Information bias may be introduced where the 
frequency and/or level of detail in record keeping for medication histories is differential between 
cases and controls307. This may be expected for patients with prevalent OAC who may be more 
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likely to seek less frequent medical attention, compared with patients with BO undergoing regular 
endoscopic surveillance (with or without outpatient follow-up) and frequent interaction with 
healthcare professionals307. 
It is likely that data for BMI is missing not at random (MNAR): completeness of BMI is plausibly 
dependent on the absolute value, with extreme values (either low or high) assumed to be more 
likely to be captured than values within the normal range308. It is therefore possible that complete 
case analysis (as used in this study) may bias associations. Sensitivity analyses represent a 
pragmatic method of assessing the impact of such bias, if it exists. However, given associations for 
statin use were non-significant, and participant numbers are small, sensitivity analyses were 
expected to be uninformative and were therefore not conducted. 
 
Conclusions 
This nested case-control study, conducted using data from hospital records from two of the 
largest contributing centres to the United Kingdom Barrett’s Oesophagus Registry, demonstrated 
non-significant inverse associations between statin use and malignant progression. No significant 
cumulative dose or duration-response relationships were demonstrated. The results were 
inconclusive and could not establish beneficial, null or harmful effects with certainty. Further 
large, well-conducted observational studies are required which adequately consider exposure 
windows, latency, immortal person-time and adjust for plausible candidate confounders. 
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5. Chapter 5 - Overall discussion 
Statins as chemopreventive agents in Barrett’s oesophagus 
Current approaches to reducing the burden of HGD/OAC in patients with known BO are primarily 
endoscopic. The purpose of endoscopic surveillance is to identify dysplastic or overtly malignant 
lesions at an early stage suitable for curative intervention (ideally endoscopic rather than 
surgical). A key challenge is the low absolute rate of malignant progression36, 309, therefore 
exposing the majority of patients with BO (of whom individually will unlikely benefit) to an 
invasive procedure, which in itself is not free of risk27. Results from the Barrett’s Oesophagus 
Surveillance Study (BOSS) are awaited with anticipation to establish the efficacy and cost-
effectiveness of surveillance versus an “at need only” approach36. Considerable global efforts 
underway are focussing on identifying those with BO at highest risk of progression to inform 
optimum surveillance strategies291, 310. There are, however, no current trial data to inform non-
endoscopic strategies to reduce malignant progression in BO populations. Such approaches would 
be welcome as they could be administered at a wider level in primary care. Results of the AspECT 
trial (Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia) could have 
substantial implications for future prevention strategy291. A role for statins as a novel future 
chemopreventive strategy would be welcome; if empirically demonstrated in the setting of a trial, 
these agents are inexpensive and easily administered and have been demonstrated as safe and 
well-tolerated at a population level148-151. 
 
There is a growing and prominent perception that statins are causally protective against the 
development of OAC3. While the sum of available epidemiological evidence would suggest 
significant inverse associations between statin use and malignant progression in BO populations 
in meta-analyses311, 312; a wider appreciation of the strengths and limitations of the current 
observational literature is warranted. Such significant inverse associations, if causal, would have 
important implications, and as such, alternative explanations deserve consideration. While the 
available results are encouraging, most published studies suffer such significant methodological 
limitations, such as immortal-time bias222, 224, time-window bias188, 221, 222, with little consideration 
of temporality, let alone latency188, 221, 223-226, and confounding222, 226; that drawing dichotomous 
conclusions are difficult. To summarise understanding of the current observational literature 
(including the present study), the evidence base is best considered inconclusive. Furthermore, 
because of these inherent limitations, a more contemporaneous meta-estimate of all currently 
available studies in their current form, would not be expected to further this position.  
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On the background of this uncertainty, future epidemiological investigation would be 
recommended. An attractive research strategy would be in an individual patient data (IPD) meta-
analysis. Such an approach would yield particular advantages over a traditional meta-analysis: 
cohorts may have been followed up for longer periods of time since original publications (to 
therefore better capture long term outcomes which are of particular relevance to BO 
populations); results of unpublished studies can be included (reducing publication bias); model 
assumptions for complex time-dependent associations can be checked across populations; and 
meta-analysis of subgroups effects can be assessed across individuals313. This would need to be an 
international collaboration to combine datasets of individual participants from a number of BO 
populations. A strict, pre-specified assessment of the suitability of included populations would be 
required in advance, together with strict inclusion and exclusion criteria for individual participants 
included. Particular essential criteria would be a standardised agreement for the definition of 
ascertainment of the BO population; exposures and outcomes. A critical issue will be the quality 
of available prescription information. Electronic prescription data, such as those used in 
population-based datasets would be the most desirable: they are suited to capturing particularly 
longer term prescriptions dispensed in primary care, for statins and other medications which may 
confound associations. Although information on adherence is usually not available, the benefits of 
accurately capturing the timing and posology of dispensed routine medication would represent a 
substantial advantage. Capture of routine over-the-counter medications is a consideration, 
although potentially of lesser significance, where cumulative dosage and duration of prescription 
medication would likely have primary influence. Datasets would need to be relatively 
contemporaneous, during periods where prevalent statin use is sufficient to estimate significant 
associations where they exist. In addition to an approved protocol, a detailed pre-specified data 
management and statistical analysis plan would be required, with the aim of introducing by 
design and analysis, standard processes of data extraction to ensure comparability of studies, and 
valid means of addressing relevant time-related biases, consideration of temporality and latency, 
and confounding.  
 
Should the results of such research suggest persistent significant (statistically and clinically) 
inverse associations, with evidence of dose-response relationships, clinical practice would not 
necessarily change. As with all observational research, the effects of bias (particularly 
unmeasured confounding and selection bias) cannot be excluded. Such research may, however, 
more reliably inform the decision to conduct a trial of the efficacy of statins as a chemopreventive 
agents in patient with non-dysplastic BO. A tentative and well justified approach to this decision is 
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necessary given the substantial considerations required for the design and conduct of such a trial. 
Assuming an absolute cumulative risk of HGD/OAC (as a composite outcome) of 2% at 10 years28, 
314 in the unexposed group, with 1:1 allocation of a statin and placebo, 10% drop-out rate 
(including withdrawals and contamination of the exposure), a HR of 0.60225, 312 for the effect of 
allocation to statins on progression, with alpha set at 5% (two-sided) and power set at 80%, the 
required estimated sample size for such a trial would be 8, 838. While, this is not outside the 
realms of possibility, it would be a considerable undertaking, require international collaboration 
and be dependent on prioritisation for funding. Further challenges to such a trials’ conduct would 
be the high prevalence of statin use in at-risk populations (potentially excluding approximately 
half of eligible patients immediately) and the long durations required to observe the events 
needed to meet assumptions of the sample size calculation. Further threats to the interpretation 
of such a trial would be use of current endoscopic techniques (particularly radiofrequency 
ablation for LGD) which alter the natural history of the disease and would lower event rates 
further41. Should high dose esomeprazole and/or aspirin be regarded as a new standard of non-
endoscopic management in the future (if demonstrated efficacious), further reductions in event 
rates would be expected and sample size considerations would need to adequately reflect this. A 
body of well-conducted observational research, such as an IPD meta-analysis could provide 
further detail which would be of considerable importance for the design of such a trial: a more 
reliable estimate of effect size could better inform the sample size considerations of a future trial; 
and a contemporaneous estimate of the cumulative risk of progression over time among non-
statin users. Should high-dose statin use be associated with further increments in effect size, with 
consequent reductions in sample size, the feasibility of a future trial would be further supported. 
For example, holding all other assumptions constant, with an effect size of 0.31 for high dose 
statin use221, the required sample size would be 2400. Empirical RCT evidence that statins exert 
causative chemopreventive effects to prevent the malignant progression would have profound 
implications for reducing disease burden in populations with BO.  
 
Statins as adjuvant and maintenance therapy in patients with operable 
oesophageal adenocarcinoma 
 
OAC is an aggressive malignancy with a dismal prognosis overall5. Even patients selected for 
treatment with curative intent for invasive disease, at best 5 year survival is 45%, with mortality 
largely attributable to recurrent disease113, 114. Aside from current primary surgical and oncological 
treatment modalities there are no other evidence-based interventions to reduce the risk of 
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recurrence and improve related-prognosis. For particular solid organ tumours, longer-term 
maintenance modalities are advocated to reduce the risk of recurrent disease and death; for 
example, androgen deprivation therapy is recommended for 2-3 years in men with prostate 
cancer at high risk of prostate-cancer mortality receiving neoadjuvant hormonal therapy and 
radical radiotherapy315; and aromatase inhibitors (or tamoxifen if these are contra-indicated) are 
recommended for the adjuvant treatment of early oestrogen receptor-positive invasive breast 
cancer in postmenopausal women for 2-3 years316. Given risk of death from recurrent disease is 
substantial in patients with OAC selected for treatment with curative intent, consideration is 
required for novel, safe and tolerable adjuvant therapies, of which statins are a potentially logical 
candidate. 
 
Existing in vitro evidence demonstrates the anti-proliferative, pro-apoptotic, and anti-metastatic 
effects of statins in validated OAC cell lines179-182. These studies establish a role for mevalonate 
pathway products in mediating and propagating the activity of relevant downstream signalling 
cascades, which are potently and dose-dependently inhibited by statins. However, it is not clear 
whether these effects would be manifest and hence relevant in patients with OAC. A significant, 
clinically evident cytotoxic effect of statins (to the same degree as current chemotherapeutic 
regimens in OAC) in patients, lacks face validity and would seem highly improbable. However, a 
predominant cytostatic role may seem more plausible. Statin use measured prior to diagnosis of 
OC in large population-based cohorts have demonstrated significant reductions in risk of cancer-
related mortality189. Furthermore, we have for the first time demonstrated significant reductions 
in cancer-specific and all-cause mortality with post-diagnostic statin use in patients with OC and 
OAC specifically207. In both studies, censoring for deaths due to other causes appropriately 
accounted for competing risk of death244, of particular relevance given the established efficacy of 
statins in reducing cardiovascular-related mortality148-151. Although we demonstrate evidence to 
suggest reverse causation bias and confounding by staging is unlikely a prominent explanation for 
these associations, we are unable to completely exclude this. As with all observational research, 
the role of unknown confounders cannot be discounted.  
 
Although there are biologically plausible and highly supportive experimental and epidemiological 
evidence to suggest a potential role for statins in the treatment of OAC, there exists clinical 
equipoise: an RCT is required to definitively determine whether statins are efficacious adjuvant 
agents in this setting, and therefore whether they should be used for this indication in clinical 
practice. We hypothesise that if statins are a viable treatment strategy, they would be most likely 
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to be shown to be effective in a patient cohort treated with curative intent to prevent recurrence, 
a group with minimal disease burden (following surgery +/- chemotherapy), in contrast to cohorts 
with advanced metastatic disease at diagnosis. We have estimated “real world”, feasibility 
parameters in the setting of a multi-centre feasibility RCT across four UK NHS sites. In doing so we 
have demonstrated the feasibility of assessing statin therapy in patients with invasive OAC 
selected for oesophagectomy in a future phase III RCT. We know that clinicians support the trial 
and their patients are willing to be recruited. Estimates of recruitment and retention are 
favourable. Adherence to trial medication improves after the first three months of treatment. 
Simvastatin allocation was sufficient to cause significant reductions in LDL cholesterol comparable 
to estimates in patients with cardiovascular disease285, confirming drug absorption and a 
pharmacodynamic effect. There was no evidence to suggest an unfavourable adverse event 
profile in this patient population. Feasibility of trial-related procedures, such as patient-
completion of quality of life questionnaires was demonstrated. These estimates, together with 
the effect size derived from observational data have informed the design of a potential future 
trial. 
 
A future trial would require essentially the same eligibility criteria as the feasibility work to ensure 
feasibility estimates remain valid. Survival estimates for all-cause mortality for patients with OAC 
(including Siewert I and II lesions) at three (46%)317 and five years (45%)118 are similar in large UK 
patient cohorts following oesophagectomy, a finding also reflected in relevant clinical trials, 
where absolute differences are small between these time points113, 318. This would suggest most 
recurrences occur within the first three years, with few occurring between years three to five, as 
demonstrated in observational cohorts288. For this reason, we propose a treatment duration of 
three years, during the period of highest risk of recurrence. This has practical advantages, as it 
would help ensure more efficient delivery of the trial overall, it would restrict the burden of trial 
involvement for participants to the minimum duration possible and would likely be more 
acceptable to clinical investigators who may not necessarily follow-up their cohort for longer 
periods. To ensure the greatest chance of demonstrating a significant difference between groups 
and a successful trial outcome, it follows the most potent statin at the highest tolerated dose be 
used for the intervention. Simvastatin 40mg was originally selected as the intervention for the 
feasibility study as it is the most widely used statin for which the adverse event profile has been 
best characterised285. However, doses as high as 80mg are associated with higher risk of 
myopathy (0.9%)319, precluding their routine use at this dose. Atorvastatin 80mg may be a more 
logical candidate statin to select as the intervention for a future trial: it potently inhibits of the 
mevalonate pathway without the risk of myopathy151, has a higher bioavailability (12% vs 5% for 
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simvastatin) and longer half-life (15-30 hours vs 2-3 hours for simvastatin)170. The feasibility 
estimates derived from the STAT-ROC feasibility study would be expected to remain valid even if 
an alternative statin was selected. The primary outcome would be overall survival by three years, 
with secondary outcomes including disease-free survival, health-related quality of life and cost-
effectiveness. Assuming a HR for all-cause mortality of 0.63 based on our observational 
estimates207,  baseline survival at three years of 45% in the unexposed group118, 317, 15% drop out 
overall (including treatment withdrawals, with and without contamination of the exposure, and 
complete withdrawal from the trial), with 90% power, at the 5% significance level (two-sided), a 
sample size of 508 (254 per arm) would be required. This would detect an absolute difference of 
15.5% in all-cause mortality between groups. Even with 80% power, for this number of 
participants a HR for all-cause mortality of 0.68 could be detected, with an absolute difference in 
mortality between groups of 13.3%. Assuming recruitment rates from our feasibility work are 
applicable across 25 prospective NHS sites (with the highest oesophago-gastric surgical case-loads 
nationally264), weighted for case load, an estimated 657 participants due surgery for OAC could be 
recruited over a three year period. The STAT-ROC phase III trial would need to involve not only 
the major oesophago-gastric surgical centres, but also the peripheral NHS trusts in order to 
facilitate recruitment and follow-up, and in doing so operate a hub and spoke system. Current 
recruitment estimates for the feasibility work include the impact of competing trials, however, 
this landscape during a future recruitment period would be expected to change, particularly with 
recruitment to Add-Aspirin290 and Neo-AEGIS320. For future trial success, a collaborative approach 
will be required in which co-enrolment between trials is permitted. Co-enrolment should still 
enable valid treatment estimates to be made (a product of randomisation), and ensures that 
estimates of effect remain contemporaneous given that interventions in current trials may 
become established as the future standard of care.  If statins are empirically demonstrated to be 
efficacious agents in patients with operable OAC in improving mortality, this would represent a 
major advance in treatment strategy to benefit patients and the wider NHS.  
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Appendix A 
Description Code 
Cancinoma of the oesophagus or 
gastro-oesophageal junction 
(Read/OXMIS code) 
B110z00, B103.00, B10z.11, B110000, B801200, 
B102.00, B101.00, B110111, B10y.00, B10z.00, B801.00, 
B801000, 150 A, B10..00, B104.00, B801z00, B100.00, 
B110100, B801100, 150 C 
Oesophagectomy, oesophago-
gastrectomy, gastrectomy 
(OPCS code v4.6) 
G01.1, G01.2, G01.3, G27.1, G27.2, G27.3, G27.4, G27.5, 
G02.1, G02.2, G02.3, G02.4, G02.5 
(Read/OXMIS code) 
7600z00, 7610.12, 7600013, 7601.11, 7600.11, 
7600012, 7601000, 7601, 7600000, 7602y00, 7602, 
7602000, 7600, 7420300, 7610400, 7601z00, 7600100, 
7601y00, 7601200, 7601400, 7601111, 7600200 
Adenocarcinoma (Morphology code, national cancer data repository) 
81403, 81443, 81453, 82603, 82113, 84803, 84903, 
81402, 85743, 84813 
Squamous cell carcinoma (Morphology code, national cancer data repository) 
80703 
Cerebrovascular disease (Read/OXMIS code) 
G65z.00, G63..12, Gyu6600, G65zz00, G671.00, 
G65y.00, G677400, G63y.00, G65..00, G671z00, 
G641000, 4350, G633.00, G660.00, G661.00, G666.00, 
G665.00, G662.00, G64..13, G613.00, G6...00, G67..00, 
G61X100, G63z.00, 4380, G63..00, G61z.00, 4389, 
Gyu6.00, 1477, G61X000, G61X.00, Gyu6F00, G617.00, 
4319CR, G61..12, G61..00, G66..11, G66..00, G667.00, 
G66..13, G663.00, G664.00, G668.00, G66..12, 14A7.00, 
14A7.12, 4369B 
Ischaemic heart disease (Read/OXMIS code) 
G301.00, G30z.00, G30..14, G30..15, G305.00, 4109TC, 
G307.00, 14AH.00, G30y.00, G303.00, 4109NC, G30..00, 
G300.00, G32..12, G30X000, G30..13, G307100, 
G307000, G301100, G32..00, G30..17, G32..11, G30..12, 
429 AH, G30yz00, G302.00 
Peripheral vascular disease (Read/OXMIS code) 
4439A, G732100, G732200, G73z000, G73z011, 
G73..11, 7A13411, R054.00, G715.00, 14AE.00, G73..00, 
Gyu7100, G710.00, G73y.00, G731100, G713000, 
G715000, g71..00, R054200, G732000, G732.00, 
G716000, G732400, 4459TE, 7A13.11, 7A11311, 
G73yz00, C107.12, 4459FT, R054300, G714100, 
R054z00, G716.00, 4410N, 7A11211, G712.00, 4459CR, 
G711.00, G73z.00, G73zz00, G71z.00, G713.00, 
7A14.11, 4419, 14NB.00, G71..00, G713.11, Gyu7200, 
G732300, R054000, G714.11, G714.00, Gyu7400, 
G718.00, 7A14411, 4439GD, 4459N, 4430G, G711.11 
Beta blockers (Product code) 
5, 24, 26, 197, 220, 297, 472, 581, 594, 599, 707, 739, 
751, 753, 769, 786, 817, 822, 940, 1006, 1048, 1050, 
1124, 1288, 1290, 1295, 1333, 1334, 1448, 1572, 1597, 
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1684, 1788, 2361, 2414, 2432, 2499, 2587, 2590, 2629, 
2775, 2780, 3005, 3087, 3167, 3344, 3474, 3516, 3526, 
3588, 3691, 3748, 3827, 4004, 4025, 4265, 4410, 4429, 
4542, 4588, 4605, 4725, 4771, 4796, 4983, 5284, 5330, 
5478, 5713, 5721, 5858, 5968, 6066, 6751, 7049, 7066, 
7091, 7429, 7474, 7528, 7543, 7553, 7620, 7852, 7853, 
7974, 8023, 8061, 8068, 8071, 8113, 8147, 8172, 8189, 
8262, 8290, 8331, 8369, 8555, 8623, 8642, 8673, 8707, 
8807, 8935, 8978, 8987, 9016, 9143, 9178, 9185, 9273, 
9292, 9783, 10191, 10294, 10429, 10627, 10716, 10777, 
10892, 11338, 11380, 11711, 11793, 12037, 12054, 
12141, 12296, 12456, 12495, 12517, 12519, 12651, 
13051, 13394, 13415, 13487, 13499, 13526, 13871, 
14030, 14057, 14058, 14117, 14126, 14146, 14438, 
14502, 14552, 14673, 14808, 15042, 15117, 15176, 
15488, 15619, 15730, 16645, 16776, 16786, 17082, 
17149, 17322, 17462, 17615, 17679, 17783, 18185, 
18287, 18414, 18743, 18950, 19055, 19068, 19142, 
19172, 19178, 19182, 19191, 19200, 19202, 19437, 
19853, 19858, 19998, 20012, 20082, 20093, 20169, 
20468, 20502, 20728, 21025, 21133, 21182, 21838, 
21839, 21866, 21873, 21885, 21905, 21966, 22208, 
22793, 22912, 23131, 23134, 23326, 23587, 24083, 
24094, 24191, 24195, 24218, 24280, 24461, 24635, 
24832, 25359, 25363, 25367, 25462, 25644, 25730, 
26211, 26228, 26229, 26248, 26255, 26529, 26741, 
26895, 26922, 27357, 27486, 27700, 27719, 27727, 
27946, 27964, 28048, 28128, 28177, 28700, 28788, 
28996, 29180, 29230, 29368, 29398, 29427, 29610, 
29762, 29763, 29827, 29998, 30400, 30519, 30541, 
30636, 30770, 31214, 31470, 31536, 31708, 31776, 
31833, 31934, 32094, 32114, 32135, 32162, 32552, 
32630, 32787, 32836, 33079, 33085, 33092, 33184, 
33374, 33376, 33569, 33578, 33602, 33644, 33650, 
33657, 33659, 33836, 33839, 33850, 33909, 34012, 
34034, 34092, 34094, 34125, 34171, 34177, 34185, 
34188, 34208, 34214, 34265, 34365, 34371, 34378, 
34407, 34430, 34443, 34449, 34492, 34501, 34509, 
34520, 34575, 34584, 34585, 34600, 34640, 34690, 
34695, 34740, 34741, 34754, 34783, 34804, 34821, 
34825, 34854, 34867, 34868, 34882, 34884, 34890, 
34899, 34925, 34945, 34949, 34963, 34976, 35054, 
35062, 35695, 35710, 35778, 35938, 35940, 36261, 
36576, 36603, 37118, 37725, 37837, 38370, 38433, 
38498, 38991, 39233, 39423, 39646, 39819, 39846, 
40167, 40240, 40241, 40761 
Angiotensin converting enzyme 
inhibitors 
(Product code) 
65, 69, 78, 80, 82, 97, 147, 196, 277, 448, 593, 633, 654, 
709, 756, 761, 1021, 1121, 1143, 1144, 1299, 1520, 
1807, 1904, 2982, 3069, 3203, 3310, 3720, 3839, 3929, 
4103, 4571, 5047, 5159, 5189, 5275, 5612, 5735, 5800, 
5861, 6078, 6200, 6261, 6288, 6314, 6359, 6362, 6364, 
6408, 6468, 6765, 6786, 6794, 6806, 6807, 7314, 7419, 
8025, 8026, 8105, 8106, 8268, 8800, 8830, 9646, 9693, 
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9731, 9764, 9915, 9948, 10882, 10902, 11133, 11197, 
11351, 11561, 11567, 11641, 11937, 11965, 11983, 
11987, 12313, 12411, 12412, 12574, 12815, 12858, 
13026, 13589, 13755, 14228, 14387, 14477, 14478, 
14960, 15031, 15085, 15096, 15108, 15121, 15135, 
15605, 15958, 16196, 16197, 16212, 16701, 16708, 
16710, 16924, 17006, 17120, 17474, 17624, 17633, 
17655, 18219, 18223, 18263, 18269, 18325, 19198, 
19204, 19208, 19223, 19690, 20188, 20579, 20849, 
20975, 21053, 21162, 21231, 21943, 22439, 22708, 
23252, 23478, 23642, 24041, 24482, 25998, 26995, 
27871, 28127, 28438, 28486, 28586, 28724, 28725, 
28820, 28902, 29130, 29530, 29627, 30039, 30921, 
31307, 31587, 31716, 31810, 32048, 32166, 32241, 
32514, 32560, 32597, 32857, 32934, 33057, 33078, 
33095, 33336, 33353, 33646, 33811, 33894, 33977, 
34357, 34382, 34390, 34400, 34412, 34429, 34431, 
34432, 34453, 34471, 34490, 34505, 34528, 34539, 
34540, 34544, 34562, 34567, 34583, 34589, 34651, 
34652, 34657, 34696, 34698, 34710, 34712, 34719, 
34732, 34768, 34798, 34799, 34877, 34893, 34936, 
34937, 34943, 34952, 34953, 35007, 35302, 35731, 
35794, 36742, 36753, 37080, 37087, 37655, 37710, 
37778, 37908, 37930, 37964, 37965, 37971, 37978, 
38026, 38034, 38285, 38308, 38510, 38854, 38899, 
38995, 39137, 39147, 39227, 39242, 39355, 39421, 
39512, 40355, 40384 
Angiotensin receptor blocker (Product code) 
520, 529, 531, 575, 624, 764, 828, 1293, 1780, 2971, 
3222, 4155, 4226, 4540, 4645, 4685, 4741, 4818, 5013, 
5117, 5723, 5988, 6217, 6243, 6285, 6351, 6437, 6518, 
6877, 6939, 7043, 7338, 9196, 9745, 10316, 10323, 
11251, 11252, 11348, 11448, 11469, 11526, 11864, 
12836, 12874, 13123, 13821, 14283, 14738, 14870, 
14943, 14965, 14983, 16060, 16161, 16285, 16371, 
17545, 17686, 17689, 18200, 18202, 18903, 18910, 
20117, 21423, 23456, 24268, 24359, 24484, 24632, 
25382, 27520, 29634, 31072, 35096, 35173, 35174, 
35189, 35196, 35304, 35317, 35329, 35343, 35380, 
35481, 35697, 36939, 37573, 37650, 37747, 38367, 
38395, 38459, 38889, 39021, 39199, 39786, 39944, 
39984, 40316, 40571, 40639, 40668, 40711 
Statins (Product code) 
25, 28, 42, 51, 75, 379, 420, 490, 713, 730, 745, 802, 
818, 1219, 1221, 1223, 2137, 2718, 2955, 3411, 3690, 
4961, 5009, 5148, 5251, 5278, 5775, 5985, 6168, 6213, 
7196, 7347, 7374, 7552, 7554, 8380, 9153, 9315, 9316, 
9897, 9920, 9930, 10172, 10183, 10206, 11627, 11815, 
13041, 14219, 15252, 16186, 17059, 17683, 17688, 
18442, 21020, 22579, 31658, 31930, 32909, 32921, 
33082, 34312, 34316, 34353, 34366, 34376, 34381, 
34476, 34481, 34502, 34535, 34545, 34560, 34746, 
34814, 34820, 34879, 34891, 34907, 34955, 34969, 
36377, 37434, 39060, 39652, 39675, 39870, 40340, 
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40382, 40601 
Aspirin (Product code) 
3, 16, 34, 254, 306, 377, 381, 393, 395, 430, 434, 484, 
645, 657, 685, 1049, 1137, 1902, 2047, 2105, 2237, 
2607, 2628, 2986, 3155, 3275, 3309, 3386, 3726, 4319, 
4679, 5288, 6006, 6007, 6226, 6666, 6696, 7516, 7518, 
7520, 7539, 8185, 8186, 8271, 8645, 9044, 9129, 9144, 
9301, 9432, 9939, 10031, 10298, 10305, 10310, 11326, 
11951, 11961, 11977, 12047, 12964, 12976, 12992, 
13882, 14517, 15364, 15367, 15779, 16184, 16611, 
17180, 17456, 17704, 17920, 17926, 18030, 18217, 
18261, 18329, 19189, 19255, 20127, 20650, 20840, 
21067, 21380, 21382, 21770, 21921, 22138, 22232, 
22305, 22618, 22776, 23142, 23488, 23593, 23841, 
23878, 23932, 24025, 24309, 24622, 24828, 24960, 
25211, 25335, 25718, 26967, 27435, 28784, 28810, 
29054, 29759, 29848, 30022, 30920, 31001, 31210, 
31211, 31499, 31858, 31870, 31894, 31938, 31953, 
31954, 31956, 32036, 32154, 32178, 32210, 32314, 
32728, 32992, 33139, 33293, 33317, 33320, 33656, 
33662, 33668, 33676, 34233, 34309, 34385, 34386, 
34434, 34485, 34611, 34666, 34762, 34796, 34797, 
34942, 35967, 36521, 36543, 37541, 39738, 40144, 
40381 
Non-steroidal anti-inflammatory 
drugs 
(Product code) 
15, 40, 120, 126, 129, 140, 141, 157, 162, 167, 177, 259, 
296, 341, 344, 360, 387, 389, 392, 402, 407, 416, 417, 
447, 474, 497, 499, 518, 526, 538, 560, 580, 586, 589, 
597, 612, 613, 628, 637, 640, 647, 649, 650, 661, 666, 
676, 706, 723, 736, 754, 784, 807, 838, 849, 850, 917, 
919, 920, 928, 1030, 1043, 1051, 1073, 1075, 1086, 
1096, 1115, 1116, 1139, 1210, 1231, 1233, 1246, 1392, 
1446, 1468, 1469, 1470, 1496, 1571, 1621, 1688, 1692, 
1739, 1755, 1757, 1766, 1778, 1866, 1983, 1984, 2129, 
2197, 2200, 2234, 2235, 2243, 2257, 2258, 2288, 2293, 
2363, 2366, 2382, 2386, 2387, 2463, 2622, 2671, 2827, 
2863, 2904, 2938, 3043, 3053, 3168, 3170, 3182, 3216, 
3262, 3266, 3311, 3326, 3409, 3416, 3421, 3431, 3432, 
3492, 3496, 3597, 3599, 3710, 3739, 3817, 3852, 3897, 
3899, 3901, 3935, 3939, 3958, 3972, 3974, 4043, 4045, 
4049, 4095, 4216, 4298, 4320, 4368, 4469, 4506, 4564, 
4565, 4625, 4631, 4692, 4710, 4713, 4731, 4806, 4880, 
4911, 4965, 4984, 5080, 5085, 5173, 5175, 5200, 5254, 
5266, 5268, 5401, 5407, 5455, 5482, 5648, 5695, 5739, 
5812, 5841, 5938, 6249, 6460, 6464, 6498, 6663, 7058, 
7118, 7424, 7426, 7432, 7434, 7481, 7483, 7490, 7522, 
7524, 7535, 7667, 7688, 7840, 7913, 8062, 8145, 8385, 
8401, 8451, 8544, 8600, 8663, 8672, 8789, 8969, 9222, 
9439, 9465, 9474, 9500, 9637, 9688, 9736, 9822, 9886, 
9899, 9912, 9978, 10033, 10149, 10169, 10209, 10212, 
10295, 10325, 10336, 10481, 10558, 10589, 10625, 
10678, 10711, 10785, 10792, 10917, 10978, 11168, 
11215, 11322, 11466, 11495, 11550, 11907, 11952, 
11970, 11980, 11995, 11999, 12000, 12075, 12122, 
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12188, 12766, 13347, 13380, 13459, 13606, 13627, 
13639, 13818, 14084, 14085, 14333, 14380, 14385, 
14422, 14476, 14541, 14672, 14678, 14707, 14776, 
15005, 15023, 15068, 15104, 15180, 15201, 15286, 
15501, 15732, 16001, 16170, 16176, 16192, 16193, 
16194, 16221, 16222, 16225, 16272, 16286, 16473, 
16474, 17029, 17030, 17124, 17126, 17128, 17131, 
17165, 17201, 17491, 17525, 17532, 17572, 17680, 
17733, 17750, 17754, 17818, 18066, 18196, 18234, 
18364, 18371, 18448, 18527, 18640, 18647, 18662, 
18798, 18812, 18820, 18921, 19007, 19036, 19046, 
19320, 19322, 19382, 19575, 20016, 20059, 20105, 
20230, 20384, 20385, 20386, 20395, 20621, 20805, 
20978, 21045, 21050, 21123, 21150, 21387, 21419, 
21421, 21444, 21610, 21807, 21811, 21813, 21815, 
21816, 21821, 21824, 21831, 21840, 21843, 21846, 
21864, 21955, 22206, 22230, 23026, 23121, 23204, 
23323, 23795, 24007, 24020, 24121, 24122, 24128, 
24137, 24193, 24212, 24236, 24305, 24308, 24320, 
24356, 24469, 24531, 24682, 25205, 25257, 25283, 
25329, 25341, 25342, 25358, 25361, 25362, 25619, 
25643, 25701, 25750, 25790, 25794, 25800, 26083, 
26165, 26205, 26214, 26216, 26231, 26234, 26242, 
26247, 26351, 26404, 26522, 26575, 26631, 26888, 
26970, 26994, 27013, 27055, 27082, 27200, 27362, 
27366, 27484, 27490, 27677, 27723, 27782, 27783, 
27968, 28168, 28171, 28255, 28256, 28332, 28348, 
28383, 28390, 28479, 28553, 28695, 28764, 28816, 
28888, 28900, 29010, 29037, 29068, 29110, 29181, 
29316, 29330, 29332, 29345, 29352, 29455, 29465, 
29524, 29587, 29674, 29704, 29749, 29772, 30122, 
30168, 30243, 30282, 30297, 30327, 30382, 30389, 
30391, 30724, 30790, 30806, 30811, 30849, 30892, 
30923, 30942, 30982, 31064, 31383, 31429, 31469, 
31482, 31589, 31777, 31787, 31916, 31944, 31945, 
31950, 31959, 31962, 32090, 32097, 32100, 32105, 
32108, 32136, 32227, 32234, 32242, 32365, 32366, 
32509, 32536, 32601, 32641, 32854, 32862, 32875, 
32916, 33111, 33113, 33180, 33308, 33318, 33321, 
33357, 33457, 33559, 33568, 33589, 33645, 33669, 
33704, 33785, 33801, 33994, 34091, 34143, 34190, 
34199, 34212, 34218, 34271, 34289, 34290, 34354, 
34359, 34362, 34425, 34438, 34447, 34487, 34527, 
34536, 34550, 34595, 34610, 34621, 34663, 34670, 
34725, 34729, 34738, 34743, 34744, 34757, 34769, 
34793, 34850, 34889, 34898, 34910, 34911, 34922, 
34923, 34924, 34931, 34961, 34977, 34980, 35265, 
35292, 35653, 35711, 35890, 35893, 35935, 36260, 
36486, 36577, 36597, 36606, 36650, 37002, 37053, 
37094, 37253, 37553, 37562, 37587, 37648, 37750, 
37763, 38332, 38493, 38511, 38770, 38817, 38881, 
38944, 38948, 38992, 39019, 39085, 39109, 39264, 
39317, 39354, 39502, 39693, 39722, 39758, 39823, 
39873, 40083, 40086, 40141, 40185, 40215, 40253, 
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40336, 40394, 40401, 40484, 40516, 40664, 40756 
Table 32: comprehensive list of all Read/OXMIS, OPCS, morphology and product codes used to generate the study 
dataset for chapter 2. 
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Appendix H 
Abbreviations: CK, creatine kinase; ULN, upper limit of normal 
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Appendix I 
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